Molecular genetic analysis of hyperhomocysteinemia. by Gellekink, H.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/30131
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Molecular genetic analysis 
of hyperhomocysteinemia  
With a focus on remethylation and transmethylation
Gellekink, Henkjan 
Molecular genetic analysis of hyperhomocysteinemia – With a focus on remethylation and 
transmethylation, Thesis Radboud University Nijmegen with summary in Dutch 
ISBN-10: 90-9021331-7 
ISBN-13: 978-90-9021331-6 
Cover: Depiction of the Rosetta stone as a metaphor for the central dogma of molecular 
biology. The “clock” is an abstract representation of homocysteine metabolism 
Design by Bart van der Linden (www.bartvdl.nl) 
Printed by: Print Partners Ipskamp, Enschede, The Netherlands 
© 2006 Gellekink, Henkjan, Nijmegen, The Netherlands
Molecular genetic analysis 
of hyperhomocysteinemia  
With a focus on remethylation and transmethylation
Een wetenschappelijke proeve op het gebied 
van de Medische Wetenschappen 
Proefschrift
ter verkrijging van de graad van doctor  
aan de Radboud Universiteit Nijmegen 
op gezag van de Rector Magnificus prof. dr. C.W.P.M. Blom 
volgens besluit van het College van Decanen
in het openbaar te verdedigen op  
 donderdag 11 januari 2007 
om 13:30 uur precies 
door
Henkjan Gellekink 
geboren op 10 maart 1975 te Enschede 
Promotor: Prof. dr. A.R.M.M. Hermus 
Co-promotores: Dr. M. den Heijer 
 Dr. H.J. Blom 
Manuscriptcommissie: Prof. dr. J.L. Willems (voorzitter) 
 Prof. dr. Y.M. Smulders (VU Medisch Centrum, Amsterdam)  
 Dr. B. Franke 
The study described in this thesis was supported by a grant of the Netherlands Heart 
Foundation (NHF - 2002B068). 
Financial support by the Netherlands Heart Foundation for the publication of this thesis is 
gratefully acknowledged.  
Aan mijn ouders, 
Aan Nathalie

7DEOHRIFRQWHQWV
Abbreviations 8
Chapter 1 General introduction and objectives 11 
 Published in part in Seminars in Vascular Medicine 2005; 5: 98-109
3DUW,*HQHWLFGHWHUPLQDQWVRISODVPDWRWDOKRPRF\VWHLQH
)RODWHF\FOHDQGKRPRF\VWHLQHUHPHWK\ODWLRQ
Chapter 2 Disturbed vitamin B12 metabolism, variation in homocysteine 27 
 remethylation genes and recurrent venous thrombosis risk  
 Submitted for publication 
Chapter 3 Molecular genetic analysis of the human dihydrofolate reductase  39 
 gene: relation with plasma total homocysteine, serum and red  
 blood cell folate levels  
 European Journal of Human Genetics 2006; in press 
Chapter 4 Effect of common polymorphisms in the reduced folate carrier, 51 
thymidylate synthase and AICAR transformylase/IMP  
 cyclohydrolase genes on folate and homocysteine levels and  
 recurrent venous thrombosis risk 
 Submitted for publication 
+RPRF\VWHLQHDQGWUDQVPHWK\ODWLRQ
Chapter 5 Effect of genetic variation in the human S-adenosylhomocysteine 61 
hydrolase gene on total homocysteine concentrations and risk of  
 recurrent venous thrombosis 
 European Journal of Human Genetics 2004; 12: 942-8. 
Chapter 6 Catechol-O-methyltransferase genotype is associated with  73 
 plasma total homocysteine levels and may increase recurrent  
 venous thrombosis risk 
 Submitted for publication 
3DUW,,3DWKRSK\VLRORJ\ಥKRPRF\VWHLQHDQGGLVWXUEHGWUDQVPHWK\ODWLRQ
Chapter 7 Stable-isotope dilution liquid chromatography-electrospray injection  85 
 tandem mass spectrometry method for fast, selective measurement  
 of S-adenosylmethionine and S-adenosylhomocysteine in plasma 
Clinical Chemistry 2005; 51: 1487-92
Chapter 8 Investigation of the human umbilical vein endothelial cell  97 
 proteome and protein methylation by nano-LC Fourier transform  
 ion cyclotron resonance mass spectrometry 
 In preparation 
Chapter 9 Summary, general discussion and future perspectives 111 
 Part of the General discussion is published in modified form in  
Seminars in Vascular Medicine 2005; 5: 98-109
Chapter 10 Samenvatting 125 
References  131
Dankwoord 157
Curriculum vitae and list of publications 161
- 8 - 
$EEUHYLDWLRQV
AdoCbl adenosylcobalamin 
AdoHcy S-adenosylhomocysteine 
AdoMet S-adenosylmethionine 
Adox periodate-oxidized adenosine 
AHCY S-adenosylhomocysteine hydrolase 
ANOVA analysis of variance 
ATIC aminoimidazole carboxamide ribonucleotide (AICAR) 
transformylase/inositol monophosphate (IMP) cyclohydrolase 
BHMT betaine-homocysteine methyltransferase 
(k)bp (kilo)basepairs 
Cbl cobalamin 
CBS cystathionine E-synthase
CI confidence interval 
COMT catechol-O-methyltransferase 
CTH cystathionine J-lyase
CV coefficient of variation 
(k)Da (kilo)dalton 
DHFR(P) dihydrofolate reductase (pseudogene) 
DMSO dimethylsulfoxide 
(c)DNA (complementary) deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
EDTA ethylenediaminotetraacetic acid 
FR folate receptor 
FGCP folylpoly-J-glutamate carboxypeptidase 
GCPII glutamate carboxypeptidase II 
HPLC high-pressure liquid chromatography 
HUVECs human umbilical vein endothelial cells 
LD / D’ linkage disequilibrium / coefficient of LD 
MS mass spectrometry 
MeCbl methylcobalamin 
MMA methylmalonic acid 
MRM multiple reaction monitoring 
mRNA messenger ribonucleic acid 
MTHFR methylenetetrahydrofolate reductase 
MTR methionine synthase 
MTRR methionine synthase reductase 
m/z mass-over-charge ratio 
NAD+/NADP nicotinamide adenine dinucleotide / NAD phosphate 
Nano-LC FTICR MS nano-liquid chromatography Fourier transform ion cyclotron 
resonance mass spectrometry 
OR odds ratio 
PCR polymerase chain reaction 
- 9 - 
PML post-methionine load 
RBC red blood cell 
RFC1 reduced folate carrier 1 
RFLP restriction fragment-length polymorphism 
SNP single-nucleotide polymorphism 
SD standard deviation 
LC ESI MS/MS liquid chromatography electrospray injection tandem mass 
spectrometry
SPE solid-phase extraction 
SPSS statistical package for the social sciences 
tHcy plasma total homocysteine 
TYMS thymidylate synthase 
U units (enzyme activity) 
UTR untranslated region 
- 10 - 
- 11 - 
Chapter 1
General introduction 
and
objectives
Part of this chapter (1.5) is published as  
Genetic Determinants of Plasma Total Homocysteine 
Henkjan Gellekink, Martin den Heijer, Sandra G. Heil, Henk J. Blom 
Seminars in Vascular Medicine 2005; 5: 98-109
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 +RPRF\VWHLQHPHWDEROLVP
Homocysteine is a sulphur-containing intermediate produced during the conversion of the 
essential amino acid methionine to cysteine (Figure 1). Methionine metabolism is linked to 
the synthesis of glutathione and polyamines. Its unique function relates to a process called 
“transmethylation”. First, methionine is converted into S-adenosylmethionine (AdoMet), the 
principle methyl donor in the human body, by the enzyme methionine adenosyltransferase 
(MAT). AdoMet is the methyldonor in over a hundred methylation reactions including the 
methylation of nucleic acids, proteins, lipids, hormones and neurotransmitters. A group of 
enzymes, called methyltransferases, are involved in the transfer of the methylgroup to its 
specific acceptor. By donating the methylgroup, S-adenosylhomocysteine (AdoHcy) is 
formed, which is readily hydrolyzed to homocysteine and adenosine in a reversible reaction 
catalyzed by AdoHcy hydrolase (AHCY).
Homocysteine can be remethylated to methionine or irreversibly degraded via the 
transsulfuration pathway. Transsulfuration is mainly restricted to the liver and kidney and 
produces cysteine (for protein or glutathione synthesis) or sulfate. These steps are catalyzed 
by the vitamin B6-dependent enzymes cystathionine E-synthase (CBS) and cystathionine J-
lyase (CTH). In the remethylation pathway, homocysteine accepts a methylgroup to form 
methionine again. In this ubiquitously present metabolic route, folate acts as an intermediate 
methylcarrier (Figure 1). Fully reduced folate (tetrahydrofolate, THF) accepts a one-
carbongroup from the amino acid serine to produce 5,10-methyleneTHF. After reduction to 5-
methylTHF, the main circulating form of folate in blood, by 5, 10-methylenetetrahydrofolate 
reductase (MTHFR), the methylgroup is transferred via cobalamin (vitamin B12) to 
homocysteine in a reaction catalyzed by methionine synthase (MTR). Importantly, folate is 
also essential for the synthesis of purine and thymidylate nucleotides. An alternative 
homocysteine remethylation pathway exists in which betaine (=trimethylglycine) donates the 
methylgroup in a reaction catalyzed by betaine-homocysteine methyltransferase (BHMT). 
Like CBS, its activity is mainly restricted to the liver and the kidney.  
In the cell, homocysteine is mainly present as its precursor, AdoHcy. Under normal 
conditions, transsulfuration and remethylation activity determine intracellular homocysteine 
levels. If one of these pathways is compromized, for example due to enzyme dysfunction or 
low vitamin intake, the excess of homocysteine is presumed to be exported to the blood  
(reference range 5-15 Pmol/L) and metabolized in other organs, such as the kidney and liver. 
Persisting higher concentrations of homocysteine in the blood (>15 Pmol/L), also called 
“hyperhomocysteinemia”, reflects a disturbance of the critical processes mentioned above. 
 ,QERUQHUURUVRIPHWKLRQLQHPHWDEROLVP
The discovery of the inborn error of metabolism called homocystinuria initiated great interest 
in homocysteine in the early 1960s. This rare inherited disease is caused by defects in either 
homocysteine transsulfuration or homocysteine remethylation. The most common cause of 
homocystinuria involves a block in the transsulfuration pathway due to CBS deficiency, which 
*HQHUDOLQWURGXFWLRQDQGREMHFWLYHV
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is often caused by the 833T>C mutation (minor allele frequency 0.2% to 0.7% in Caucasians) 
1-3 (unpublished results). Although only sporadically seen, the two most common 
remethylation defects are MTHFR deficiency and MTR dysfunction (1:1.000.000 and 20-100 
cases worldwide, respectively). There is a large variation in clinical presentation among 
“classical” homocystinuric patients, but they all share an excessive accumulation of 
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Figure 1. Relevant enzymes in folate, vitamin B12 and homocysteine metabolism 
Abbreviations: ADA, adenosine deaminase; AdoMet, S-adenosylmethionine, AdoHcy, S-adenosylhomocysteine; AHCY, S-
adenosylhomocysteine hydrolase; ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase / inosine
monophosphate (IMP) cyclohydrolase; ATP, adenosine triphosphate; BHMT, betaine-homocysteine methyltransferase; CBS,
cystathionine E-synthase; Cbl, cobalamin; COMT, catechol-O-methyltransferase; CTH, cystathionine J-lyase; CUBN, cubulin;
D(T)HF, di(tetra)hydrofolate; DHFR, dihydrofolate reductase; DNMT, DNA methyltransferases; DMG, dimethylglycine; dUMP,
deoxyuridine monophosphate; dTMP, deoxythymidine monophosphate; FAICAR, formyl-AICAR; IMP, inosine monophosphate;
FGCP, folyl-J-glutamate carboxypeptidase; IF, intrinsic factor; FR, folate receptors; MAT, methionine-adenosyltransferase; MT,
methyltransferases; MTHFD, methylenetetrahydrofolate dehydrogenase; MTHFR, methylenetetrahydrofolate reductase;
MTR(R), methionine synthase (reductase); MUT, methylmalonyl-CoA mutase; PRMT, protein-arginine methyltransferase; RFC1,
reduced folate carrier1; SHMT, serine-hydroxymethyltransferase; TCII, transcobalamin; TCII-R, transcobalamin receptor; TYMS,
thymidylate synthase. 
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homocysteine in blood (>50 Pmol/L) and, hence, excretion of homocystine (a disulfide of 
homocysteine) in urine. Irrespective of the underlying cause, thromboembolic and arterial 
vascular disease are major clinical findings in homocystinuria. Hence, McCully postulated 
that the premature vascular complications were a consequence of the elevated 
homocysteine 4,5. This raised the question whether mild elevation of plasma total 
homocysteine (tHcy), called hyperhomocysteinemia, also increases the risk of vascular 
disease 6-8. This is of clinical importance considering the high prevalence of 
hyperhomocysteinemia (about 10-15%) in the general population. 
 +\SHUKRPRF\VWHLQHPLDDQGGLVHDVH
 $UWHULDOYDVFXODUGLVHDVHDQGYHQRXVWKURPERVLV
Cardiovascular disease is the leading cause of death in the Western industrialized world and 
a major cause of death throughout the world. Cardiovascular disease contributes to 
approximately 40% of all deaths in the United States and at least 20% in Europe 9,10. The 
increasing prevalence of obesity and diabetes among children and adults will lead to an 
additional increase in cardiovascular disease and related mortality. A common type of 
vascular disease is atherosclerosis, which results from progressive narrowing of the blood 
vessels that supply oxygen to the heart, brain or other parts of the body. It develops when 
deposits (called plaques) build up on the inner lining (endothelium) of the vessel wall. 
Ultimately, this may lead to a rupture of the atherosclerotic lesion and cause coronary artery, 
cerebral artery or peripheral artery disease. Hypertension, high LDL-cholesterol, obesity 
(body mass index >25), diabetes and smoking are among the most important risk factors for 
atherosclerosis.  
Arterial vascular disease and venous thrombosis are important clinical findings in classical 
homocystinuria 11,12. Although in the general population the incidence of venous thrombosis 
with respect to the overall cardiovascular burden is relatively low, thromboembolic disease 
accounts for substantial morbidity and mortality 13. Venous thrombosis occurs when a blood 
clot is formed in the veins due to (a combination of) tissue damage, hemostasis and a 
hypercoagulable state, also known as Virchow’s triad. In the general population, the most 
common genetic cause of venous thrombosis is activated protein C resistance due to the 
factor V Leiden mutation and hypercoagulability due to the prothrombin 20210G>A mutation 
14-16. Other, less frequent, risk factors for venous thrombosis include protein S-, protein C- 
and antithrombin deficiency 13.
In the past two decades both retro- and prospective studies identified hyperhomocysteinemia 
as an independent risk factor for arterial vascular disease and venous thrombosis 17-19. The 
current data show that the risk associated with a 5 Pmol/L higher tHcy ranges from 30% to 
60% (odds ratio 1.3 to 1.6) for venous thrombosis, stroke and ischemic heart disease 18,19.
Interestingly, homocysteine-lowering treatment in homocystinuric patients reduces the risk of 
vascular events by 90% (relative risk 0.09 [95% CI 0.036 to 0.228], P<0.0001) 20.


*HQHUDOLQWURGXFWLRQDQGREMHFWLYHV
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 +\SHUKRPRF\VWHLQHPLDDQGRWKHUGLVHDVHV
The increased disease risk associated with a disturbed homocysteine metabolism is not only 
confined to cardiovascular complications. In general, three other major domains of clinical 
conditions have been related to a disturbed homocysteine metabolism. These comprise 
pregnancy complications (including congenital defects), cancer and neuro(psycho)logical 
diseases (Figure 2).
Low folate status and the concomitant increase in tHcy are known risk factors for neural tube 
defects. Already in the nineties of the previous century the preventive effect of folate 
supplementation regarding the occurrence and recurrence of neural tube defects has been 
established 21-23. Also the risk for other pregnancy complications, like congenital heart defects 
24,25, cleft lip and palate 26, stillbirth 27, preterm delivery and preeclampsia 28, is increased in 
hyperhomocysteinemic subjects. Folate deficiency and hyperhomocysteinemia have been 
related to neoplasia, such as leukemia, colorectal and breast cancer. This may be related to 
increased uracil misincorporation, disturbed methylation of DNA or catecholestrogens 29-35.
Finally, data is emerging that low B-vitamin status and hyperhomocysteinemia are more 
prevalent in dementia and Alzheimer’s disease 36,37. Together with the finding of higher tHcy 
and disturbed transmethylation in schizophrenic patients 38,39, these data suggest the 
involvement of homocysteine-related disturbances in neuro(psycho)logical disease as well. 
The reported involvement of homocysteine in cardiovascular disease and other diseases 
encouraged many groups to search for genetic determinants of tHcy. Initial studies 
suggested that, in most cases, hyperhomocysteinemia resulted from heterozygosity for CBS 
deficiency 11,40. Others could not reproduce these findings and a role for thermolabile MTHFR 
Homocysteine
Folate
Vascular disease
- peripheral artery disease
- myocardial infarction
- venous thrombosis 
- stroke 
Neuro(psycho)logical dysfunction
- cognitive decline
- Alzheimer’s disease/dementia
- schizophrenia
Neoplasia
- colorectal cancer
- breast cancer
- leukemia
Pregnancy complications and 
congenital defects
- neural tube defects
- cleft lip and palate
- congenital heart defects
- preterm delivery/stillbirth
Figure 2. Clinical conditions that have been related to a disturbed homocysteine/folate metabolism 
*HQHUDOLQWURGXFWLRQDQGREMHFWLYHV
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in hyperhomocysteinemia was proposed 41,42. In 1995, Frosst and co-workers 43 identified the 
677C>T polymorphism in the MTHFR gene as the genetic cause of thermolabile MTHFR. 
However, the MTHFR 677C>T variant only partly explained the high homocysteine levels. 
This led to the search for other determinants of homocysteine (see section 1.5). Heritability 
studies indicate that the genetic contribution to the variation of homocysteine levels ranges 
from 20% to almost 50% 44-46, of which the MTHFR 677C>T polymorphism may explain about 
10% 47. Also “non-genetic” factors contribute to hyperhomocysteinemia, such as low vitamin 
intake, use of certain medication/drugs, smoking, renal dysfunction and coffee consumption 
48. The interaction between these environmental and genetic factors, as well as gene-gene 
interactions is thought to contribute to the complex mechanisms leading to 
hyperhomocysteinemia, and hence increase the risk of disease. 
 3DWKRJHQHVLVRIK\SHUKRPRF\VWHLQHPLD
Several mechanisms have been proposed to explain how homocysteine may lead to 
disease. Regarding cardiovascular disease, these include impaired (nitric oxide-mediated) 
vasodilation due to endothelial dysfunction 49, oxidative stress 50, asymmetric 
dimethylarginine (ADMA) accumulation 51,52 and hemostatic changes resulting in 
hypercoagulability 53. A more general mechanism was recently reviewed by Jacobsen, who  
suggests that molecular targeting of proteins by homocysteine (called “homocysteinylation”) 
may disrupt protein function and contribute to the pathogenesis of cardiovascular disease 54.
Much research has focused on the process of transmethylation, as high homocysteine levels 
may reflect a disturbed transmethylation. Under hyperhomocysteinemic conditions the 
equilibrium of the (reversible) AHCY reaction favors AdoHcy synthesis, rather than 
hydrolysis. Several studies have shown that hyperhomocysteinemia leads to an increase in 
AdoHcy 55-57, a potent inhibitor of AdoMet-dependent transmethylation reactions. Because of 
the importance of methylation of various macromolecules (nucleic acids, proteins, lipids) and 
smaller molecules (neurotransmitters, hormones), it has been suggested that 
hypomethylation may partly explain homocysteine-induced pathology of the vascular and 
central nervous system 57-60.
 *HQHWLFYDULDWLRQDQGK\SHUKRPRF\VWHLQHPLD
The identification of the MTHFR 677C>T polymorphism as an important determinant of 
plasma total homocysteine (tHcy) in the general population, has encouraged many groups to 
search for additional genetic variants that modulate tHcy. The majority of genes that were 
studied are involved in folate metabolism, which illustrates the presumed role of a disturbed 
homocysteine remethylation as a contributor to hyperhomocysteinemia. Given the 
importance of folate and vitamin B12 (cobalamin) in homocysteine remethylation, genes 
involved in their uptake and transport were studied as well. In this section, the variants in 
genes that have been assessed for their effect on tHcy are described (see Figure 1 and 
Table 1), which reflects the status of research in this field at the time the studies described in 
this thesis were initiated. 
*HQHUDOLQWURGXFWLRQDQGREMHFWLYHV
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 *HQHVLQYROYHGLQKRPRF\VWHLQHUHPHWK\ODWLRQ
0HWK\OHQHWHWUDK\GURIRODWHUHGXFWDVH
The most studied polymorphism is the 677C>T (A222V) transition in the MTHFR gene, 
yielding a thermolabile variant of the enzyme with decreased activity 43. Consequently, 
synthesis of 5-methyltetrahydrofolate (5-CH3THF), the co-substrate for the MTR-driven 
remethylation of homocysteine, may be decreased resulting in a mean increase of tHcy of 
25% in the general population 43,61-67. This effect is observed in most populations throughout 
Europe and other continents 68,69, especially when folate status is low 47,62,70. The average 
frequency of the TT genotype in Caucasians is 12% but may range from 1% to as high as 
30% in different ethnic populations 68,71-74.
By direct sequencing of the MTHFR gene of MTHFR-deficient individuals our group detected 
a second variant in this gene, the 1298A>C polymorphism (E429A) 75. This variant was 
associated with decreased enzyme activity in vivo and in vitro 75-77 although others observed 
an effect on enzyme activity only when the MTHFR 677C>T polymorphism was taken into 
account 78,79. No effect of this variant alone on tHcy was observed 64,65,75,76,79, except for one 
Table 1. Genetic variants studied for their effect on plasma total homocysteine relating to non-fortified populations 
Gene Variant 
Amino acid 
substitution
Chromosomal
Location
Allele frequency 
Effect on tHcy 
(mutant vs wild type) 
MTHFR 677C>T A222V 1p36.3 0.30-0.40 (T) +14% to +70% 
 1298A>C E429A  ~0.30 (C) No effect 
MTR 2756A>G D919G 1q43 ~0.20 (G) 0% to -20% (ns) 
MTRR 66A>G I22M 5p15.31 0.46-0.59 (G) 0% to +10% 
GCPII 1561C>T H475Y 11q11.2 ~0.06 (T) -9% (ns) 
RFC-1 80G>A R27H 21q22.3 0.38-0.51 (A) 0% to +11% (ns) 
TCN 776C>G P259R 22q12.2 0.35-0.47 (G) 0% to +15% (ns) 
 67A>G I23V  ~0.13 (G) -35% 
 280G>A G94S  0.01 (A) No effect 
 1043C>T S348F  0.11-0.17 (T) No effect 
 1196G>A R399Q  ~0.02 (A) No effect 
cSHMT 1420C>T L474F 17p11.2 ~0.30 (T) +/- 
mSHMT 7121del4 - 12q13.2 0.02 (del) No effect 
BHMT 595G>A G199S 5q13.1-15 0.01 (A) No effect 
 1218G>T Q406Hs  0.01 (T) No effect 
 716G>A R239Q  0.22-0.31 (A) No effect 
MTHFD 2011G>A R653Q 14q24 0.40-0.45 (A) No effect 
TYMS 28bp rpt - 18p11.32 0.17-0.47 (2x rpt) No effect 
 1494del6 -  0.36 (del) No effect 
CBS 1080C>T A360A 21q22.3 ~0.36 (T) No effect 
 699C>T Y233Y  ~0.36 (T) No effect 
 14037 31 bp VNTR -  ~0.77 (18x rpt) +10% (18/18 vs 17/17) 
 -5707 GT STR -  0.67 (16x rpt) No effect 
 844ins68 -  ~0.09 (ins) 0% to -23% (ns) 
CTH 1364G>T S403I 1p31.1 0.29 (T) +17% 
* ns: non-significant
*HQHUDOLQWURGXFWLRQDQGREMHFWLYHV
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group, who found increased tHcy in 1298CC compared with 1298AA/AC individuals 80. In 
addition, the combination with the MTHFR 677CC 81 or 677CT 75 genotype was shown to 
affect tHcy. 
0HWKLRQLQHV\QWKDVHDQGPHWKLRQLQHV\QWKDVHUHGXFWDVH
Both the MTR and MTRR enzymes are involved in folate-dependent homocysteine 
remethylation and the common MTR 2756A>G and MTRR 66A>G variants have been 
studied in relation to homocysteine. MTR uses cobalamin as cofactor and is directly involved 
in methyl transfer from 5-CH3THF, via cobalamin, to homocysteine. In addition, cobalamin 
may be oxidized (i.e. inactivated) and requires the activity of MTRR to be reduced in order to 
re-enter the catalytic cycle and to maintain MTR activity.
By sequencing the coding region of the MTR gene of sixteen individuals (who were 
hyperhomocysteinemic, had a history of vascular disease or were mothers with children 
suffering from neural tube defects [NTD]), we detected a common variant in the MTR gene 
(i.e. 2756A>G) 82, although no clear effect on tHcy was observed 47,82-84. Several other 
groups, however, reported that the 2756AA genotype was associated with higher tHcy levels 
85-87.
The MTRR I22M (66A>G) variant was first described by Leclerc et al. 88 and because this 
polymorphism is very common (G allele frequency between 0.46 and 0.59) there is no 
consensus concerning the wild type allele at this locus. In vitro studies showed that this 
transition mildly decreased enzyme activity 89,90, although only one study showed the MTRR 
I22M polymorphism to be a determinant of tHcy in the general population 91,92. The fact that 
other studies could not confirm this finding 47,93-97 may indicate that there is redundancy in the 
reductive reactivation of the MTR-cobalamin enzyme complex as reported by Olteanu et al.
which attenuates the effects of the 66A>G polymorphism 98.
*OXWDPDWHFDUER[\SHSWLGDVHUHGXFHGIRODWHFDUULHUDQGIRODWHUHFHSWRUV
FGCP, RFC1 and FR (D thru G) are proteins involved in intracellular folate availability. FGCP, 
encoded by the GCPII gene, hydrolyses dietary folylpoly-J-glutamates to monoglutamates, a 
process essential for cellular absorption of folates. Internalization of folate cofactors generally 
involves two primary systems in mammalian cells (i.e. the high-affinity FRs [for uptake of folic 
acid and CH3THF] and the high-capacity transporter RFC1 [for uptake of reduced folates 
including the antifolate methotrexate (MTX)] 99-102.
GCPII harbors a rare 1561C>T (H475Y) polymorphism in the putative catalytic domain that 
may reduce enzyme activity by half and therefore compromise intestinal folate absorption 103.
In the same publication, Devlin et al. reported that heterozygosity for this polymorphism leads 
to reduced plasma folates and increased tHcy compared to individuals with the wild type 
genotype. In contrast, we reported increased plasma and/or red blood cell folates in 
individuals carrying the mutant allele but did not observe an evident effect on tHcy 104,105. In 
addition, other groups reported no effects on plasma folate and tHcy in 1324 subjects of the 
Framingham Offspring Study 106 or mothers with children suffering from neural tube defects 
107.
*HQHUDOLQWURGXFWLRQDQGREMHFWLYHV
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A common 80G>A (R27H) polymorphism has been described in the RFC1 gene, which is 
thought to affect carrier function. Whetstine and co-workers convincingly showed that this 
polymorphism had no effect on MTX and N5-formylTHF uptake in vitro 108, which is supported 
by epidemiological data showing no effect of this polymorphism on folate and tHcy in renal 
patients 109 or mothers with NTD-offspring 107. However, Chango et al. found a trend towards 
higher tHcy in 80GG individuals, which increased, and inversely affected RBC folate, when 
the MTHFR 677TT genotype was taken into account 110.
The human FR family includes several glycoproteins (D - G) involved in the binding and 
internalization of 5-CH3THF. The FRD and E isoforms are membrane proteins, the FRJ
isoform is cytoplasmic and recently a FRG isoform with a restricted expression profile has 
been reported 111. Mutation-screening studies by our group and others have failed to identify 
common polymorphisms within the FRD or E gene 112,113, although some low frequency 
polymorphisms have been reported 114,115. O’Leary and colleagues also screened the FRE
gene and identified one polymorphism but did not assess the effect on folate and tHcy 116. In 
1998, Wang et al. found the FRJ gene to be polymorphic due to a two-basepair deletion, 
resulting in a truncated protein (denoted FRJ’) 117. No reports concerning genetic variation in 
the FRG 111 gene in relation to homocysteine have been published. 
7UDQVFREDODPLQ
TCII, encoded by the transcobalamin (TCN) gene, is one of the three vitamin B12- binding 
proteins in humans, next to haptocorrin (binds B12 in stomach and blood) and intrinsic factor 
(binds B12 in intestine). Intestinal absorption of vitamin B12 is facilitated by an endocytotic 
process involving the intrinsic factor-B12 receptor (i.e. cubulin 118). In the blood, only vitamin 
B12 bound to TCII (holo-TCII, 10-20%) is available for cellular uptake. The remaining 80 to 
90% of circulating vitamin B12 is bound to HC, which functions as an alternative buffer for 
this vitamin in addition to storage in the liver. Holo-TCII is therefore said to be a better 
indicator of vitamin B12 status than total plasma vitamin B12.  
By sequencing the TCN gene from mothers with NTD-offspring, we identified several 
polymorphisms including a 776C>G (P259R) transition which decreased holo-, apo- and/or 
total-TCII levels, possibly resulting from reduced B12 binding 119 120-125. We observed a trend 
toward increased tHcy levels 119, whereas Namour et al. found that heterozygosity for this 
variant was associated with significantly higher tHcy compared with both homozygous 
genotypes 124. Several other rare polymorphisms in the TCN gene have been reported by our 
group, such as 67A>G (I23V), 280G>A (G94S), 1043C>T (S348F) and 1196G>A (R399Q) 
119. Although we observed effects for some of these polymorphisms on TCII levels 119 only 
the 23VV genotype was associated with slightly reduced (p=0.05) tHcy levels 121.
6HULQHK\GUR[\PHWK\OWUDQVIHUDVH
SHMT catalyses the reversible transfer of the hydroxymethyl group of serine to THF to form 
5,10-methyleneTHF and glycine. The enzyme is present in two isoforms, a mitochondrial 
(mSHMT) and cytoplasmic (cSHMT) form, and is thought to regulate the metabolic 
competition between the MTHFR and TYMS enzymes 126. There is also indirect evidence 
that mSHMT synthesizes glycine while cSHMT may catalyze serine synthesis 127. In 2001, 
*HQHUDOLQWURGXFWLRQDQGREMHFWLYHV
- 21 - 
we performed single-strand conformation polymorphism (SSCP) analysis on DNA from 70 
cases with a NTD to identify genetic variation within both SHMT genes 128. Several variants 
were found including a 1420C>T transition in cSHMT and a 4-bp deletion in the 3’ 
untranslated region (UTR) of the mSHMT gene (delTCTT 1721-1724). No effects of these 
two polymorphisms on tHcy were observed in the general Dutch population, although 
mothers of children with a neural tube defect with the 1420CC genotype had significant 
higher fasting tHcy, which was also reflected in a lower red blood cell and plasma folate 128.
Geisel et al. did not find an effect of the 1420C>T variant on tHcy in elderly individuals 129.

%HWDLQHKRPRF\VWHLQHPHWK\OWUDQVIHUDVH
BHMT, predominantly expressed in the liver and kidneys, catalyzes the alternative 
remethylation route of homocysteine by using betaine as methyldonor. Its importance is 
demonstrated by the fact that betaine treatment significantly reduces tHcy in homocystinuric 
patients and healthy volunteers 130. In addition, the product of the BHMT reaction, 
dimethylglycine, is converted to sarcosine and further oxidized to glycine, introducing one-
carbon units into the folate pool that may be used in folate-dependent remethylation of 
homocysteine. In 2000, we sequenced the BHMT gene of 16 hyperhomocysteinemic 
vascular disease patients and reported several variants in the coding region of this gene 131.
Two of them, i.e. 595G>A and 716G>A, were assessed for their effect on tHcy. However, 
these polymorphisms had no effect on fasting and post-load tHcy levels 131. Recently, 
Weisberg and colleagues reported that the 716G>A transition had no effect on the binding 
properties of BHMT for betaine and did not affect tHcy in vascular disease patients 132.
0HWK\OHQHWHWUDK\GURIRODWHGHK\GURJHQDVH
MTHFD is a trifunctional enzyme that catalyses three sequential reactions in the 
interconversion of one-carbon derivatives of THF (i.e. 10-formyl, 5,10-methenyl, and 5,10-
methyleneTHF). We screened the MTHFD cDNA of 117 NTD cases for the presence of 
mutations by SSCP analysis and identified two common amino acid substitutions, i.e. R293H 
and R653Q 133. However, no effect on tHcy was observed in our study 133 and in two other 
studies the effect on tHcy was not assessed 134,135. The effect of these polymorphisms on 
folate distribution and tHcy needs to be further evaluated.  
'LK\GURIRODWHUHGXFWDVHDQGWK\PLG\ODWHV\QWKDVH
DHFR is an essential enzyme in the human body as it reduces folic acid to dihydrofolate 
(DHF) and DHF to THF, with the latter serving as a substrate for 5,10-methyleneTHF 
synthesis. Theoretically, reduced DHFR activity may deplete THF leading to 
hyperhomocysteinemia. Kishi et al. reported that high-dose MTX, targeting DHFR but also 
other folate enzymes, induced a transient increase in tHcy 136.  Recently, a 19-bp deletion 
variant was described in intron 1 of the DHFR gene thereby removing a potential Sp1 
transcription factor-binding site 137. However, the effect on tHcy was not assessed, and 
additional studies are warranted. 
TYMS catalyzes the reductive methylation of deoxyuridine monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP), a pyrimidine precursor, and competes with MTHFR 
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for the one-carbon unit of 5,10-methyleneTHF. Therefore, polymorphisms in these enzymes 
are potential determinants of tHcy. Two common polymorphisms have been described in the 
TYMS gene, i.e. a 28-bp repeat in the 5’ UTR (yielding the common genotypes 2/2, 2/3 and 
3/3) 138 and a 6bp deletion in the 3’ UTR (denoted 1494del6) 139. The 3-repeat allele is 
associated with enhanced translation efficiency 140 but not gene expression 141. Several 
groups studied the effect of the 28-bp repeat on tHcy. Trinh et al. found reduced plasma 
folate and increased tHcy in the Chinese population for TYMS 28-bp repeat 3/3 individuals, 
an effect that became more pronounced when the MTHFR 677TT genotype was taken into 
account 142. In contrast, others did not find an effect on tHcy nor on plasma folate 129,143.
The 1494del6 variant was identified by in silico screening of expressed sequence tags 139.
The deletion is said to cause mRNA instability in vitro and decreases mRNA levels 
intratumorally 144, but no studies regarding the effect of this polymorphism on tHcy have been 
reported.

 *HQHVLQYROYHGLQKRPRF\VWHLQHGHJUDGDWLRQ
&\VWDWKLRQLQHEV\QWKDVH
CBS catalyzes the first step in the transsulfuration pathway  (i.e. the condensation of 
homocysteine and serine to form cystathionine). Deficiency for this enzyme results in 
classical homocystinuria, and is in many cases caused by the 833C>T mutation. 
Transsulfuration is the only way to dispose homocysteine from the body. The enzyme is 
predominantly expressed in the liver and kidneys and hence important in the clearance of 
tHcy originating from peripheral tissues. The CBS gene harbors many polymorphisms, 
including a common 68 bp insertion (844ins61) 145, a 31-bp variable number of tandem 
repeats (14037 31-bp VNTR), a GT short tandem repeat (-5707 GT STR) and single-
nucleotide polymorphisms like 1080C>T (A360A) and 699C>T (Y233Y) 146.
The 31 bp VNTR was first identified by Kraus et al. 146 and further characterized in our 
laboratory 147. The repeat consists of 15 to 21 repeats, the 18 repeat being the most common 
146-148. Because it is located at the exon 13-intron 13 boundary the repeat can, theoretically, 
create multiple alternate splice sites 148. We were able to show that the repeat results in 
alternative splicing and reduces CBS activity in extracts of cultured fibroblasts 147. We also 
demonstrated that a higher repeat-length increased tHcy, in particular after methionine 
loading, by about 10% (18/18 vs. 17/17 genotype). In addition, we found that individuals 
homozygous for the 18 repeat had higher tHcy than their 17-18 and 17-19 peers when the 
MTHFR 677TT genotype was taken into account 149. However, Yang et al. observed 
significantly decreased tHcy levels in individuals carrying the 16-17 and 17-18 genotype 
when compared to 17-17 individuals 148.
In 1996 a 68 bp insertion (844ins68 bp), located at the junction of intron 7-exon 8 of the CBS 
gene, was described in American and European populations 145,150,151. The insertion is 
surprisingly common in some 150,151, but not all 152, populations, with a frequency ranging from 
less than 1% up to about 17%. No effect of this insertion on fasting or post-load tHcy was 
observed in North Americans or young Irish adults 47,150, but DeStefano et al. showed that 
heterozygosity for this variant abolished the tHcy-increasing effect of the MTHFR 677TT 
genotype 153. Another group observed increased post-load tHcy in heterozygous individuals 
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85, especially when vitamin B6 (<38 nmol/L) was low 154, whereas we found decreased fasting 
and post-methionine load tHcy in Dutch individuals carrying the mutant allele 155. The 
844ins68 bp variant was found in cis with the pathogenic 833T>C mutation. The in cis double 
mutation appeared not to be pathogenic since the splicing of intron 7 eliminates both the 
insertion and the pathogenic 833T>C mutation, leaving a normal mRNA 150,155.
A GT-dinucleotide STR has been identified upstream of the –1a promoter region of the CBS 
gene (position -5707 bp) displaying between 14 and 20 repeats 146,156, the 16 repeat being 
the most common. No data on the effect of this repeat on CBS expression is available, but 
we could not reveal an association of this STR with fasting or post-load tHcy in the Dutch 
population 156.
Two silent mutations, i.e. 699C>T and 1080C>T, have been studied for their effect on tHcy. 
Most studies did not reveal an association of these two polymorphisms with fasting tHcy 
153,157 and post-load tHcy 156 although Aras et al. did find an effect of the 699C>T variant, 
though only on post-load tHcy values in cardiovascular disease patients. This lowering effect 
of the 699TT genotype on tHcy became more pronounced when individuals carrying the CBS 
844ins68 bp and the CBS 1080T allele were excluded from the analyses. They observed a 
similar effect for the 1080C>T variant in which 1080TT individuals had lower post-load tHcy 
levels, but only after excluding individuals with the 844ins68 bp variant and 699T allele 158.
&\VWDWKLRQLQHJO\DVH
Very recently, Wang et al. reported a 1364G>T polymorphism (S403I) in the CTH gene, 
encoding the second enzyme in the homocysteine transsulfuration pathway.  They found that 
1364TT individuals had significantly higher tHcy compared to their wild type peers 159.
 *HQHVLQYROYHGLQKRPRF\VWHLQHIRUPDWLRQ
&DWHFKRO2PHWK\OWUDQVIHUDVH
Transmethylation is essential to cellular function and the activity of methyltransferases is the 
only mechanism for homocysteine synthesis. Goodman and colleagues reported a common 
polymorphism (i.e. 324 G>A, Val108Met) in the COMT gene resulting in reduced enzyme 
activity 160. COMT is involved in methylation of catecholamines (inactivation) and uses 
AdoMet as a methyldonor. COMT transcripts originate from one gene but two distinct 
promoters regulate its expression. This results in a short transcript (soluble form) and a long 
transcript (membrane-bound form) of the COMT enzyme, both containing the 324G>A 
transition. Homozygosity for the mutant allele (also denoted as the low activity allele) resulted 
in lower tHcy compared to their wild type peers 160. Another group could not confirm these 
observations in a group of elderly subjects and vegetarians 129.
In conclusion, although a large number of polymorphisms in genes involved in homocysteine, 
folate, and cobalamin metabolism have been identified and assessed for their effects on tHcy 
(see Table 1), the MTHFR 677C>T polymorphism is by far the strongest genetic determinant 
of tHcy in the general population. This leaves part of the genetic contribution in the variation 
of tHcy unexplained, which is the rationale to continue the search for determinants of tHcy as 
described in this thesis. 
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 2EMHFWLYHVDQGRXWOLQHRIWKLVWKHVLV
The genetic contribution to the variation in homocysteine levels (heritability) is only partly 
explained. The main goal (Part I) of this thesis was to identify novel genetic determinants of 
tHcy in the general population, and especially those that are also associated with a higher 
risk of disease. In this thesis we focused on recurrent venous thrombosis. The identification 
of determinants of tHcy will also provide information about the pathways and, hence, 
pathophysiological mechanisms involved in homocysteine-related diseases. The second goal 
(Part II) was to develop the tools for exploring the role of disturbed transmethylation in 
homocysteine-related pathology. A detailed knowledge of the pathophysiological processes 
initiated by high homocysteine may lead to new therapies, other than folic acid and B-vitamin 
supplementation, as a means to lower homocysteine levels in healthy subjects and patients 
in order to prevent or treat hyperhomocysteinemia and its related diseases.
Part I of this thesis describes the search for novel genetic determinants of tHcy. Because the 
folate cycle plays an essential role in homocysteine remethylation we focused on variation in 
genes encoding folate-converting enzymes as potential determinants of homocysteine. 
These studies are described in Chapters 2 to 4. In Chapter 2 we studied common variants in 
genes encoding homocysteine remethylation enzymes (methionine synthase and methionine 
synthase reductase) and their relation to venous thrombosis risk, tHcy and serum folate. 
Given the importance of vitamin B12 in homocysteine remethylation we also assessed 
vitamin B12 status in relation to venous thrombosis. In Chapter 3 we describe the molecular 
genetic analysis of the dihydrofolate reductase gene and the effect of newly identified 
variants on tHcy, serum and red blood cell folate. The effect of common variants in three 
enzymes of folate metabolism (thymidylate synthase, reduced folate carrier and AICAR 
transformylase/IMP cyclohydrolase) on tHcy and venous thrombosis risk is shown in 
Chapter 4. There is accumulating evidence that disturbed transmethylation may partly 
explain hyperhomocysteinemia-related pathology. Therefore, we also studied polymorphisms 
in genes involved in transmethylation processes, and their association with tHcy levels and 
disease (Chapters 5 to 8). In Chapter 5 we describe the molecular genetic analysis of the S-
adenosylhomocysteine hydrolase gene and investigated the effect of newly identified 
variants on tHcy levels and venous thrombosis risk. In Chapter 6 we performed haplotype 
analysis in order to examine the role of catechol-O-methyltransferase in 
hyperhomocysteinemia and risk for venous thrombosis.  
Part II of this thesis describes the studies that were performed to enable the investigation of 
a disturbed homocysteine metabolism in relation to transmethylation. In response to the 
increasing interest in transmethylation parameters for research and (future) diagnostic 
purposes we developed a method for the determination of AdoMet and AdoHcy in plasma 
and other body fluids, which is described in Chapter 7. Because elevated homocysteine is 
thought to affect transmethylation reactions, we aimed to investigate protein methylation in 
cultured human umbilical vein endothelial cells (HUVECs). The preliminary results of these 
experiments are described in Chapter 8.
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
$EVWUDFW
Some studies have shown that a decreased vitamin B12 level is associated with a higher risk 
of venous thrombosis, independent of its relation with homocysteine. Variation in genes 
involved in cobalamin metabolism and/or redox status, e.g. methionine synthase (MTR) and 
methionine synthase reductase (MTRR), may modulate cellular processes and predispose to 
vascular disease as well. We examined whether low vitamin B12 status and genetic variants 
in the MTR and MTRR genes were associated with disease risk in a case-control study on 
recurrent venous thrombosis. We measured vitamin B12, methylmalonic acid (MMA), plasma 
total homocysteine (tHcy) and folate and screened for the MTR 2756A>G and MTRR 66A>G 
variants in cases and controls. High plasma MMA (>0.24 Pmol/L), but not low plasma vitamin 
B12 (<156 pmol/L), was suggestive for an increased risk of recurrent venous thrombosis 
(crude odds ratio 1.44 (95% CI 0.96 to 2.17, p=0.07). The risk estimate for the top (>0.24 
Pmol/L) versus bottom quintile (<0.13 Pmol/L) was 2.10 (95% CI 1.21 to 3.57; p=0.03). An 
interaction for MMA above the 80th percentile of the control range and the MTRR 66GG 
genotype was observed, increasing the risk of venous thrombosis five times (crude odds 
ratio 5.4 [95% CI 1.3 to 21.6], p=0.02). Our results suggest that high plasma MMA, indicative 
of low intracellular vitamin B12 status, may increase the risk of recurrent venous thrombosis, 
especially in combination with the MTRR 66GG genotype. 
&KDSWHU
- 30 -
,QWURGXFWLRQ
Venous thrombosis is a complex disease that involves both genetic and environmental 
factors. Hyperhomocysteinemia is an established risk factor for cardiovascular disease, 
including venous thrombosis 18,19. Several B-vitamins (such as B6, B12 and folate) are 
essential for homocysteine metabolism but recent studies suggest that low 5-
methyltetrahydrofolate or vitamin B6 increases thrombosis risk, independent of homocysteine 
161,162. Some studies 163-167, but not all 168, show that low plasma vitamin B12 increases the 
risk of thrombosis as well. Vitamin B12 (cobalamin) is cofactor in two metabolic pathways 
either as adenosylcobalamin (AdoCbl) or methylcobalamin (MeCbl). AdoCbl is a cofactor of 
methylmalonyl-CoA mutase, an enzyme that converts methylmalonyl-CoA into succinyl-CoA, 
whereas MeCbl is a cofactor in the remethylation of homocysteine. Plasma vitamin B12 
levels do not always reflect vitamin B12 status, because only the fraction bound to 
transcobalamin (about 10-20%) is available for cellular uptake. In that respect, plasma 
methylmalonic acid (MMA) is regarded a sensitive indicator of intracellular vitamin B12 status 
169 and shows a positive correlation with plasma total homocysteine levels (tHcy) 170. Given 
the multifactorial nature of cardiovascular diseases, variation in genes affecting the function 
of the encoded enzymes that need vitamin B12 as a cofactor (such as methionine synthase, 
MTR) or maintain cobalamin redox status (such as methionine synthase reductase, MTRR) 
may further increase disease risk, in addition to suboptimal vitamin B12 levels. In the past 
decade, polymorphisms in MTR (c.2756A>G, D919G) and MTRR (c.66A>G, I22M) have 
been described 82,93. MTR catalyzes the remethylation of homocysteine by 5-
methyltetrahydrofolate to methionine in which cobalamin serves as an intermediate methyl 
carrier. Oxidation of cobalamin, however, inactivates the MTR-cobalamin enzyme complex 
and needs reactivation by MTRR 88 (Figure 3). Both polymorphisms have been studied as a 
possible risk factor for cardiovascular diseases 83,84,87,95,96,171-174, although data are not 
consistent.  










In this study we examined plasma vitamin B12 and MMA as a risk factor for recurrent venous 
thrombosis. The MTRR 66A>G and MTR 2756A>G polymorphisms were assessed as 
Figure 3. Role of methionine synthase reductase
(MTRR) and the methionine synthase (MTR)-cobalamin
complex in homocysteine remethylation. Homocysteine
is remethylated by the MTR-cob(III)alamin enzyme
complex. Occasionally, cob(I)alamin is oxidized to
cob(II)alamin thereby inactivating the enzyme complex.
MTRR catalyzes the reductive methylation of cob(II)alamin
to methylcob(III)alamin thus rendering MTR into the active
cycle. Co: cobalamin AdoHcy: S-adenosylhomocysteine,
AdoMet: S-adenosylmethionine, NADPH: reduced
nicotinamide adenine dinucleotide phosphate, (CH3)THF:
(methyl)tetrahydrofolate 
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genetic risk factors for venous thrombosis as well. We also studied the effect of both genetic 
variants on tHcy, folate, MMA and vitamin B12. 

0DWHULDODQG0HWKRGV
3DWLHQWVDQGFRQWUROV
We used data and DNA samples of a case-control study including 185 recurrent venous 
thrombosis patients and 500 control subjects. Patients were selected from the files of the 
anticoagulant clinic of The Hague and are described in more detail elsewhere 6. In the 
Netherlands, virtually all patients with a history of recurrent venous thrombosis have long-
term coumarin therapy and are registered at an anticoagulant clinic. It has been shown that 
coumarin therapy does not influence tHcy 175. All patients between 20 and 90 years old, who 
had two or more episodes of venous thrombosis (ratio pulmonary embolism / deep-vein 
thrombosis is 1:1.5), were invited to take part and 185 patients were enrolled in this study. 
The control group was recruited via a general practice in The Hague 6. We obtained a short 
medical history of all patients by interview and of all controls by questionnaire. DNA for 
genotyping was available from 178 patients and 446 population-based controls from whom 
relevant biochemical data had already been obtained 6. Factor V Leiden and prothrombin 
20210G>A mutation analysis has been described previously 176. The medical ethics 
committee approved the study protocol and informed consent was obtained from all study 
participants.  
%LRFKHPLFDOSDUDPHWHUV
Blood samples were drawn from the antecubital vein in 5 mL Vacutainer tubes and 4.5 mL 
EDTA vacuum glass tubes for determination of plasma vitamin B12, MMA, tHcy and folate, 
and for DNA extraction. EDTA samples for plasma total homocysteine (tHcy) measurement 
were placed on ice immediately and centrifuged at 3500 g for 5 minutes with minimal delay. 
The plasma was separated and stored at -20 ºC until analysis. Plasma MMA levels were 
measured, using HPLC combined with electrospray ionization tandem mass spectrometry 
(LC-ESI-MS/MS). The LC-ESI-MS/MS system consists of a Quattro LC (Waters Corporate, 
Milford, MA) connected to an HP1100 HPLC (Agilent Technologies, Palo Alto, CA) and a 232 
XL autosampler (Gilson, Middleton, WI). Hundred ȝl of plasma together with 100 ȝl of 0.8 ȝM
stable isotope-labeled methyl-d3-malonic acid (MMA-d3) (Cambridge Isotope Laboratories, 
Andover, MA) as an internal standard, was deproteinized using ultra filtration (Microcon 
YM30 filter, cut-off value 30 kDa, Millipore). Subsequently, 20 Pl 1M formic acid was added to 
150 Pl of the ultra filtrate and was injected onto a Waters Symmetry column (2.1mmX100mm 
3.5 μM). The mobile phase consisted of 15% Methanol / 0.3% formic acid and is eluted at 
200 μl/min. Thereafter, 10 Pl was analysed by tandem MS monitoring the carbonyl loss of 
MMA and MMA-d3; recording the transition of m/z 117 to m/z 73 and m/z 120 to m/z 76, 
respectively. This method was compared with an established LC-MS/MS method as 
published by Schneede et al. 177. Deming linear regression formula (MMA range 0.10 to 1.60 
Pmol/L) Y = 1.013 (r0.011) X – 0.0218 (r0.0038), confidence interval of the slope 0.9919 to 
1.035 (n=125). Within- and between-day coefficients of variation were below 6%, and the 
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limit of quantitation is 100 nmol/L. tHcy was measured using an automated high-performance 
liquid chromatography method with reverse phase separation and fluorescent detection 
(Gilson 232-401 sample processor, Spectra Physics 8800 solvent delivery system and LC 
304 fluorometer), as described earlier 178. Vitamin B12 and folate concentrations were 
measured with the Dualcount Solid Phase No Boil Radioassay (Diagnostic Product 
Corporation, Los Angeles, CA, USA). DNA extraction was performed as described previously 
179 and was stored at 4 ºC. 
0755$!*DQG075$!*JHQRW\SLQJ
Since the MTRR 66A>G (I22M) polymorphism does not create or abolish a restriction site we 
used a PCR-heteroduplex generator (HG)-based technology to screen for this polymorphism, 
essentially as described earlier 91,180. In short, a HG is a DNA molecule that is identical to a 
short sequence flanking the site of interest, except for a microdeletion close to the 
polymorphic site. This HG and the DNA under test are amplified and diluted 1:1. After a 
denaturation and reannealing step homoduplexes and heteroduplexes are generated. These 
products have a characteristic migration pattern on a polyacrylamide gel due to their 
differently-sized protruding loops. The HG used for MTRR 66A>G genotyping was 
synthesized by PCR-mediated site-specific mutagenesis (using the A allele as a template). A 
3 bp deletion was introduced 3 bp downstream of the polymorphic site and the HG was 
cloned into the pGEM-T Easy vector (Promega, WI, USA), resulting in plasmid 
pMTRR66A>G. Positive clones were identified by sequence analysis and served as a 
positive control in every experiment. The primers MTRR1 (fw 5’-
GAGGAGGTTTCTGTTACTATATGC-3’) and MTRR4 (rv 5’-
GTGAAGATCTGCAGAAAATCCATGTA-3’) were used to amplify HG and genomic DNA 
separately under the following PCR conditions: an initial denaturation step for 5 minutes at 
94ºC; 35 cycles of 1 minute at 95ºC, 1 minute at 55ºC and 30 seconds at 72ºC followed by a 
final extension for 7 minutes at 72ºC. PCR amplifications were performed in a total volume of 
50 PL in an iCycler (Biorad, The Netherlands); each mixture contained 50 nmol/L of both the 
forward and reverse primer (Biolegio BV, Malden, The Netherlands), 200 PM dNTPs, 10 mM 
Tris-HCl buffer (pH 8.2), 50 mM KCl, 2.0 mM MgCl2, 0.5 U of recombinant Taq polymerase, 
5% DMSO (all from Invitrogen, The Netherlands) and 75 ng genomic DNA or 1 pg HG. To 
facilitate heteroduplex formation both PCR products were mixed (1:1), followed by 
denaturation for 5 minutes at 95ºC and allowed to re-anneal upon cooling to room 
temperature.
Figure 4. Migration pattern of positive controls for the MTRR
66 A>G polymorphism analysed by the heteroduplex
generator method The primers were designed to amplify
fragments of 103 and 106 bp from pMTRR66A>G and genomic
DNA, respectively. Reannealing of both products results in duplex
formation and hence an allele-specific migration pattern is
established. In this case, the A and G alleles are identified by
heteroduplexes that migrate as a 130 bp or 120 bp dsDNA
fragment, respectively. The lower bands at a100 bp are
homoduplexes and the upper bands are non-specific
heteroduplexes. The position of the molecular weight marker is
shown on the left. 
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The products (diluted 1:1 with loading buffer; 2.5 g/L bromophenol blue, 0.36 v/v 87% 
glycerol and 10 mM Tris-HCl, pH 9.2) were analysed by electrophoresis on 17% 
polyacrylamide (19:1) gels at 150 V for 5-6 hours. To identify the MTRR 66A>G genotypes, 
the gels were stained with ethidium bromide (20 mg/L) and illuminated using UV-light (Figure 
4). The MTR 2756A>G polymorphism was assayed as described earlier 82. MTR 2756A>G 
genotype data was not available for six controls and five cases. 

6WDWLVWLFV
Odds ratios and 95% confidence intervals were calculated to estimate the relative risk for 
venous thrombosis conferred by MMA and plasma B12 levels or genotypes using logistic 
regression analysis. Logistic regression analysis was also used to study interactions and 
linear regression analysis was applied to assess differences in (log-transformed) metabolite 
concentrations between different genotypes. A two-tailed p<0.05 was accepted as 
statistically significant. For all analyses SPSS 12.0 for Windows was used. 

5HVXOWV
3ODVPDYLWDPLQ%DQG00$OHYHOVLQFDVHVDQGFRQWUROV
The baseline characteristics of our study populations are presented in Table 2. Mean plasma 
vitamin B12 level (95% CI) was 228 (210 to 246) pmol/L and 218 (210 to 230) pmol/L for 
cases and controls, respectively (p=0.17). We stratified plasma vitamin B12 levels of both 
cases and controls into quintiles and calculated the relative risk for each stratum compared 
with the top quintile (Table 3). Plasma vitamin B12 concentrations were not related to 
recurrent venous thrombosis risk.  The crude relative risk for recurrent venous thrombosis at 
plasma vitamin B12 below the 20th percentile (156 pmol/L) of the control distribution was 
1.12 (95% CI 0.72 to 1.73) (Table 4).  
Table 2. Baseline characteristics of recurrent venous thrombosis cases and population-based controls 
Variable Cases (n=185) Controls (n=500) p value 
Age (range) 61 (21 to 81) 51 (23 to 87) <0.01 
Sex (men, %) 94 (50.8) 208 (41.6) 0.03 
Factor V Leiden (MAF, %a) 14.6 3.3 <0.01 
Prothrombin G20210A (MAF, %a) 2.9 1.6 0.12 
Post-menopausal women, n (%) 64 (34.6) 138 (27.6) <0.01 
Time between 1st event and study 17 (range 1 to 58) y -  
Time between last event and study 7 (range 1 to 30) y -  
Creatinine (Pmol/L) 82.4 (77.9 to 86.6) 74.0 (72.4 to 75.7) <0.01 
tHcy (Pmol/L) 12.4 (11.5 to 13.3) 10.4 (10.0 to 10.8) <0.01 
Plasma folate (nmol/L) 13.0 (12.2 to 13.7) 13.8 (12.5 to 15.0) 0.25 
a MAF, minor allele frequency
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Mean plasma MMA levels (95% CI) were higher in cases than controls [0.20 (0.18 to 0.22) 
Pmol/L and 0.18 (0.17 to 0.19) Pmol/L respectively, p=0.03]. Stratification of MMA level into 
quintiles showed that the risk estimates increased with MMA concentration (p-trend=0.11, 
Table 3). The relative risk for recurrent venous thrombosis was 2.10 (95% CI 1.21 to 3.57, 
p=0.03) for subjects in the top quintile, using the bottom quintile as a reference. The crude 
relative risk for subjects with a plasma MMA level above versus below the 80th percentile 
(0.24 Pmol/L) was 1.44 (95% CI 0.96 to 2.17, p=0.07) (Table 4).  
Adjustment for possible confounders like age, sex, creatinine, or other risk factors of venous 
thrombosis, such as the factor V Leiden and Prothrombin 20210G>A mutation and 
menopausal status did not affect the risk estimates (Table 4). In addition, exclusion of factor 
V Leiden and prothrombin 20210G>A mutation carriers yielded an odds ratio of 1.69 (95% CI 
1.05 to 2.73, p=0.03) (not shown).  
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075DQG0755JHQRW\SHVDQGDVVRFLDWHGUHFXUUHQWYHQRXVWKURPERVLVULVN
The genotype distributions of both the MTR 2756 A>G and MTRR 66A>G polymorphisms in 
the control population were in Hardy-Weinberg equilibrium (P>0.75) and similar in cases and 
controls (Pearson’s F2, p=0.85 and p=0.52, respectively). MTR 2756GG, GA and AA 
genotype frequencies were 70.7 (n=118), 27.5 (n=46) and 1.8% (n=3) for cases and 72.3 
Table 3. Recurrent venous thrombosis (RVT) risk for each quintile of plasma vitamin B12 and MMA
Variable Percentile Cut-off value RVT Patients, n Controls, n OR (95% CI) p value 
Vitamin B12 0 – 20 < 156 33 98 1.48 (0.88 to 2.50) 0.14 
 20 – 40 157 – 194 26 101 1.26 (0.74 to 2.15) 0.39 
 40 – 60 195 – 239 32 99 0.96 (0.55 to 1.68) 0.89 
 60 – 80 240 – 315 43 101 0.76 (0.43 to 1.37) 0.37 
 80 – 100 > 316  50 100 1.0a - 
MMA 0 – 20 < 0.13 29 122 1.0a - 
 20 – 40 0.13 – 0.16 43 115 1.57 (0.92 to 2.69) 0.10 
 40 – 60 0.16 – 0.19 36 93 1.63 (0.93 to 2.85) 0.09 
 60 – 80 0.19 – 0.24 30 73 1.73 (0.96 to 3.11) 0.07 
 80 – 100 > 0.24 45 91 2.10 (1.21 to 3.57) 0.008 
a reference category
Table 4. Odds ratios (OR) of recurrent venous thrombosis (RVT) associated with low plasma vitamin B12 or high 
plasma MMA level 
Variable Cut-off value RVT Patients 
n (%) 
Controls
n (%) 
Crude odds ratio 
(95% CI) 
Odds ratio
(95% CI) b
Odds ratio 
(95% CI) c
Vitamin B12 <156 pmol/L 33 (17.9) 98 (19.6) 0.89 (0.58 to 1.38) 0.88 (0.57 to 1.37) 1.11 (0.52 to 2.38) 
 >156 pmol/L 151 (82.1) 401 (80.4) 1.0a 1.0a 1.0a
    P=0.62  p=0.58 p=0.79 
MMA <0.24 Pmol/L 138 (74.6) 403 (80.6) 1.0a 1.0a 1.0a
 >0.24 Pmol/L 45 (24.3)  91 (18.2) 1.44 (0.96 to 2.17) 1.49 (0.98 to 2.25) 1.65 (0.80 to 3.42) 
    p=0.07 p=0.06 p=0.17 
a reference category, b risk estimates were adjusted for age, sex and creatinine, c risk estimates were adjusted for age, sex, 
creatinine, menopausal status, factor V Leiden and prothrombin 20210G>A mutations
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(n=318), 25.7 (n=113) and 2.0% (n=9) for controls, respectively. The odds ratio for MTR 
2756GG individuals compared to 2756AA individuals for venous thrombosis was 0.87 (95% 
CI 0.23 to 3.26). MTRR 66AA, AG and GG genotype frequencies were 19.1 (n=34), 44.4 
(n=79) and 36.5% (n=65) for cases and 19.1 (n=85), 48.9 (n=218) and 32.1% (n=143), 
respectively (odds ratio 1.14 [95% CI 0.69 to 1.86] for MTRR 66GG compared with 66AA 
subjects). In addition, compound genotypes of MTR and MTRR variants did not affect risk of 
disease (not shown). 

,QWHUDFWLRQEHWZHHQSODVPD00$DQG0755JHQRW\SH
Because the cobalamin-MTR complex is reductively methylated by the MTRR enzyme, we 
assessed whether the MTR 2756A>G or MTRR 66A>G polymorphisms modified the effect of 
vitamin B12 status on disease risk. We observed an interaction between the MTRR 
genotype and high MMA levels. The adjusted odds ratios for recurrent venous thrombosis in 
subjects with the MTRR 66AG or 66GG genotype and high MMA (>80th percentile) were 2.4 
(95% CI 0.6 to 9.5, p=0.18) and 5.1 (95% CI 1.3 to 20.5, p=0.03) (Table 5). No such 
association was observed for low plasma vitamin B12 and MTRR genotype. In addition, no 
interaction between high MMA (Table 5) or low vitamin B12 and MTR 2756A>G genotype on 
disease risk was observed. 
$VVRFLDWLRQEHWZHHQ075DQG0755YDULDQWVDQGPHWDEROLWHV
The separate effects of the MTR 2756A>G and MTRR 66A>G genotypes on tHcy, vitamin 
B12, MMA and folate in our control group are shown in Table 6. No evident effects of the two 
polymorphisms on tHcy, MMA and folate were observed. MTR 2756GG subjects had a 
decreased plasma vitamin B12 (-30%, p=0.007) compared to the 2756AA genotype, but this 
was not reflected in plasma MMA or tHcy levels. Creatinine levels were similar for the 
different genotypes in cases and controls (p-ANOVA=0.40 and 0.80 for the MTR and MTRR 
variant, respectively). In addition, low vitamin B12 status (B12 <156 pmol/L or MMA >0.24 
Pmol/L) did not affect tHcy in the different genotype groups defined by the MTRR and MTR 
variants (not shown). 
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Table 5. Interaction analysis for recurrent venous throm
bosis (R
VT) risk 
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 (>0.24 Pm
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C
ontrols, n 
C
rude O
R
 (95%
 C
I) 
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TR
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 66A
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A
A
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28 
69 
1.0 c 
- 
1.0 c 
- 
 
A
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61 
176 
0.85 (0.50 to 1.45) 
0.56 
0.74 (0.42 to 1.30) 
0.29 
 
G
G
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o 
44 
116 
0.94 (0.53 to 1.64) 
0.81 
0.80 (0.44 to 1.46) 
0.47 
 
A
A
 
Yes 
5 
16 
0.77 (0.26 to 2.30) 
0.64 
0.38 (0.12 to 1.24) 
0.11 
 
A
G
 
Yes 
17 
38 
1.68 (0.47 to 5.97) 
0.43 
2.43 (0.62 to 9.47) 
0.20 
 
G
G
 
Yes 
21 
25 
2.88 (0.79 to 10.42) 
0.10 
5.12 (1.28 to 20.45) 
0.02 
M
TR
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>G
 
A
A
 
N
o 
94 
264 
1.0
 c 
- 
1.0
 c 
- 
 
A
G
 
N
o 
32 
87 
1.0 (0.65 to 1.65) 
0.89 
1.01 (0.61 to 1.68) 
0.96 
 
G
G
 
N
o 
2 
7 
0.80 (0.16 to 3.93) 
0.79 
1.17 (0.23 to 5.92) 
0.85 
 
A
A
 
Yes 
26 
49 
1.49 (0.88 to 2.53) 
0.14 
1.15 (0.64 to 2.04) 
0.65 
 
A
G
 
Yes 
16 
25 
1.17 (0.47 to 2.92) 
0.74 
1.08 (0.40 to 2.92) 
0.88 
 
G
G
 
Yes 
1 
2 
1.17 (0.06 to 21.72) 
0.91 
1.60 (0.08 to 31.42) 
0.76 
aM
M
A
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ol/L corresponds w
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djusted for age, sex and creatinine, cR
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M
A
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 of the corresponding m
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M
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 66A
>G
 genotype 
M
TR
 2756A
>G
 genotype 
M
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plasm
a level 
66A
A
 (n=85) 
66A
G
 (n=218) 
66G
G
 (n=143) 
2756A
A
 (n=318) 
2756A
G
 (n=113) 
2756G
G
 (n=9) 
 tH
cy Pm
ol/L [95%
 C
I] 
10.3 [9.5 to 11.2] 
10.2 [9.3 to 11.2] 
10.9 [9.8 to 12.0] 
10.4 [10.0 to 10.9] 
10.2 [9.4 to 11.1] 
10.5 [8.1 to 13.5] 
R
elative change (95%
 C
I) 
0
a 
-1.2 %
 (-10.2 to 8.8) 
5.1 %
 (-5.2 to 16.5) 
0
a 
-2.5 %
 (-10.3 to 5.9) 
0.2 %
 (-22.2 to 29.3) 
V
itam
in B
12 pm
ol/L [95%
 C
I] 
216 [196 to 236] 
227 [203 to 253] 
215 [191 to 242] 
225 [215 to 236] 
217 [198 to 239] 
152 [114 to 202]
b
R
elative change (95%
 C
I) 
0
a 
5.4 %
 (-5.5 to 17.6) 
-0.3 %
 (-11.3 to 12.1) 
0
a 
-3.4 %
 (-12.0 to 6.0) 
-32.6 %
 (-49.3 to -10.3) 
M
M
A
Pm
ol/L [95%
 C
I] 
0.17 [0.16 to 0.19] 
0.18 [0.16 to 0.20] 
0.17 [0.16 to 0.20] 
0.17 [0.16 to 0.18] 
0.18 [0.17 to 0.20] 
0.19 [0.15 to 0.26] 
R
elative change (95%
 C
I) 
0
a 
6.0 %
 (-4.6 to 17.9) 
1.5 %
 (-9.4 to 13.7) 
0
a 
7.1 %
 (-2.2 to 17.4) 
11.1 %
 (-15.9 to 46.8) 
Folate nm
ol/L [95%
 C
I] 
13.2 [11.9 to 14.7] 
12.5 [11.1 to 14.2] 
13.6 [11.9 to 15.5] 
12.7 [12.0 to 13.4] 
13.6 [12.2 to 15.1] 
15.4 [11.2 to 21.4] 
R
elative change (95%
 C
I) 
0
a 
-5.2 %
 (-16.2 to 7.3) 
3.1 %
 (-9.6 to 17.7) 
0
a 
7.5 %
 (-3.3 to 19.4) 
21.9 %
 (-12.0 to 68.8) 
a reference category, b P
A
N
O
V
A
<0.05
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Several studies have shown that low plasma vitamin B12 status increases the risk for venous 
thrombosis 163-167,181, although not all studies could confirm this finding 168. We investigated 
vitamin B12 status and the MTR 2756 A>G and MTRR 66A>G polymorphisms as a risk 
factor for recurrent venous thrombosis. 
In the present study, high plasma MMA seems a modest risk factor for recurrent venous 
thrombosis, independent of known risk factors for venous thrombosis. We observed that the 
MTRR 66A>G genotype modified the risk associated with high plasma MMA levels. 
Recurrent venous thrombosis risk increased more than five-fold in subjects with the MTRR 
66GG genotype and a plasma MMA above the 80th percentile (>0.24 Pmol/L). No such 
associations were observed for plasma vitamin B12 levels and disease risk.  
Vitamin B12 status is difficult to assess, as low plasma vitamin B12 levels do not always 
indicate low vitamin B12 status and normal plasma vitamin B12 levels do not always exclude 
intracellular vitamin B12 deficiency 182,183. Plasma MMA is regarded a better indicator of 
intracellular vitamin B12 status than total plasma vitamin B12 concentrations 169. Holo-
transcobalamin, the vitamin B12 carrier in the blood that is required for cellular uptake, could 
be measured in order to verify our observation that low vitamin B12 status may increase 
recurrent venous thrombosis risk. Although the cause of the lower vitamin B12 status is 
unclear, it may partly explain the high tHcy in our cases (Table 2). Possibly, mild dysfunction 
of one of the vitamin B12 carriers/transporters such as cubulin or low vitamin B12 intake may 
be involved. 
We show that the MTRR 66A>G and MTR 2756A>G polymorphisms in themselves did not 
affect venous thrombosis risk in the general population. This is in agreement with some 
studies 96,171,172, but not all 83,95. One group reported an interaction between these two 
variants on thrombosis risk in a small population 184, but we could not reproduce their finding. 
We did observe an interaction between MMA and the MTRR genotype on disease risk, 
suggesting that mild MTRR dysfunction due to the 66A>G polymorphism may affect disease 
risk but only at suboptimal vitamin B12 status. The functional effect of the MTR 2756A>G 
polymorphism is not known, but the group sizes in our study do not allow definite conclusions 
to be drawn as to whether this variant is a risk factor for recurrent venous thrombosis or not. 
Like other groups, we did not observe an effect of the MTRR 66A>G variant on tHcy or other 
metabolites 94-96, although some studies did find an effect of the MTRR 66A>G variant on 
tHcy 91,92,174,185. These inconsistencies may be attributed to differences in lifestyle or nutrition 
between these populations. We, and others, observed that the MTR 2756A>G variant did not 
alter tHcy, plasma MMA and folate 82,94. The low plasma vitamin B12 level in MTR 2756GG 
subjects was not reflected by plasma MMA or tHcy levels, and may be influenced by chance 
(n=9).
The mechanism via which low vitamin status or hyperhomocysteinemia causes disease is 
not well understood. The observation that low vitamin B12 status affects transmethylation 
processes 186 may have implications for methylation of DNA, proteins or hormones. The 
measurement of methylation parameters like S-adenosylmethionine and S-
adenosylhomocysteine, and methylation status may provide more insight into the association 
between suboptimal vitamin B12 status and venous thrombosis. In addition, vitamin B12 
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deficiency was shown to increase the levels of the pro-inflammatory cytokine, tumor necrosis 
factor D (TNF-D) 187. TNF-D is known to affect coagulation via downregulating 
thrombomodulin expression, thus contributing to a pro-coagulable state 188,189. The former 
association is likely to be mediated by homocysteine, while the latter may be independent 
from one carbon metabolism and directly due to the effects of low vitamin B12 status. 
There are some limitations of this study to consider. Our study concerns subjects with two or 
more episodes of venous thrombosis, which may result in slightly higher risk estimates. An 
effect of low plasma vitamin B12 on a first thrombotic event has been demonstrated 181, but 
the investigation of plasma MMA as a risk factor for a first thrombotic event is awaited. 
Secondly, our study may be too small to detect small changes in metabolites or relative risk 
conferred by the separate polymorphisms. Our study demonstrated an overall effect of high 
MMA on recurrent venous thrombosis risk, which remained after adjustment for possible 
confounders. Although the risk profile may be different for specific subgroups (e.g. age, sex), 
the size of our study population is too small to perform proper subgroup analysis. The 
investigation of suboptimal vitamin B12 status as a risk factor for (recurrent) venous 
thrombosis in larger populations and specific subgroups is warranted. 
In conclusion, our results show that high plasma MMA, indicative of low intracellular vitamin 
B12 status, may increase the risk of venous thrombosis, independent of established risk 
factors for venous thrombosis. Mild dysfunction of the homocysteine remethylation pathway, 
by virtue of the MTRR 66A>G polymorphism may further increase that risk.  
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$EVWUDFW
Disturbances in folate metabolism may increase the risk of certain malignancies, congenital 
defects and cardiovascular diseases. The gene dihydrofolate reductase (DHFR) is primarily 
involved in the reduction of dihydrofolate, generated during thymidylate synthesis, to 
tetrahydrofolate in order to maintain adequate amounts of folate for DNA synthesis and 
homocysteine remethylation. In order to reveal possible variation that may affect plasma total 
homocysteine, serum folate and red blood cell folate levels, we sequenced the DHFR coding 
region as well as the intron-exon boundaries and DHFR flanking regions from twenty 
Caucasian individuals. We identified a 9-bp repeat in the 5’ upstream region that partially 
overlapped with the 5’ untranslated region, and several single-nucleotide polymorphisms, all 
in non-coding regions. We screened subjects for the 9-bp repeat (n=417), as well as the 
recently reported 19-bp deletion in intron 1 (n=330), and assessed their associations with 
plasma total homocysteine, serum and red blood cell folate levels. The 19-bp del/del 
genotype was associated with a lower plasma total homocysteine (-14.4% [95% CI -23.5 to -
4.5], p=0.006) compared with the wild type genotype. This may suggest that intracellular 
folate levels are affected.  
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Folate, a water-soluble B-vitamin, has gained increasing interest for its essential role in DNA 
synthesis/repair and the transmethylation pathway. The primary function of folate is as a 
carrier of one-carbon units for purine and thymidine synthesis and the conversion of 
homocysteine to methionine. Because of the close interrelation between folate and 
homocysteine, low folate status is reflected by elevated plasma total homocysteine 
concentrations (tHcy) 190,191. A number of diseases have been linked to disturbances in the 
above-mentioned pathways. For example, low folate status increases the risk of certain 
cancers 29,32,33 and is related to congenital malformations, such as neural tube defects 22.
Moreover, an increase in tHcy increases the risk of cardiovascular disease and congenital 
abnormalities 18,19,192.
Dietary folates, present in reduced and partially reduced form 193, exist as polyglutamates 
and require hydrolysis to monoglutamates before absorption in the intestine. After release 
into the portal circulation, folate (mainly as 5-methyltetrahydrofolate) is distributed throughout 
the body and is used for homocysteine remethylation, leaving tetrahydrofolate (THF) and 
methionine (Figure 1). Methionine is used for protein synthesis or converted to S-
adenosylmethionine (AdoMet), the principle methyl donor in the human body. THF is 
converted to methyleneTHF, among others, and used for thymidylate synthesis. The latter 
generates dihydrofolate (DHF) that requires the action of dihydrofolate reductase (DHFR) to 
be reduced to THF again. In addition, folic acid present in vitamin pills and fortified foods 
requires full reduction by DHFR via DHF into THF in order to become metabolic active. This 
makes DHFR an essential enzyme not only for the initial reduction of dietary folates (and folic 
acid) but also for the continuous reduction of DHF into THF generated during thymidylate 
synthesis 194.
DHFR (EC 1.5.1.3) is located on chromosome 5q11.2-q13.2 and spans about 30 kb. The 
gene consists of 6 exons, yielding a mRNA of about 3.9 kb 194. DHFR enzyme (AC 008434.5) 
is a cytosolic protein of 21.3 kDa and requires NADP as a cofactor. At least three 
pseudogenes of DHFR are known, i.e. DHFRP1 (chromosome 18), DHFRP2 (chromosome 
6) and DHFRP4 (chromosome 3, also denoted DHFRL1) 195,196, which are highly homologous 
to the corresponding DHFR coding regions. Outside these regions sequence homology is 
relatively low 197. DHFR deficiency (OMIM 126060) is sporadically seen and results in severe 
megaloblastic anaemia and mild to moderate mental retardation 198,199. The antifolate 
methotrexate (MTX) is well known for its inhibitory effect on DHFR thereby preventing DNA 
synthesis and, hence, tumor growth 200. In addition, inhibition of DHFR by MTX and the 
antibiotic trimethoprim were shown to increase tHcy levels by 50% 136,201, suggesting that 
DHFR dysfunction due to genetic variants may affect tHcy as well. Recently, Johnson et al.
described a 19-bp deletion that may affect gene expression 137.
In this study we aimed to identify genetic variation within the DHFR gene by sequencing the 
entire coding region, including the intron-exon boundaries and DHFR flanking regions. Newly 
identified variants, and the 19-bp deletion in intron 1 137, were assessed for their effect on 
tHcy and serum and red blood cell folate concentrations in population-based controls.  
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DNA from twenty individuals of Caucasian origin, who had participated in an earlier study 6,
were used for DHFR sequence analysis. Functional polymorphisms in the DHFR gene are 
likely to be reflected in plasma folate and homocysteine levels. The subjects were selected 
based on these criteria: six subjects had low folate (<10th percentile = 7.0 nmol/L) and high 
homocysteine levels (>90th percentile = 15.5 Pmol/L), nine subjects had a plasma total 
homocysteine above 15.5Pmol/L and 5 subjects were selected randomly. Subjects with low 
vitamin B12 (<10th percentile = 124.7 pmol/L) or the MTHFR 677TT genotype were excluded. 
We aimed to identify common genetic variants that may contribute to changes in tHcy or 
folate at the population level. According to a binomial distribution, the chance of finding an 
allele with a frequency of 2.5% in 1 out of 40 alleles is 0.64. In addition, the minimum allele 
frequency required to find at least 1 out of 40 alleles (with 95% confidence) is 7.2%. The 
population used for the association study was recruited via a general practice in The Hague 
(The Netherlands) and has been described in more detail elsewhere 6. In total 2812 people, 
20-90 years of age, were invited to take part in a health survey on risk factors for 
cardiovascular disease. From the group that agreed to participate (n=532), the first 500 were 
included. For the current study, DNA was available of 438 individuals. All participants gave 
their informed consent.
6HTXHQFHDQDO\VLVRIWKH'+)5JHQH
Blood samples were drawn from the antecubital vein. DNA was extracted 179 and then stored 
at 4 ºC. Genomic DNA sequencing of the entire coding region (GenBank accession number 
NT_006713, AC008434.5) was performed in order to screen the DHFR gene for variation. 
We also sequenced 665 bp of the 5’ upstream region, which included the 5’ UTR of about 
500 bp (NM_000791), and 1300 bp downstream of DHFR. Intron-based primers were 
developed to avoid amplification of pseudogenes and to reveal potential splice site variants. 
Concerning amplification of both 5’ and 3’ UTRs, primer sets were developed taking into 
account the homology with the known pseudogenes. In addition, alignment of these primer 
sets showed no matches with any of the known DHFR pseudogenes. PCR amplifications 
were performed in a total volume of 50 PL on an iCycler (Biorad, the Netherlands). For 
details see Table 7. The reaction mixture contained 200 nmol/L of both forward and reverse 
primer (Biolegio BV, The Netherlands); 200 Pmol/L dNTPs, 0.5 U of recombinant Taq 
polymerase (both from Invitrogen, The Netherlands); PCR buffer containing 20 mmol/L Tris-
HCl buffer (pH 8.4), 50 mmol/L KCl and 5% DMSO; 1.0-4.0 mmol/L MgCl2 and 75 ng DNA. 
An alternative PCR buffer, containing 50 mmol/L Tris-HCl pH 9.2, 16 mmol/L (NH4)2SO4, 2% 
DMSO and 0.1 % Tween-20 (Roche Applied Science, Switzerland), was used where 
necessary (see Table 7). PCR conditions were as follows: initial denaturation of 4 minutes at 
94qC, 35 cycles of 94qC/60s, 55-65qC/30s, 72qC/30s, and a final extension of 7 minutes at 
72 qC. The PCR products obtained were analysed on a 2% agarose gel and subsequently 
sequenced on an ABI Prism 3730 automated sequencer using the ABI Prism Big Dye 
Terminator cycle sequence kit according to the instructions of the manufacturer (PE  
&KDSWHU
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Biosystems, the Netherlands). Newly identified variants were confirmed on both DNA strands 
by direct sequencing. 
*HQHWLFDQDO\VLVRI'+)5ESUHSHDW
We identified a 9-bp repeat in the 5’ upstream region of the DHFR gene. We obtained the 
most frequent alleles (3x, 6x and 7x repeat) by cloning PCR fragments (450 bp) into the 
pGEM-T vector system and transformation of E. coli JM109 High-efficiency Competent cells 
(Promega). After ampicillin selection on LB-plates (IPTG/X-gal screening) and plasmid DNA 
isolation (Wizard plus SV, miniprep kit, Promega), these alleles were used as positive 
controls in the genotype analyses. In order to facilitate genotyping, a new primer set was 
chosen for the analysis (F 5’-GCCCAGTCCCAGACAGAAC-3’ and R 5’- 
GAGCCGATTCTTCCAGTCTAC-3’). The resulting PCR product was 180 bp (for the 6x 
repeat allele), allowing a clear distinction between the alleles. PCR conditions: 4 minutes at 
94qC, 35 cycles of 94qC/60s, 59qC/30s, and 72qC/30s, and a final extension of 7 minutes at 
72qC. The reaction mixture (50 Pl) contained 200 nmol/L of both forward and reverse primer 
(Biolegio BV, The Netherlands); 200 Pmol/L dNTPs, 0.5 U of recombinant Taq polymerase 
(both from Invitrogen, The Netherlands); PCR buffer containing 50 mmol/L Tris-HCl pH 9.2, 
16 mmol/L (NH4)2SO4, 2% DMSO and 0.1 % Tween-20 (Roche Applied Science, 
Switzerland); 2.0 mmol/L MgCl2 and 75 ng DNA. The PCR products were analysed on large 
3% agarose gels by running the samples at least four hours at 125V. In each PCR, DNA 
samples with a known (sequence confirmed) genotype were run as positive controls. When 
PCR products were not in control range or difficult to genotype, they were excised and 
purified from the agarose gel (Gel extraction kit, Qiagen) and sequenced to identify the 
length of the allele. Genotype data was obtained from 417 subjects.
Table 7. Primer sequences and PCR conditions used for amplification of the DHFR gene  
Primer Sequence (5’Æ 3’) Product Size, bp (seqb) Tann (qC)c [MgCl2] (mM) 
5’ UTR F a
5’ UTR R 
CCTCAGCGCTTCACCCAATTTG 
CCGGGCTGCCATCCTTGC 
450 (-664 to -213) 65 4.0 
Exon 1 F a
Exon 1 R 
GGAGGAGGAGGTGGATTTC 
GCAGCAGAAAAGGGGAATC 
591 (-358 to 233) 55 2.0 
Exon 2 F 
Exon 2 R 
CCCTACCCACAGCGCTCCG 
GCCTGATAATTTGCTCGTGCG 
348 (343 to 691) 60 1.5 
Exon 3 F 
Exon 3 R 
GCATGCAGACTCCACACAGACG 
GCAGCTTCATCAATAGCTCC 
372 (4833 to 5205) 65 1.5 
Exon 4 F 
Exon 4 R 
GTTCTCTCCTGCCCTGTCCAAG 
GGCAAGGAAGCTGAAAGTAGAAC 
491 (16176 to 16667) 65 1.5 
Exon 5 F 
Exon 5 R 
GTAAGCAAACTGGAGGCCAGAC 
GCACCCATCATCCTAGCAGTACAC 
490 (20245 to 20735) 65 1.5 
Exon 6 F+3’ UTRa
Exon 6 R+3’ UTR 
GAAACTGCTGACTGGTTTTTGAG 
GGTTCAAGCAACCATCATCCC 
1666 (25036 to 26702) 65 4.0 
ISP 3’ UTR1 F CTAGTTTAAGTTGTTCCCC - (25417 to 25803) 58 - 
ISP 3’ UTR2 F CGTGTATATCCAGAGGTTTGTAG - (25780 to 26235) 66 - 
ISP 3’ UTR3 F GGGAACAGTGAATGCCAAAC - (26215 to 26702) 60 - 
a An alternative buffer (see Materials and Methods section) was used for the PCR amplification reaction, b sequence 
covered by primer(set), positions are relative to the A in the translation initiation codon, c Tann =annealing temperature, d
ISP: internal sequence primer 
&KDSWHU
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Screening for the 19-bp deletion in intron 1 of the DHFR gene was essentially as described 
previously 137. In short, the PCR reaction mix (25 ȝl) contained 75 ng of genomic DNA, 1x 
Ampli Taq Gold Buffer, 1.5 mmol/L MgCl2, 250 Pmol/L dNTPs, 1 Pmol/L of each primers 
(FW1 5’-CCACGGTCGGGGTACCTGGG-3’, FW2 5’-ACGGTCGGGGTGGCCGACTC-3’ and 
RV 5’-AAAAGGGGAATCCAGTCGG-3’), 1 mol/L betaine and 0.5 U Taq Polymerase. PCR 
conditions were as follows: initial denaturation of 4 minutes at 94 qC, 35 cycles of 94qC/60s,
58qC/60s, 72 qC/60s, and a final extension of 7 minutes at 72 qC. The PCR products were 
analysed on a 3% agarose gel, stained with ethidium bromide and visualized by UV light. On 
each gel, DNA samples with a known (sequence confirmed) genotype (no del/no del, no 
del/del, del/del) were run as positive controls. Genotype data was obtained from 330 
subjects.
%LRFKHPLFDOSDUDPHWHUV
Blood samples were drawn from the antecubital vein for determination of total plasma 
homocysteine and folate. EDTA samples for homocysteine and folate measurement were 
placed on ice immediately and centrifuged at 3500 g for 5 minutes with minimal delay. The 
plasma or serum was separated and stored at -20 ºC. Total plasma homocysteine 
concentrations were measured by an automated high-performance liquid chromatography 
method with reverse phase separation and fluorescent detection (Gilson 232-401 sample 
processor, Spectra Physics 8800 solvent delivery system and LC 304 fluorometer) 178. DNA 
extraction was performed as described previously 179. Serum and red blood cell folate 
concentrations were measured with the Dualcount Solid Phase No Boil Radioassay 
(Diagnostic Product Corporation, Los Angeles, CA, USA).  
6WDWLVWLFV
Total homocysteine and folate concentrations were logarithmically transformed prior to all 
analyses, and are expressed as a geometric mean with a 95% confidence interval. 
Differences in metabolite concentrations were determined by linear regression analysis and 
expressed as changes relative to the wild type. A two-tailed p<0.05 was accepted as 
statistically significant. For all analyses SPSS 12.0 for Windows was used. 
5HVXOWV
+XPDQ'+)5VHTXHQFHDQDO\VLV
We sequenced the coding region, including intron-exon boundaries, and UTRs of the DHFR 
gene (nucleotide -664 to 26702 relative to the A in the translation initiation codon)(see Table 
7 for details). We observed no genetic variation within the coding region, but did identify a 9-
bp repeat in the highly GC-rich 5’ upstream region of DHFR. The repeat was located 388 bp 
upstream of the first nucleotide of the translation initiation codon (-388 bp), and partially 
overlapped with the 5’ UTR. We observed alleles ranging from 162 bp (i.e. 3x repeat) to 
216bp (i.e. 9x repeat), of which the determined DNA sequences are shown in Figure 5. The 
most common genotypes (%) were 3/3 (10.6), 3/6 (30.9), 6/6 (41.0) and 6/7 (9.6). Less 
frequent genotypes (%) were 3/7 (4.1%), 6/9 (1.4%), 3/5, 3/8, 5/6, 6/8 (all 0.5%), 4/7 and 7/7 
&KDSWHU
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(both 0.2%). The general consensus sequence of the repeat was A/CGCTGG/CG/AGG/C. In 
addition, we found three single-nucleotide polymorphisms in the 5’ UTR, one in intron IV and 
three in the 3’ UTR (see Table 8).  
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$VVRFLDWLRQEHWZHHQ'+)5YDULDQWVDQGW+F\DQGIRODWH
Because the 9-bp repeat is located in the promoter region and the 19-bp deletion is thought 
to affect gene expression 137, we only screened these potentially most important variants for 
their effect on tHcy, serum and RBC folate in our study population. As shown in Table 9, the 
9-bp repeat was not associated with tHcy in our study population. Although the 3/6 and 3/7 
repeat compared to the 3/3 repeat genotype showed a trend towards higher plasma folate 
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Figure 5. DHFR gene structure and DNA sequence of the 5’ upstream region 9-bp repeat as observed for the different 
alleles
Table 8. Observed sequence variants in the human dihydrofolate reductase gene in twenty subjects 
Region Location Variant Allele frequency 
5’  UTR a -388 bp b 9-bp repeat c 0.29 (3x rpt), 0.62 (6x rpt) 
   0.09 (7x rpt), <0.01 (4, 5, 8, 9x rpt) 
 -204 bp T>C 0.50 (C) 
 -95 bp G>A 0.13 (A) 
 -82 bp DelG 0.13 (delG) 
Intron I 146 bp 19-bp deletion c, d 0.43 (del) 
Intron IV 20404 bp G>C 0.03 (C) 
3’ UTR 25508 bp A>T 0.14 (T) 
 25979 bp C>T 0.13 (T) 
 26095 bp G>A 0.13 (A) 
 26493 bp delT 0.21 (delT) 
a UTR: untranslated region, b Locations are relative to the A in the translation initiation codon,  
c screened in the whole population, d First reported by Johnson et al. 18
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levels (p trend=0.015 for the 3/3, 3/6 and 3/7 repeat genotype), this increment did not persist 
in the 6/6 and 6/7 repeat genotypes. The 19-bp deletion was associated with a 2.5% (95% CI 
-10.8 to 6.5) and 14.4% (95% CI -23.5 to -4.5) decrease in tHcy for the heterozygous and 
homozygous genotype, respectively, compared with the wild type genotype (p
ANOVA=0.016)(Table 9). Adjustment for age and sex did not change the association 
between this deletion and tHcy. Serum and red blood cell folate levels were similar between 
the genotypes. No interaction between the 9-bp repeat and 19-bp deletion or between low 
folate (<30th percentile, 10.0 nmol/L) and either variant on tHcy was observed (not shown). 

'LVFXVVLRQ
In this study we searched for genetic variation in the DHFR gene that may affect tHcy, serum 
and red blood cell folate levels. We identified a 9-bp repeat in the 5’ upstream region of 
DHFR that partially overlapped with the 5’ UTR. The 9-bp repeat may affect mRNA stability 
or translation efficiency, similarly as described for the 28-bp repeat in the functionally related 
thymidylate synthase 140. The repeat appeared highly polymorphic with alleles ranging from 3 
to 9 repeats. In 1995 Nakajima and co-workers 202 described, in Japanese subjects, a 9-bp 
repeat in exon 1 of the DNA repair gene mutS homolog3 (MSH3), which partially overlaps 
with the DHFR gene and may share promotor elements. Our repeat most likely represents 
the same repeat, as the consensus sequence highly resembled that reported by Nakajima, 
although higher repeat sizes were present in our, predominantly Caucasian, population. The 
repeat may have arisen from duplications of one (or more) ancestral allele(s) or result from 
DNA replication errors. Despite its location in the promoter region, the length of this repeat 
was not associated with tHcy, serum and red blood cell folate levels.  
In 2001, Goto and co workers reported a functional variant (829C>T) in the 3’ UTR of DHFR 
203. We did not observe this variant in the subjects that were included in the sequence 
analysis, suggesting that it is a population-specific polymorphism or has a minor allele 
frequency below 2.5%. Johnson and colleagues identified a 19-bp deletion in the highly 
conserved intron 1, that may be a maternal risk factor for having a child with spina bifida and 
preterm delivery 137,204. It has been postulated that this variant deletes a putative SP1 
transcription factor-binding site (required for transcriptional activation/repression) or may 
affect the splicing process. We show that the 19-bp del/del genotype is associated with a 
reduced plasma total homocysteine of about 1.5 Pmol/L (14%) compared to wild type 
subjects. This may suggest that the 19-bp deletion indeed increases DHFR expression 
thereby facilitating homocysteine remethylation. Unfortunately, no RNA was available from 
our study population to support its effect at the expression level, which warrants further 
investigation.  
We detected several other variants in non-coding regions of DHFR which, based on the 
sequence, could not be ascribed to known pseudogenes. The main part of the introns has 
not been screened, but these may contain functional variants as well. It is possible that 
intronic polymorphisms represent a functional variant although the intronic sequences, 
except for intron 1, are not well-conserved across species 205. We assessed linkage 
disequilibrium (LD) between the 19-bp deletion and the most common alleles of the 9-bp 
repeat (3x and 6x), and found them to be in almost complete LD (D’ 0.9).  However, the 
&KDSWHU
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squared correlation coefficient was low (R2 = 0.3). The HapMap consortium investigated LD 
between existing DHFR single nucleotide polymorphisms (http://www.hapmap.org/), and 
showed that one haplotype block of about 24 kbp almost completely covers the DHFR gene. 
This suggest that the number of allelic variants of the DHFR gene present in the population is 
limited and may be captured by genotyping just a small number of polymorphisms in the 
gene.
In conclusion, the coding region of DHFR harbours no variation in our population, which 
illustrates its importance in folate metabolism. Several variants were found within the non-
coding regions of DHFR, potentially the most interesting being the 9-bp repeat in 5’ UTR. 
The 19-bp deletion in intron 1 was associated with lower tHcy levels and may be a genetic 
risk factor for cardiovascular disease and cancer, in addition to its reported effect on neural 
tube defect risk. 
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Introduction: Folate is important in processes like purine and thymidylate synthesis and S-
adenosylmethionine-dependent transmethylation. Low availability of folate leads to 
hyperhomocysteinemia, which is a risk factor for arterial vascular disease and venous 
thrombosis. Genetic variation in folate metabolizing genes may affect folate availability and, 
hence, exert a greater risk for venous thrombosis.
Materials and Methods: We genotyped the thymidylate synthase (TYMS) 28-bp repeat and 6-
bp deletion and the reduced folate carrier (RFC1) 80G>A and AICAR transformylase / IMP 
cyclohydrolase (ATIC) 346G>C polymorphisms in population-based controls, and assessed 
their effect on plasma total homocysteine (tHcy), serum and red blood cell (RBC) folate. We 
investigated whether these variants are risk factors for venous thrombosis as well.  
Results: None of the genotypes, singularly or in combination, were associated with major 
changes in tHcy, serum or RBC folate levels. In addition, we found no evidence that the 
genetic variants were associated with recurrent venous thrombosis risk.  
Conclusion: The TYMS 28-bp repeat and 6-bp deletion, RFC1 80G>A and ATIC 346G>C 
polymorphisms are not associated with tHcy, serum or RBC folate in the general population, 
nor did any of the polymorphisms affect venous thrombosis risk.  
&KDSWHU
- 54 -
,QWURGXFWLRQ
Folate plays an essential role in the human body as carrier and donor of one-carbon groups 
in DNA synthesis and homocysteine remethylation. As such, folate is involved in the 
formation of purine and thymidine nucleotides, and S-adenosylmethionine (AdoMet) 
synthesis required for transmethylation processes. A disturbed folate and, the closely related, 
homocysteine metabolism has been implicated in several diseases, including arterial 
vascular disease and venous thrombosis 18,19, neurological and congenital disorders and 
cancer 22,29,36,39. In addition, there is accumulating evidence that low B-vitamin levels, such as 
folate, vitamin B12 and B6, increase the risk of thrombosis independent of their effect on 
homocysteine levels 166,167,206. Given the effect of the methylenetetrahydrofolate reductase 
(MTHFR) 677C>T polymorphism on folate distribution and homocysteine levels 47,207, one 
may speculate that other variants in genes encoding folate metabolizing enzymes also affect 
folate and homocysteine levels. In addition, based on segregation analysis, Jee et al.
suggest the presence of other important determinants of tHcy besides the MTHFR 677 C>T 
polymorphism 45.
The main two mechanisms for cellular uptake of folates involves a relatively slow endocytotic 
process mediated by folate receptors while the second process involves the high-capacity 
uptake of reduced folates (and the antifolate methotrexate) by the reduced folate carrier 
(RFC1, or SLC19A1) 99. After uptake, the folates need to be reduced and methylated (if not 
already) to become metabolically active. The enzymes thymidylate synthase (TYMS, EC 
2.1.1.45) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase / 
inosine monophosphate (IMP) cyclohydrolase (ATIC, EC 2.1.2.3 / 3.5.4.10) are two other 
enzymes involved in folate metabolism (Figure 1). TYMS uses 5,10-
methylenetetrahydrofolate (THF) for the reductive methylation of deoxyuridine 
monophosphate (dUMP) into deoxythymidine monophoshate (dTMP), a pyrimidine 
nucleotide essential for DNA synthesis and repair. ATIC, requiring 10-formylTHF as a co 
substrate, catalyzes the successive transformylation and hydrolysis of AICAR into IMP, 
which are the two final steps in the de novo purine synthesis.  
In the past decade, our group assessed variants in the majority of folate genes for their effect 
on plasma total homocysteine (tHcy) (for review, see Gellekink et al. 208). Yet, some genes of 
folate metabolism have not been explored.  The RFC1, ATIC and TYMS genes contain 
genetic variants, e.g. 80G>A in RFC1 (Arg27His), 346C>G (Thr116Ser) in ATIC, 5’ 
untranslated region (UTR) 28-bp repeat and 3’ UTR 6-bp deletion (1494del6) in TYMS. 
Higher repeat sizes of the TYMS 28-bp repeat were shown to increase translation efficiency 
141 and tHcy in subjects with the MTHFR 677TT genotype 142. The 6-bp deletion in TYMS is 
reported to decrease mRNA stability 144. RFC1 represents the major internalization route for 
reduced folates and the 80G>A polymorphism, causing an arginine to histidine amino acid 
change at codon 27, was shown to affect thrombosis risk in one study 209, but not tHcy or 
folate 110,210. The ATIC 346C>G polymorphism converts a threonine to serine at position 116, 
but the functional impact of this variant has not been studied. All four genetic variants may 
affect folate distribution and homocysteine levels and in this way confer a risk for thrombosis 
as well.
&KDSWHU
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The main goal of the study was to assess these four genetic variants for their effect on tHcy 
and serum and red blood cell (RBC) folate concentrations in the general population. The 
second aim was to estimate the risk of disease for each of the variants in a case-control 
study on recurrent venous thrombosis. The effect of gene-gene combinations on tHcy and 
venous thrombosis risk is also studied. 
0DWHULDODQG0HWKRGV
3DWLHQWVDQGFRQWUROVXVHGLQWKHFDVHFRQWUROVWXG\
The control group was recruited via a general practice in The Hague (n=500). Patients 
(n=185) were selected from the files of the anticoagulant clinic of The Hague. All patients had 
two or more episodes of venous thrombosis (pulmonary embolism or deep-vein thrombosis). 
Both study populations participated in a case-control study on venous thrombosis and have 
been described in more detail previously 6. We obtained a short medical history of all patients 
by interview and of all controls by questionnaire. DNA for genotyping was available from 178 
patients and 446 population-based controls from which relevant biochemical data had 
already been obtained. The medical ethics committee approved the study protocol and 
informed consent was obtained from all study participants.  
%LRFKHPLFDOSDUDPHWHUV
Blood samples were drawn from the antecubital vein in 5 mL Vacutainer tubes and 4.5 mL 
EDTA vacuum glass tubes for determination of folate and total plasma homocysteine and for 
DNA extraction. EDTA samples for homocysteine measurement were placed on ice 
immediately and centrifuged at 3500 g for 5 minutes with minimal delay. The plasma was 
separated and stored at -20 ºC until analysis. Total plasma homocysteine concentration was 
measured by an automated high-performance liquid chromatography method with reverse 
phase separation and fluorescent detection (Gilson 232-401 sample processor, Spectra 
Physics 8800 solvent delivery system and LC 304 fluorometer) 178. Samples for serum and 
RBC folate measurement were stored at -70 ºC and measured with the Dualcount solid-
phase no boil Radioassay (Diagnostic Products Corporation, Los Angeles, CA, USA). RBC 
folate levels reflect long-term folate status whereas plasma folate reflects daily intake. DNA 
extraction was performed as described previously 179 and the DNA was stored at 4 ºC. 

*HQRW\SHDQDO\VHV
We genotyped four polymorphisms in three genes involved in folate metabolism: RFC 
80G>A (Arg27His) 110, TYMS 28-bp repeat 141 and 6-bp deletion (1494del6, rs28365050) 139
and ATIC 348C>G (Thr116Ser, rs2372536). Three of these variants were screened for by 
means of PCR followed by restriction fragment-length analysis (PCR-RFLP). The TYMS 28-
bp repeat was analysed by means of PCR amplification alone 211. For details about the 
variants under study and validation method used, see Table 10.  
Screening conditions were similar in all analyses. PCR conditions: 4 minutes at 94qC, 35-40 
cycles of 94qC/60s, 51-63qC/60s, and 72qC/30s, and a final extension of 7 minutes at 72qC.
Each PCR reaction mixture contained 50 ng of both forward and reverse primer (Biolegio BV, 
The Netherlands), 200 PM dNTPs, 0.5 U of recombinant Taq polymerase (Invitrogen, The 
&
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Table 10. R
elevant data of analysed polym
orphism
s and m
ethod of screening 
G
ene 
V
ariant 
Location 
R
eported M
A
F
a 
P
rotein 
P
rim
ers (5’Æ
 3’) 
R
estriction enzym
e 
M
g
2+ (m
M
) 
P
roduct size 
T
ann (qC
)
TYM
S
 
28-bp repeat 
5’ U
TR
 
0.17-0.47 (2 x repeat) 
- 
F aaggcgcgcggaaggggtcc 
R
 tccgagccggccacaggcat 
- 
1.0 
114bp (2 x repeat) 
63 
TYM
S
 
6-bp deletion 
3’ U
TR
 
0.39 (del) 
- 
F caaatctgagggagctgagt 
R
 cagataagtggcagtacaga 
+D
raI 
1.0 
152bp (del) 
55 
R
FC
1 
60G
>A
 
E
xon 2 
0.38-0.51 (A
) 
A
rg27H
is 
F atggtgccctccagcccagc 
R
 catgaagccgtagaagcaaagg 
-H
haI 
1.5 
114bp 
57 
A
TIC
 
346C
>G
 
E
xon 5 
0.18-0.37 (G
) 
Thr116S
er 
F cctagatagctgtaaaccac 
R
 gtaatcccaaaacacaatc 
-H
pyC
H
4III 
2.0 
305bp 
51 
a M
A
F, m
inor allele frequency
Table 11. A
ssociation betw
een variants in folate genes and fasting tH
cy and folate levels in population-based controls 
V
ariant 
G
enotype 
M
ean tH
cy 
(Pm
ol/l) [95%
 C
I] 
A
djusted
a m
ean tH
cy 
(Pm
ol/l) [95%
 C
I] 
M
ean folate 
(nm
ol/l) [95%
 C
I] 
A
djusted
a m
ean folate 
(nm
ol/l) [95%
 C
I] 
M
ean R
B
C
 folate 
(nm
ol/L) [95%
 C
I] 
A
djusted
a m
ean R
B
C
 folate 
(nm
ol/L) [95%
 C
I] 
TYM
S
 28-bp rpt 
2/2 
10.5 [9.7 to 11.4] 
10.0 [9.1 to 10.9] 
13.7 [12.4 to 15.2] 
13.8 [12.1 to 15.8] 
444 [402 to 490] 
429 [378 to 486] 
 
2/3 
10.3 [9.3 to 11.3] 
9.9 [9.1 to 10.8] 
13.2 [11.7 to 14.9] 
13.1 [11.5 to 14.9] 
395 [352 to 445] 
394 [349 to 444] 
 
3/3 
10.6 [9.5 to 11.8] 
10.3 [9.4 to 11.4] 
12.1 [10.5 to 13.9] c 
12.2 [10.6 to 14.1] 
387 [340 to 440] b 
384 [336 to 439] 
TYM
S
 6-bp del 
no del/no del 
10.4 [9.8 to 11.0] 
9.8 [9.1 to 10.6] 
13.1 [12.2 to 14.1] 
13.3 [12.0 to 14.8] 
419 [391 to 449] 
408 [369 to 451] 
 
no del/del 
10.5 [9.7 to 11.3] 
10.1 [9.4 to 10.8] 
13.1 [11.9 to 14.5] 
13.1 [11.8 to 14.5] 
388 [352 to 426] 
382 [346 to 421] 
 
del/del 
10.3 [9.2 to 11.5] 
9.9 [8.9 to 11.0] 
12.4 [10.7 to 14.3] 
12.2 [10.5 to 14.2] 
404 [352 to 463] 
403 [351 to 461] 
R
FC
1 80 G
>A
 
G
G
 
10.9 [10.3 to 11.6] 
10.3 [9.6 to 11.1] 
13.5 [12.5 to 14.5] 
13.6 [12.2 to 15.1] 
422 [393 to 454] 
427 [386 to 471]
 
G
A
 
10.3 [9.5 to 11.1] 
9.8 [9.1 to 10.5] 
12.7 [11.5 to 14.1] 
12.8 [11.5 to 14.2] 
381 [347 to 439] 
370 [336 to 407] 
 
A
A
 
9.6 [8.6 to 10.8]  b 
9.8 [8.7 to 10.8] 
12.3 [10.7 to 14.2] 
12.4 [10.7 to 14.4] 
405 [372 to 462] 
390 [341 to 448] 
A
TIC
 346 C
>G
 
C
C
 
10.5 [9.9 to 11.1] 
10.0 [9.2 to 10.7] 
13.3 [12.4 to 14.3] 
13.6 [12.2 to 15.1] 
401 [375 to 429] 
394 [356 to 435]
 
G
C
 
10.3 [9.6 to 11.2] 
9.9 [9.3 to 10.7] 
13.2 [11.9 to 14.5] 
12.9 [11.7 to 14.4] 
405 [369 to 445] 
397 [361 to 438] 
 
G
G
 
9.9 [8.7 to 11.2] 
9.7 [8.7 to 10.9] 
11.7 [10.2 to 13.7] 
11.8 [10.0 to 13.9] 
402 [347 to 467] 
375 [322 to 437] 
a  adjusted for age, sex, creatinine and M
TH
FR
 677C
>T genotype, bP
<0.05,
cP
=0.06 
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Netherlands), 10 mM Tris-HCl buffer (pH 8.2), 50 mM KCl, 1.0-2.0 mM MgCl2, 5% DMSO 
(Sigma, The Netherlands) and 75 ng DNA. The resulting PCR product was digested by at 
least 10 units of restriction enzyme (all from New England Biolabs, Inc.) and incubated for 3 
hours or overnight at 37qC. The digests (or PCR product in case of the TYMS 28-bp repeat) 
were analysed by gel electrophoresis on agarose gel, stained with ethidiumbromide and 
visualized by UV. DNA samples from which the genotype had been identified by sequence 
analysis served as positive controls. Due to poor PCR amplification, genotype data was only 
available from at least 413 control individuals and 130 venous thrombosis cases.  
6WDWLVWLFV
Metabolite concentrations were logarithmically transformed prior to all analyses, and are 
expressed as a geometric mean with a 95% confidence interval. Differences in metabolite 
concentrations were determined by linear regression analysis. Odds ratios and 95% 
confidence intervals were calculated to estimate the relative risk of recurrent venous 
thrombosis in individuals that carry the mutant allele using logistic regression analysis. A two-
tailed p<0.05 was accepted as statistically significant. For all analyses SPSS 12.0 for 
Windows was used. 
5HVXOWV
%DVHOLQHFKDUDFWHULVWLFVRIVWXG\SRSXODWLRQV
The control group consisted of 431 individuals (average age 50.7 r 13.3 y) from which 41.1% 
was male (n=177). The case group consisted of 173 recurrent venous thrombosis patients 
(average age 61.5 r 14.2 y) from which 50.9% was male (n=88). Fasting tHcy was 10.4 (95% 
CI 10.1 to 10.8) Pmol/L and 12.5 (95% CI 11.8 to 13.3) Pmol/L in controls and cases, 
respectively (p<0.01). Serum creatinine was 74.1 (95% CI 72.5 to 75.7) Pmol/L and 83.3 
(95% CI 78.9 to 87.7) Pmol/L in controls and cases, respectively (p<0.01). Mean serum folate 
(95% CI) was 12.9 (12.2 to 13.7) nmol/L and 13.8 (12.5 to 15.1) in controls and cases, 
respectively (p=0.21), and the corresponding RBC folate level (95% CI) was 399 (378 to 420) 
and 404 (340 to 468) nmol/L (p=0.23). 

$VVRFLDWLRQEHWZHHQJHQHWLFYDULDQWVDQGPHWDEROLWHVLQSRSXODWLRQEDVHGFRQWUROV
The effects of the genetic variants on tHcy, folate and RBC folate levels in the control group 
are shown in Table 11. The crude analyses show that subjects with the TYMS 28-bp 3/3 
repeat have the lowest RBC folate levels when compared to 2/2 repeat subjects (p 
trend=0.05), while plasma folate was the lowest in 3/3 subjects too (p trend=0.06). In 
addition, we observed a decrease in tHcy of about 12% in RFC1 80AA compared to 80GG 
subjects (p=0.03) in the crude analyses. However, after adjustment for age, sex, serum 
creatinine and MTHFR 677C>T genotype these associations disappeared (p>0.05)(Table 
11). The ATIC 346C>G and TYMS 6-bp deletion variant had no effect on any of the 
metabolites. 



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&RPSRXQGJHQRW\SHVDQGW+F\IRODWHDQG5%&IRODWHOHYHOVLQFRQWUROV
We tested whether the combinations of genotypes, defined by the variants under study, were 
associated with tHcy, serum folate or RBC folate levels. In subjects with the TYMS 28-bp 3/3 
repeat genotype, the RFC1 80 G>A variant was associated with tHcy levels (95% CI), that is 
12.1 (10.2 to 14.2), 10.7 (9.2 to 12.4) and 9.2 (7.3 to 11.5) Pmol/L for 80GG (n=46), GA 
(n=56) and AA (n=15) individuals, respectively (p=0.02). In subjects with the TYMS 6-bp no 
del/del genotype, the ATIC 346 C>G variant was significantly associated with serum but not 
RBC folate levels. Serum folate (95% CI) was 14.1 (12.1 to 16.5), 12.3 (10.6 to 14.2) and 
10.8 (8.6 to 13.5) nmol/L for 346CC (n=20), 346CG (n=82) and 346GG (n=87) individuals, 
respectively (p=0.02). Adjustment for confounders like age, sex, creatinine and MTHFR 
677C>T genotype did not affect these associations. None of the other genotype 
combinations were associated with tHcy, serum folate or RBC folate levels (data not shown). 








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
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

*HQRW\SHGLVWULEXWLRQDQGUHFXUUHQWYHQRXVWKURPERVLVULVN
The genotype distributions of the variants in the control population were all in Hardy-
Weinberg equilibrium (p>0.50). Details on genotype frequencies and associated recurrent 
venous thrombosis risk are shown in Table 12. The minor allele frequencies for RFC1 
80G>A, ATIC 346C>G, TYMS 28-bp repeat and 6-bp deletion were 0.39/0.39 (A allele), 
0.37/0.33 (G allele), 0.44/0.46 (2x repeat allele) and 0.34/0.36 (6-bp deletion allele) for cases 
and controls, respectively. The corresponding odds ratios indicate that none of the analysed 
variants were separately associated with venous thrombosis risk (Table 12). In addition, 
none of the genotype combinations were significantly associated with recurrent venous 
thrombosis risk (data not shown). 
'LVFXVVLRQ
In this study we assessed four common variants, that is TYMS 28-bp repeat and 6-bp 
deletion, the ATIC 346C>G and RFC1 80G>A polymorphisms, for their effect on serum and 
Table 12. Association between variants in folate genes and venous thrombosis risk 
Variant Genotype Controls, n (%) MAFa controls Cases, n (%) MAFa cases Odds ratio (95% CI) 
TYMS 28-bp rpt 2/2 85 (20.2) 0.46 (2x rpt) 33 (20.2) 0.44 (2x rpt) 1.0b
 2/3 214 (51.0)  78 (47.9)  0.94 (0.58 to 1.51) 
 3/3 119 (28.3)  50 (30.7)  1.08 (0.64 to 1.82) 
TYMS 6-bp del no del/no del 176 (40.8) 0.36 (del) 66 (40.2) 0.34 (del) 1.0b
 no del/del 196 (45.5)  83 (50.6)  1.13 (0.77 to 1.66) 
 del/del 59 (13.7)  15 (9.1)  0.68 (0.36 to 1.28) 
RFC1 80 G>A GG 158 (36.8) 0.39 (A) 65 (37.6) 0.39 (A) 1.0b
 GA 208 (48.5)  82 (47.4)  0.96 (0.65 to 1.41) 
 AA 63 (14.7)  26 (15.0)  1.00 (0.58 to 1.72) 
ATIC 346 C>G CC 183 (44.3) 0.33 (G) 57 (43.8) 0.37 (G) 1.0b
 GC 184 (44.6)  51 (39.2)  0.89 (0.58 to 1.37) 
 GG 46 (11.1)  22 (16.9)  1.54 (0.85 to 2.77) 
a MAF, minor allelefrequency, b reference category
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RBC folate and tHcy. In addition, we investigated the prevalence of these polymorphisms in 
a case-control study on venous thrombosis. 
We found no indications that the RFC1 80G>A, TYMS 28-bp repeat and TYMS 6-bp deletion 
were singularly associated with tHcy, serum or folate levels in the general population, which 
corresponds with the observations of other groups for the RFC1 and TYMS variants 110,210,212.
Likewise, the ATIC 346C>G variant was not associated with these metabolites as well.  
There is much evidence that multiple genetic variants contribute to phenotypic changes, like 
hyperhomocysteinemia. For example, Trinh et al. observed an effect for the 3/3 repeat 
genotype on tHcy and plasma folate but only in MTHFR 677TT subjects 142. A recent study 
by Yates and Lucock suggests that common folate polymorphisms and B-vitamin status 
modulate tHcy levels 184. Lastly, Devlin et al. observed a gene-gene interaction between the 
MTHFR 677TT and RFC1 80GG genotypes on tHcy in a large group of elderly controls 210.
However, we found only slight indications that some genotype combinations may affect tHcy 
or serum folate levels, such as the RFC1 80G>A polymorphism in combination with the 
TYMS 28-bp 3/3 repeat. The TYMS 28-bp repeat was shown to increase translation 
efficiency with higher repeat sizes 141. Although no evident functional effect was found for the 
80G>A polymorphism on reduced folate cofactor transport in vitro 108, the combination may 
disturb folate metabolism and, hence, affect tHcy levels. The finding that no effect for this 
genotype combination on serum and RBC folate was observed, may be related to the fact 
that total folate is measured, leaving small changes in folate vitamer distribution unnoticed.  
Regarding the genetic variants being a risk factor for venous thrombosis, only one group 
reported a protective effect of the RFC1 80A allele in a small study on thrombosis (OR 0.56 
[95% CI 0.34 to 0.92]) 209. Despite the fact that our study populations were larger we could 
not confirm their findings, as none of the genotypes were singularly associated with recurrent 
venous thrombosis risk. The genotype combinations did not affect disease risk as well, but 
our study populations may have been too small to detect slight changes, if any, in disease 
risk.
Given the complex etiology of hyperhomocysteinemia and thrombosis, studying the effect of 
genotype combinations in relation to multifactorial traits and diseases is of great interest. This 
will require large study populations in order to detect small phenotypic changes that may, 
consequently, modulate disease risk. 
In conclusion, our data suggests that the TYMS 28-bp repeat and 6-bp deletion, RFC1 
80G>A and ATIC 346G>C polymorphisms are not associated with tHcy, serum or RBC folate 
in the general population, nor did any of the polymorphisms affect venous thrombosis risk.  
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Effect of Genetic Variation in the Human S-adenosylhomocysteine Hydrolase 
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$EVWUDFW
Hyperhomocysteinemia is an independent and graded risk factor for arterial vascular disease 
and venous thrombosis. It is still debated via which mechanism homocysteine (Hcy) causes 
vascular disease. S-adenosylhomocysteine hydrolase (AHCY) catalyzes the reversible 
hydrolysis of S-adenosylhomocysteine (AdoHcy) to Hcy. As an increase in AdoHcy, a strong 
inhibitor of many methyltransferases, is observed in hyperhomocysteinemic individuals, 
AdoHcy may play a role in the development of cardiovascular diseases by inhibiting 
transmethylation reactions. We sequenced the entire coding region and parts of the 
untranslated regions (UTRs) of the AHCY gene of 20 patients with recurrent venous 
thrombosis in order to identify genetic variation within this gene. We identified three 
sequence variants in the AHCY gene: a C>T transition in the 5’ UTR (-34 C>T), a missense 
mutation in exon 2, which mandates an amino acid conversion at codon 38 (112 C>T; 
Arg38Trp), and a silent mutation in exon 4 (390 C>T; Asp130Asp). We studied the effect of 
the first two variants on total plasma homocysteine and venous thrombosis risk in a case-
control study on recurrent venous thrombosis. The two polymorphisms under study seem to 
have no evident effect on tHcy. The adjusted relative risk of venous thrombosis associated 
with the 112CT genotype compared with 112CC individuals was 1.27 (95% CI [0.55 to 2.94]), 
whereas the -34CT genotype confers a risk of 1.25 (95% CI [0.44 to 3.52]) compared with 
the wild type genotype at this locus. However, the wide confidence intervals do not allow firm 
conclusions to be drawn. 
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,QWURGXFWLRQ
An elevated total plasma homocysteine (tHcy) concentration, also referred to as 
hyperhomocysteinemia, is an independent and graded risk factor for cardiovascular disease, 
including venous thrombosis, peripheral, cerebral and coronary artery disease 6,8,17,40,213,214.
Homocysteine is formed following S-adenosylmethionine (AdoMet)-dependent methylation 
reactions and subsequent hydrolysis of S-adenosylhomocysteine (AdoHcy) by AdoHcy 
hydrolase (AHCY; EC 3.3.1.1). Removal of homocysteine is essential as the equilibrium of 
the reaction catalyzed by AHCY strongly favours the formation of AdoHcy. Under normal 
conditions, the turnover rate of homocysteine is sufficient enough to favour the hydrolysis of 
AdoHcy. This is important as AdoHcy is a potent inhibitor of most methyltransferases thereby 
affecting DNA, RNA, protein and lipid methylation 59,60. For example, in vivo studies have 
demonstrated that an elevated tHcy is associated with increased plasma and intracellular 
AdoHcy levels, which correlates well with DNA hypomethylation in different tissues including 
lymphocytes, brain and liver 34,55,57,60. Therefore, it has been postulated that the increase in 
AdoHcy and associated inhibition of transmethylation may, in part, explain the increased risk 
of cardiovascular disease in hyperhomocysteinemic individuals.  
The AHCY gene has been assigned to chromosome 20cen-q13.1 (Ensembl locus 20q11.22) 
and consists of 10 exons spanning about 23 Kb. Native human AHCY is a cytosolic protein 
composed of four identical subunits and requires NAD+ as a cofactor 215. In the past, three 
electrophoretic isoforms of AHCY have been identified 216-218, but the molecular basis 
underlying these isoforms is still obscure. Coulter-Karis and Hershfield were the first to report 
a full-length cDNA of AHCY from a human placental cDNA library 219. They identified a 
transcript of 1299 bp encoding a 432 amino acid protein of approximately 48 kDa and 
reported a G>A transition at nucleotide 256 of this transcript. However, no AHCY sequence 
data or frequency data of this 256 G>A transition in a larger group of individuals is available 
yet.
Very recently, Baric and colleagues reported an AHCY-deficient patient with strongly reduced 
activity in liver (10%) and fibroblasts (3%) compared with controls. This 8-month-old boy 
suffered from severe myopathy and slow psychomotor development but showed no signs of 
cardiovascular disease, yet. In addition, an increased tHcy of 15.9 Pmol/L (normal <8.9 
Pmol/L) was observed, while AdoMet and AdoHcy levels were increased a30-fold and ~150-
fold, respectively. Surprisingly, this condition was accompanied by DNA hypermethylation in 
leucocytes 220.
It is still debated via which mechanism homocysteine induces arterial vascular diseases and 
venous thrombosis. Because AHCY is thought to play a pivotal role in the control of 
transmethylation reactions via regulation of intracellular Hcy and AdoHcy levels we 
sequenced the AHCY gene of 20 patients with a history of venous thrombosis. We aimed to 
identify genetic variation in order to assess a possible effect on tHcy and disease risk in a 
group of recurrent venous thrombosis patients and population-based controls. We 
hypothesized that if a disturbed methylation increases the risk of venous thrombosis, 
functionally relevant polymorphisms within the AHCY gene may increase disease risk even 
without concomitant hyperhomocysteinemia. 
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0DWHULDOVDQG0HWKRGV
3DWLHQWVDQGFRQWUROVXVHGLQWKHFDVHFRQWUROVWXG\
Patients were selected from the files of the anticoagulant clinic in Leyenburg Hospital in The 
Hague 6,176 and a population-based control group was recruited via a general practice in The 
Hague 6. Each study participant was subjected to a standardised methionine-loading test. 
This test included a basal homocysteine measurement (after overnight fasting) and a second 
homocysteine assessment 6 h after an oral methionine loading (100 mg L-methionine per kg 
body weight dissolved in 200 mL orange juice). During these 6 h, the subjects obtained a 
protein-restricted diet. For the current study, DNA was available of 173 recurrent venous 
thrombosis patients and 438 controls.
3DWLHQWVHOHFWLRQIRUVHTXHQFHDQDO\VLVRIWKH$+&<JHQH
We hypothesised that functional polymorphisms in the AHCY gene would decrease the 
conversion of methionine to homocysteine, which could be visualised by a diminished 
increase in tHcy upon methionine-loading; This so called delta (') tHcy can be calculated by 
subtracting fasting tHcy from post-methionine load (PML) tHcy. A total of 10 recurrent venous 
thrombosis patients were selected for sequence analysis of the AHCY gene based on their 
capacity to convert methionine to homocysteine after a methionine load (' tHcy 15.1 r 4.3 
Pmol/L; range 4 to 18 Pmol/L). Another ten venous thrombosis patients were selected 
randomly (' tHcy 29.7 r 10.0; range 20 to 53 Pmol/L). Mean ' tHcy in the entire case group 
was 33.1 r 14.0 Pmol/L (range 4 to 98 Pmol/L).
%LRFKHPLFDOSDUDPHWHUV
Blood samples were drawn from the antecubital vein for determination of total plasma 
homocysteine and for DNA extraction. EDTA samples for homocysteine measurement were 
placed on ice immediately and centrifuged at 3500 g for 5 minutes with minimal delay. The 
plasma was separated and stored at -20 ºC. Total plasma homocysteine concentrations were 
measured in our laboratory by an automated high-performance liquid chromatography 
method with reverse phase separation and fluorescent detection (Gilson 232-401 sample 
processor, Spectra Physics 8800 solvent delivery system and LC 304 fluorometer). The 
detection limit was less than 0.5 Pmol/L with inter- and intra run variation was less than 6% 
178. A comparative study in which plasma total homocysteine was determined batch-wise in 
the laboratory of Pediatrics and Neurology of the University Medical Centre Nijmegen (The 
Netherlands) and at the Department of Pharmacology at the University of Bergen (Norway) 
showed a systematic overestimation in tHcy concentration in the Nijmegen laboratory of 2.4 
Pmol/L but the ranking of the subjects was found not to be different between the two tests 
(precision 93%). Therefore it was decided to subtract 2.4 Pmol/L from all tHcy measurements 
(fasting and post-methionine load) conducted in Nijmegen 178,221. DNA extraction was 
performed as described previously 179 and the DNA was stored at 4 ºC. 
6HTXHQFHDQDO\VLVRIWKH$+&<JHQH
The molecular analysis of the AHCY gene was performed by genomic DNA sequencing of 
the entire coding region, including 75 nucleotides of the 5’ untranslated region (UTR) and the 
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entire 3’ UTR. Intron-based primers were developed to avoid amplification of pseudogenes 
(GenBank accession number NT_028392.4) and to reveal potential splice site variants. PCR 
amplifications were performed in a total volume of 50 PL on an iCycler (Bio-Rad, the 
Netherlands); each mixture contained 50 ng of both the forward and reverse primer (Biolegio 
BV, The Netherlands), 200 PM dNTPs, 10 mM Tris-HCl buffer (pH 8.2), 50 mM KCl, 1.0 to 
2.0 mM MgCl2 (see Table 13), 0.5 U of recombinant Taq polymerase, 5% DMSO (all from 
Invitrogen, The Netherlands) and 75 ng DNA. PCR conditions were as follows: initial 
denaturation of 4 minutes at 94qC, 35 cycles of 94qC/30s (denaturation), 50-60qC/30s
(annealing, see Table 13), and 72qC/60s (elongation), and a final extension of 7 minutes at 
72qC. The PCR products obtained were analysed on a 2% agarose gel and subsequently 
sequenced on an ABI Prism 377 automated sequencer using the ABI Prism Big Dye 
Terminator cycle sequence kit according to the instructions of the manufacturer (PE 
Biosystems, The Netherlands). Sequence variants identified during the experiment were 
screened for in our study populations using PCR-RFLP analyses. 
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0XWDWLRQDQDO\VLVRI$+&<&!7YDULDQW
A C>T transition in exon 2 at nucleotide position 112 (relative to the adenosine in the 
translation initiation codon; AHCY mRNA reference sequence NM_000678) of the AHCY 
gene was found. This transition abolishes a BsrB1 restriction site, allowing RFLP analysis. 
Table 13. Primer sequences and PCR conditions used for amplification of the AHCY gene 
Primer Sequence (5’o 3’) [MgCl2] (mM) Tann (qC) Product size (bp) 
5’ UTR+exon1 F  cgccacgcgcatatccctg    
5’ UTR+exon1 R  cccccgccacgaacaagc 2.0 60 195 
Exon 2 F  gtgaccgcccctcttggttgg    
Exon 2 R  ccaccctggcacagtcgtcttc 1.5 51 338 
Exon 3 F  caccctttcccttccacacag    
Exon 3 R  gctaggattttgtggcggtgac 1.5 51 442 
Exon 4 F  gttgggaaggaggtagttttggc    
Exon 4 R  gctgcttgaggtgatgggagtc 1.5 51 350 
Exon 5 F  gctttagggggtaaagatgagg    
Exon 5 R  gcctgtctataaccgcttttgcc 1.0 55 330 
Exon 6 F  ggccttgcctgcccctattg    
Exon 6 R  ctctggccccagtggctgac 1.5 51 295 
Exon 7/8 F  ggcaagggttggttgtcagc    
Exon 7/8 R  ccatctcctcagctctcctccc 1.0 60 476 
Exon 9 F  ggcactgttggaggcagagag    
Exon 9 R  ctctggcaagccctgtgtgg 1.0 60 363 
Exon 10 F  cagacgcgtgtaggggtcc    
Exon 10 R  gaggagaggtggggcctg 1.5 60 254 
3’ UTR1 F  cctccagctgctgtccttgc    
3’ UTR1 R  gggctgaagaaccactggacc 1.5 59 383 
3’ UTR2 F  ggacttatacctgtgtgcttgg    
3’ UTR2 R  gcagagtaccccgtgaatgc 1.0 59 513 
Tann = annealing temperature
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PCR amplification, using primerset 2 (see Table 13), resulted in a fragment of 338 bp and 
was digested by 5 units of the restriction enzyme BsrB1 (New England Biolabs, Inc.) for 2 
hours at 37qC, followed by gel electrophoresis analysis on a 2% agarose gel. Fragments of 
159 bp and 179 bp identify the 112C allele, while the 112T allele shows only one fragment of 
338 bp. Genotype data was not available from one recurrent venous thrombosis patient 
(n=172) and one control individual (n=437). 
0XWDWLRQDQDO\VLVRI$+&<&!7YDULDQW
We found a C to T transition (nucleotide -34 relative to the adenosine in the translation 
initiation codon; AHCY mRNA reference sequence NM_000678) in the 5’ untranslated region 
(UTR) of the AHCY gene. This transition creates an additional MnlI restriction site, allowing 
RFLP analysis. PCR amplification, using primerset 1 (see Table 13), resulted in a fragment 
of 195 bp, which was digested by 5 units of the restriction enzyme MnlI for 2 hours at 37qC, 
followed by gel electrophoresis analysis on a 4% agarose gel. Fragments of 148 and 47 bp 
identify the -34C allele, while the -34T allele shows fragments of 121, 47 and 27 bp. The 
additional MnlI restriction site forms an internal control of the assay. Genotype data was not 
available for three recurrent venous thrombosis patients (n=170) and thirteen control 
individuals (n=425). 
6WDWLVWLFV
All the analyses were performed using SPSS software. Total homocysteine concentrations 
were logarithmically transformed prior to all analyses, and are expressed as a geometric 
mean with a 95% confidence interval (CI). Differences in tHcy concentration were determined 
by linear regression analysis and expressed as changes relative to the wild type. Odds ratios 
and 95% confidence intervals were calculated to estimate the relative risk of venous 
thrombosis in individuals that carry the mutant allele using logistic regression analysis.  
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$+&<VHTXHQFHDQDO\VLV
In order to identify genetic determinants of homocysteine we sequenced the AHCY gene of 
20 recurrent venous thrombosis patients. Sequence analysis of all 10 exons, part of the 5’  
UTR (from nucleotide -75 to the translation initiation codon) and the entire 3’ UTR (nucleotide 
+22353 to +23369) of the AHCY gene revealed 3 sequence variants (Table 14 and Figure 6). 
The first was located in the 5’ UTR 34 bp upstream of the translation initiation codon (-34 
C>T). In one patient a C>T transition was found in exon 2 of the AHCY gene at cDNA 
position 112 (112 C>T). This mutation mandates an amino acid substitution of a basic 
arginine to a neutral tryptophan at codon 38 (R38W). Finally, a synonymous C>T variant was 
Table 14. Sequence variants in the S-adenosylhomocysteine hydrolase gene identified in this study
DNA variants Location Amino acid (substitution) Screening method 
-34 C>T 5’ UTR Untranslated region RFLP; -BsrB1 
112 C>T Exon 2 Arg38Trp RFLP; +MnlI 
390 C>T Exon 4 Asp130Asp Not screened 
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detected in exon 4 (nucleotide position 390, amino acid D130D). The variants were present 
in three separate patients, all in a heterozygous state. Because the -34 C>T variant may 
affect gene expression and the 112 C>T variant mandates an amino acid change and 
potentially affects protein function, we screened our population of recurrent venous 
thrombosis patients and population-based controls for these variants to assess their effects 
on tHcy levels and recurrent venous thrombosis risk. The synonymous 390 C>T variant was 
not studied in further detail, although an effect on mRNA stability or the splicing process 
cannot be ruled out.  

%DVHOLQHFKDUDFWHULVWLFVRIVWXG\SRSXODWLRQ
The control group consisted of 438 individuals (average age 50.7 r 13.3 y) from which 41.1% 
was male (n=180). Fasting and post-load tHcy were 10.4 (95% CI 10.1 to 10.8) Pmol/L and 
38.3 (95% CI 37.2 to 39.5) Pmol/L, respectively. The case group consisted of 180 recurrent 
venous thrombosis patients (average age 61.5 r 14.2 y) from which 50.9% was male (n=88). 
Fasting and post-load tHcy were 12.5 (95% CI 11.8 to 13.3) Pmol/L and 44.4 (95% CI 42.3 to 
46.6) Pmol/L, respectively. 
$VVRFLDWLRQRI$+&<VHTXHQFHYDULDQWVDQGWRWDOKRPRF\VWHLQH
Fasting tHcy concentrations did not differ between the AHCY 112 C>T genotypes in 
recurrent venous thrombosis patients and controls (Table 15). However, in heterozygous 
subjects tHcy concentrations seemed to be increased after a methionine load compared with 
112CC individuals but only in the case group. With respect to the -34 C>T variant, no 
differences in tHcy (fasting or PML) were observed between the genotypes (Table 16). 



1 2        3 4                 5 6 7          8 9 10
mRNA
*          *                 *
Position   0 28        219  295      448    558            766  857                975      1167   1299
AAAAA
-34C>T   112C>T  256G>A   390C>T 654G>A
Figure 6. Schematic representation of the AHCY gene  
A) The coding regions are depicted as white boxes and the intronic regions as a horizontal line. The black boxes represent 
the untranslated regions. The arrows indicate the location of the (intronic) primers used for sequence analysis. B) In this 
mRNA representation sequence variants are indicated by vertical arrows (identified in this study denoted by *) with their 
cDNA position and corresponding codon.
A
B
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$+&<JHQRW\SHDQDO\VHVDQGDVVRFLDWHG597ULVN
In the control group, the distribution of the genotypes defined by the 112 C>T variant was in 
Hardy-Weinberg equilibrium (p=0.19) with a 112T allele frequency of 3.0% among recurrent 
venous thrombosis patients and 2.7% among the controls. The crude odds ratio as an 
estimation of the relative risk of recurrent venous thrombosis for the 112CT genotype 
compared with the 112CC genotype was 1.22 (95% CI [0.56 to 2.65]). Adjustment for age 
and sex did not change this risk estimate (Table 17). 
The genotype distribution defined by the -34 C>T transition in the control group was in 
Hardy-Weinberg equilibrium (p=0.73). The frequency of the -34T allele was 1.8% among the 
recurrent venous thrombosis patients and 1.6% among the controls. The -34TT genotype 
was not observed in our study populations. The relative risk of recurrent venous thrombosis 
due to the -34CT genotype compared with the wild type was 1.07 (95% CI [0.41 to 2.84]). 
After adjustment for age and sex this odds ratio increased to 1.25 (95% CI [0.44 to 3.52]) 
(Table 17). 

Table 15. Association between AHCY genotypes defined by the 112 C>T variant and fasting and post-methionine load 
(PML) tHcy concentrations in venous thrombosis patients versus control individuals  
AHCY genotype n Geometric mean tHcy 
[95% CI] (Pmol/l) 
Crude increase % 
[95% CI] 
Adjusted increase % 
[95% CI]a
Control 112CC 415 10.4 [10.0 to 10.8] 1.0b 1.0 b
 112CT 21 11.3 [9.5 to 13.3] 8.3 [-9.0 to 28.0] 14.4 [-2.1 to 33.6] 
 112TT 1 13.3 28.1 13.0 
Case 112CC 162 12.5 [11.8 to 13.3] 1.0 b 1.0 b
Fasting tHcy 
 112CT 10 12.5 [9.8 to 16.0] 0 [-23.0 to 29.0] 3.8 [-16.6 to 29.3] 
Control 112CC 415 38.2 [37.1 to 39.5] 1.0 b 1.0 b
 112CT 21 39.3 [34.2 to 45.1] 2.7 [-11.0 to 18.0] 6.1 [-7.7 to 22.1] 
 112TT 1 36.5 -4.5 -4.5 
Case 112CC 162 43.8 [41.7 to 46.1] 1.0 b 1.0 b
PML tHcy 
 112CT 10 54.8 [44.8 to 67.2] 25.1 [1.5 to 54.3] 27.7  [3.9 to 56.8] 
a adjusted for age, sex and serum creatinine, b reference category 
Table 16. Association between AHCY genotypes defined by the -34 C>T variant and fasting and post-methionine-load 
(PML) tHcy concentrations in recurrent venous thrombosis patients versus control individuals 
AHCY genotype n Geometric mean tHcy  
[95% CI] (Pmol/l) 
Crude increase %  
[95% CI] 
Adjusted increase %
[95% CI]a
Control -34CC 411 10.4 [10.1 to 10.8] 1b 1 b
 -34CT 14 11.5 [9.5 to 14.1] 10.5 [-9.9 to 35.4] 11.1 [-7.8 to 33.7] 
Case -34CC 164 12.7 [11.9 to 13.5] 1 b 1 b
Fasting tHcy 
 -34CT 6 11.0 [8.0 to 16.0] -12.9 [-37.1 to 20.6] -5.7 [-29.0 to 25.3] 
Control -34CC 411 38.3 [37.1 to 39.5] 1 b 1 b
 -34CT 14 39.3 [33.0 to 46.9] 2.8 [-14.1 to 22.9] 6.1 [-7.7 to 22.1] 
Case -34CC 164 44.4 [42.3 to 46.6] 1 b 1 b
PML tHcy 
 -34CT 6 48.4 [37.4 to 62.6] 9.0 [-16.2 to 41.7] 11.7 [-13.6 to 44.5] 
a adjusted for age, sex and serum creatinine, b reference category
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Coulter-Karis and Hershfield 219 were the first to report a sequence of a full-length human 
placental cDNA of the AHCY gene. They reported a G to A transition in exon 3 at nucleotide 
256, which results in an aspartic acid to asparagine conversion and abrogates a Sau96I
restriction site. We screened 50 randomly selected controls for this polymorphism but did not 
detect this variant in the 100 alleles screened, nor did we find this mutation in 40 recurrent 
venous thrombosis patients (including the 20 patients used for the sequence analysis).  
From these findings we conclude that this transition may either represent a sequence artifact 
or is present only at a frequency <0.5%. In addition, a synonymous mutation in exon 8 (954 
G>A, K318K) reported in the NCBI SNP Database was not found by sequencing analysis of 
the AHCY gene in the 20 recurrent venous thrombosis patients, and was not studied in 
further detail. 
'LVFXVVLRQ
It is still debated via which mechanism hyperhomocysteinemia induces arterial vascular 
disease and venous thrombosis. In addition to the direct effects of homocysteine, the parallel 
increase in AdoHcy observed in hyperhomocysteinemic individuals 55,56 and associated 
effects on adenosine 222 and transmethylation 59,60 have emerged as alternative mechanisms 
for hyperhomocysteinemia-related cardiovascular disease. Laukkanen and colleagues found 
that local CpG-methylation in the superoxide dismutase gene in rabbit atherosclerotic aortas 
was reduced 223, while others observed global DNA hypomethylation in atherosclerotic 
lesions and leucocytes of cardiovascular disease patients 57,224.
This is the first report of a systematic sequence analysis of the human AHCY gene in a group 
of recurrent venous thrombosis patients. We found three sequence variants of which two, 
that is 112 C>T and -34 C>T, were studied in a group of recurrent venous thrombosis cases 
and population-based controls to assess their effect on tHcy and recurrent venous 
thrombosis risk.
No effect of both sequence variants on fasting tHcy was observed in our case and control 
group. A higher tHcy after a methionine-load was observed but only in 112CT cases. This is 
in contrast to our expectations but may be explained by an effect of the polymorphism on the 
Table 17. Distribution of AHCY 112 C>T and -34 C>T genotypes among recurrent venous thrombosis patients 
and control individuals and risk for recurrent venous thrombosis 
Genotype RVT Patients, n (%) 
(N=172)
Controls, n (%) 
(N=437)
Crude odds ratio 
[95% CI] 
Adjusted odds ratio 
[95% CI]a
112 CC 162 (94.2) 415 (95.0) 1.0b 1.0b
112 CT 10 (5.8) 21 (4.8) 1.22 [0.56 to 2.65] 1.27 [0.55 to 2.94] 
112 TT n.o. 1 (0.2) - - 
RVT patients, n (%)  
(N=170)
Controls, n (%)  
(N=425)
Crude odds ratio [ 
95% CI] 
Adjusted odds ratio
[95% CI]a
-34 CC 164 (96.5) 411 (96.7) 1.0b 1.0b
-34 CT 6 (3.5) 14 (3.3) 1.07 [0.41 to 2.84] 1.25 [0.44 to 3.52] 
-34 TT n.o. n.o. - - 
a adjusted for age and gender, b reference category, n.o. not observed
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synthesis of AdoHcy out of homocysteine resulting in elevation of tHcy, especially after 
increased methionine-intake (i.e. methionine-load). However, this effect was not observed in 
our control population making it questionable whether the effect on tHcy is due to the 
polymorphism or simply a chance finding (due to low number of individuals carrying the T 
allele). Expression studies are needed to study the impact of these polymorphisms at the 
protein level that may reveal if and how the reversible AHCY-catalyzed reaction is affected. 
The effect of these polymorphisms on electrophoretic mobility may also be investigated since 
differently migrating isoforms have been described in the past 216-218. However, no tissue 
samples were available to assess whether a mobility shift of the AHCY enzyme was 
correlated with the polymorphisms. 
Very recently, Baric and colleagues reported an AHCY deficient patient with only a slightly 
elevated tHcy (15.9 Pmol/L) while AdoHcy levels were increased a150-fold. This case shows 
that inhibition of AHCY, and associated changes in AdoHcy, does not necessarily lead to a 
dramatic change in tHcy 220. It would be interesting to measure AdoMet and AdoHcy levels, 
the ratio of which is an important predictor of cellular methylation capacity, to test the 
hypothesis that the polymorphisms described in this study affect AdoHcy and AdoMet levels. 
Unfortunately, AdoMet is very unstable in untreated blood samples and is partly degraded 
into AdoHcy 225 making it impossible to measure these metabolites in the stored plasma 
samples of our study populations. This also prompted us to use tHcy levels as a selection 
criterion although AdoHcy would have been a better candidate. 
We assessed the relative risk conferred by these variants on developing two or more venous 
thrombosis events. The odds ratio for recurrent venous thrombosis was 1.22 (95% CI [0.56 
to2.65]) for the 112 CT genotype compared with the 112CC genotype. Similar results were 
obtained for the -34bp C>T variant; an odds ratio of 1.07 (95% CI [0.41 to 2.84] was 
observed for the -34CT genotype, which increased to 1.25 (95% CI [0.44 to 3.52]) after 
adjustment for age and sex. Although these risk estimates are in the range of venous 
thrombosis risk associated with the MTHFR 677 TT genotype 18, the low frequency of the 
polymorphisms described above underpowers this study to draw firm conclusions on disease 
risk conferred by these variants. 
In conclusion, the AHCY gene harbors only little variation in our Dutch population of recurrent 
venous thrombosis patients. This underlines the importance of AHCY in methionine 
metabolism. The detected polymorphisms seem to have no important effect on tHcy, but an 
effect on AdoHcy and recurrent venous thrombosis risk cannot be ruled out and needs 
additional studies in larger populations. These studies, in which AdoMet and AdoHcy 
concentrations are measured as well, may contribute to our understanding via which 
mechanism a disturbed homocysteine metabolism is associated with cardiovascular disease. 

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Background: A disturbed methylation has been proposed as a mechanism via which 
homocysteine is associated with diseases like vascular disease, neural tube defects and 
mental disorders. Catechol-O-methyltransferase (COMT) is involved in the S-
adenosylmethionine-dependent methylation of catecholamines and catecholestrogens and in 
this way contributes to homocysteine synthesis. COMT dysfunction has been related to 
schizophrenia and breast cancer. Objectives: We hypothesized that COMT dysfunction 
affects plasma total homocysteine (tHcy). Because we did find an association between 
COMT genotype and tHcy we also evaluate this genotype as a risk factor for recurrent 
venous thrombosis. Methods: We obtained genotype data from four polymorphisms in the 
COMT gene (rs2097603, rs4633, rs4680 [324G>A] and rs174699) from 401 population-
based controls. We performed haplotype analysis to investigate the association between 
common haplotypes and tHcy. In addition, we assessed the rs4680 variant as a genetic risk 
factor in a case-control study on recurrent venous thrombosis (n= 169). Results: We 
identified a common haplotype that was significantly associated with tHcy levels. This effect 
was largely explained by the rs4680 variant, resulting in an increase in tHcy of 10.4% (95% 
CI 0.01 to 0.21, p=0.03) for 324AA compared with 324GG subjects. Interestingly, we found 
that the 324AA genotype was more common in venous thrombosis patients (OR 1.61 [95% 
CI 0.97 to 2.65], p=0.06) compared to control subjects. Conclusion: We show that the COMT 
rs4680 variant modulates tHcy, and might be associated with venous thrombosis risk as well. 
&KDSWHU
- 76 -
,QWURGXFWLRQ
A disturbed homocysteine metabolism has been associated with diseases of the vascular 
system, both of arterial and venous origin 17-19. In addition, high plasma total homocysteine 
(tHcy) increases the risk of spina bifida, and mental disorders like schizophrenia and 
Alzheimer’s disease 23,36,39. The mechanism of how homocysteine is related to disease is still 
obscure, but there are strong indications that a disturbed transmethylation may partly explain 
this association 60,226,227. Several studies show that plasma total homocysteine levels (tHcy) 
correlate well with plasma S-adenosylhomocysteine (AdoHcy) 55,57, a strong inhibitor of S-
adenosylmethionine (AdoMet)-dependent methylation. Given the importance of methylation 
of nucleic acids, proteins, lipids but also hormones and neurotransmitters, it seems plausible 
that the inhibition or dysfunction of specific methyltransferases affect critical processes and 
hence confer a higher risk of disease. 
The enzyme Catechol-O-methyltransferase (COMT, E.C. 2.1.1.6) is one of the 
methyltransferases that is highly susceptible to inhibition by AdoHcy 228. COMT represents a 
major pathway in the degradation of catecholamine neurotransmitters, like dopamine and 
(nor)adrenaline, and catecholestrogens. Hence, COMT dysfunction has been implicated in 
complex diseases like schizophrenia, Parkinson’s disease and breast cancer 34,160,229,230.
COMT enzyme exists as a membrane-bound (MB) and soluble (S) isoform, the expression of 
which is regulated by two different promotors. A common 324G>A polymorphism (rs4680) in 
the COMT gene, resulting in a valine-to-methionine substitution at position 108 (S-isoform) 
and 158 (MB-isoform), has been studied extensively for its effect on enzyme activity and 
expression, although the data is nonconsistent 231,232.
The metabolic pathways of COMT and homocysteine are interconnected as the O-
methylation of catecholamines and catecholestrogens catalyzed by COMT produces 
homocysteine (Figure 1). Therefore, functional variants within the COMT gene may influence 
tHcy levels and possibly reflect disturbed transmethylation capacity implicated in COMT-
related diseases.  
The aim of our study was to investigate the effect of COMT variants on tHcy. Considering the 
controversy whether the 324G>A variant is causally related to decreased enzyme activity or 
expression, we included three other variants (rs2097603 231, rs4633 and rs174699) in or 
directly adjacent to the COMT gene and performed haplotype analysis. Because we did find 
an association between COMT genotype and plasma homocysteine levels we also evaluate 
this genotype as a risk factor for recurrent venous thrombosis, which is also related to 
homocysteine.

0DWHULDODQG0HWKRGV
6XEMHFWVXVHGLQWKHSUHVHQWVWXG\
The study group was recruited via a general practice in The Hague, the Netherlands, and 
has been described in more detail elsewhere 6. Recurrent venous thrombosis cases were 
selected from the files of the anticoagulant clinic in Leyenburg Hospital in The Hague, The 
Netherlands 6. For the association study, DNA was available from 438 subjects. For the 
case-control study, COMT 324 G>A genotyping was performed in 169 recurrent venous 
thrombosis patients.
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Blood samples were drawn from the antecubital vein in 5 mL Vacutainer tubes and 4.5 mL 
EDTA vacuum glass tubes for determination of total plasma homocysteine and for DNA 
extraction. EDTA samples for homocysteine measurement were placed on ice immediately 
and centrifuged at 3500 g for 5 minutes with minimal delay. The plasma was separated and 
then stored at -20 ºC. Total plasma homocysteine concentrations were measured by an 
automated high-performance liquid chromatography method with reverse phase separation 
and fluorescent detection (Gilson 232-401 sample processor, Spectra Physics 8800 solvent 
delivery system and LC 304 fluorometer) 178. DNA extraction was performed as described 
previously 179 and the DNA was stored at 4 ºC. 

*HQRW\SHDQDO\VLV
We genotyped four single nucleotide polymorphisms (SNPs) distributed over the gene of 
interest: rs2097603, rs4633, rs4680 (sometimes referred to as rs165688) and rs174699.  The 
SNPs were chosen based on frequency, functionality and location within the gene. All four 
created or abolished an enzyme restriction site allowing a simple screening based on 
restriction-fragment length polymorphism (RFLP) analysis. Screening conditions were similar 
in all analyses. For details see Table 18. PCR conditions: 4 minutes at 94qC, 35 cycles of 
94qC/60s, 52-60qC/60s, and 72qC/30s, and a final extension of 7 minutes at 72qC. Each PCR 
reaction mixture contained 50 ng of both forward and reverse primer (Biolegio BV, The 
Netherlands), 200 PM dNTPs, 10 mM Tris-HCl buffer (pH 8.2), 50 mM KCl, 2.0-4.0 mM 
MgCl2, 0.5 U of recombinant Taq polymerase, 5% DMSO (Invitrogen, The Netherlands) and 
75 ng DNA. The resulting PCR product was digested by at least 10 units of restriction 
enzyme (all from New England Biolabs, Inc.) and incubated for 3 hours or overnight at 37qC.
The digests were analysed by gel electrophoresis on a 3 or 4% agarose gel, stained with 
ethidiumbromide and visualized by UV. In all PCR amplifications and restriction analyses, 
DNA samples from which the genotype had been identified by sequence analysis served as 
positive controls. From 401 population-based controls, genotype data was available for all 
four SNP’s (although the total number of genotyped individuals were different for each 
polymorphism). In addition, data of four other reported variants (i.e. rs6267 [Ala22Ser] 233,
rs740602, rs13306281 and rs3218737) was obtained from 150 subjects from the same 
population by means of sequence analysis using the ABI Prism 3130XL automated 
sequencer according to the instructions of the manufacturer (Applied Biosystems, The 
Netherlands). However, three of them appeared non-polymorphic, while rs740602 was found 
only once in the heterozygous state (minor allele frequency of <0.01) and all were excluded 
from further analysis. For the case-control study, additional screening (rs 4680) was 
performed in 169 cases with a history of venous thrombosis 6.
6WDWLVWLFDODQDO\VHV
Haploview 234 was used to evaluate linkage disequilibrium (LD) and correlations between the 
SNPs. Haplotype association analyses for homocysteine levels were performed using Whap. 
Whap (http://pngu.mgh.harvard.edu/purcell//whap) takes the ambiguity in individual 
haplotype estimations into account by applying a weighted likelihood approach. Prior to the 
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haplotype analyses, the log transformed Hcy values were standardized. We used 
permutation testing as implemented in the Whap program to correct for multiple testing in all 
analyses. Haplotypes with a frequency of less than 2% were excluded from the analysis. 
Single-locus genotype effects were evaluated by linear regression analysis (SPSS 12.0). In 
the haplotype analysis, changes in homocysteine levels are expressed relative to the most 
frequent haplotype group. Odds ratios were estimated using logistic regression analysis 
(SPSS 12.0). A p-value <0.05 was considered statistically significant. 
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613JHQRW\SLQJDQGOLQNDJHGLVHTXLOLEULXP
For details about these SNPs regarding location, function and validation method, see Table 
18 and Figure 7. The four COMT SNPs under study were all in Hardy-Weinberg equilibrium 
(P>0.4). Minor allele frequencies for rs2097603, rs4633, rs4680 and rs174699 were 0.48 (G 
allele), 0.47 (C allele), 0.49 (G allele) and 0.068 (C allele), respectively. Of note, the 324G 
allele (which is presumed to be the wild type allele of rs4680) had a lower frequency than the 
324A allele, which is also observed in other studies (Table 18). Linkage disequilibrium (D’) 
and squared correlation coefficients (r2) between each of the genotyped variants are shown 
in Table 19. The SNP pair rs4680 (324G>A) and rs4633 (36T>C) was in almost complete 
LD, with a D’ of 0.96 and r2 of 0.89. No strong LD was observed for the other SNP pairs.  
Table 18. Relevant data of analysed polymorphisms and method of screening 
Variant Reported 
MAFa
DNA Proteinb HW P 
value 
Primers (5’Æ 3’) Validation 
method
[Mg2+]
(mM)
Tann
(qC)
rs2097603 0.39 (G) 
5’ region A>G 
(P2 promoter) 
-
0.87
F aatttggctattgccgtgtc 
R gtcccataaaaggggattcg +HindIII 2.0 52
rs4633 0.39 (T) 36T>C H12H 0.52 
F acaacctgctcatgggtgac 
R tcctgtaagggctttgatgc +PmlI 4.0 60
rs4680 0.36-0.52 (A) 324G>A V108M 0.40
F tactgtggctactcagctgtgc 
R gtgaacgtggtgtgaacacc +NlaIII 2.0 59
rs174699 0.19 (C) Intron 3 T>C - 1.0
F cctctgtgaggctccaactc 
R gaaagaaggcagcacctgtc -NcoI 3.0 59
a MAF, minor allele frequency (source: NCBI), b amino acid change using the (short) soluble form as reference, c Hardy-
Weinberg (HW) P value 
Table 19. Linkage disequilibrium coefficient (D’) between SNPs across the COMT gene in the general population  
Above the diagonal the D’-values are shown and below the diagonal their corresponding squared correlation coefficients (in 
italics) 
Variant Rs number Distance from 
rs2097603 (bp) 
rs2097603 rs4633 rs4680 rs174699 
1 rs2097603 0 - 0.427 0.438 0.50 
2 rs4633 22143 0.149 - 0.964 0.627 
3 rs4680 23179 0.165 0.89 - 0.695 
4 rs174699 26366 0.016 0.033 0.038 -
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Genotype data for all four polymorphisms was obtained from 401 individuals (mean age 50.6 
r 13.3 y), from which 41.0% was male (n=164). Mean fasting tHcy was 10.4 (95% CI 10.0 to 
10.8) Pmol/L, serum creatinin was 74.3 (9% CI 72.7 to 75.9) Pmol/L, vitamin B12 was 221 
(95% CI 208 to 234) pmol/L and folate was 13.1 (95% CI 12.3 to 13.9) nmol/L. 
The haplotype frequencies and their effects on tHcy relative to the most frequent haplotype 
(G-T-A-T) are presented in Table 20. By omitting the haplotypes with a frequency of less 
than two percent, 95% of the haplotypes was covered. The omnibus association test using all 
haplotypes for crude fasting tHcy showed a bordeline significant effect (p=0.05). Haplotype 
specific analysis, i.e. analysis of the effect of the haplotype relative to the most common 
haplotype, showed that the effect was mainly due to the G-C-G-T haplotype that was 
statistically significant associated with low tHcy levels (-13.3% [95% CI -23.6 to -3.1], 
p=0.01). Adjustment for age, sex, serum creatinine, MTHFR 677C>T polymorphism and 
plasma folate did not change this point estimate (not shown). The omnibus haplotype test 
was no longer significant when the analysis was conducted conditional on rs4680 or on 
rs4633 (p=0.28 and p=0.26, respectively). This means that the haplotype analysis did not 
reveal major additional effects besides that observed for the single-loci. Indeed, an increase 
of 10.4% (95% CI 0.01 to 0.21, p=0.03) and 8.8% (95% CI -0.00 to 0.18, p=0.06) in tHcy was 
observed for COMT 324AA and 324GA (rs 4680) individuals, respectively, when compared 
with 324GG subjects (Table 21). Furthermore, by comparing a model in which the effects of 
the 3 haplotypes containing allele C and G at the second and third locus were constrained to 
be equal to a model in which all haplotype effects were estimated separately, we found that 
the effects of the N-C-G-N haplotypes (where N represents one of the alleles observed at the 
first and fourth locus) were not different (p=0.18). This suggests that the haplotype 
background on which these variants appear had no major influence on tHcy.  
Figure 7. Gene structure of the COMT gene 
The boxes represent exons and the thin lines in between represent introns. Gray boxes indicate protein-coding regions. The
length (bp) of each region is indicated, as are the translation initiation codons for the soluble (S-ATG) and membrane-bound  
(MB-ATG) COMT isoform. In the lower part of the figure the polymorphic variants assessed in this study are shown (rs
number, relative position, type of polymorphism), while four other variants that appeared non-polymorphic are depicted in the
upper part. TXNDR2=thioredoxin reductase 2. Adapted from Zhu et al., 2002 59.
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Genotype data of the COMT 324G>A (rs4680) polymorphism was obtained from 424 controls 
and 169, from which 41% (n=174) and 51% (n=86) were male, respectively. For the controls, 
mean age en blood parameters were similar as those of the individuals included in the 
haplotype analysis. For the recurrent venous thrombosis cases (mean age 61.5 r 14.3 y) 
geometric mean (95% CI) tHcy was 12.6 (11.6 to 13.6) Pmol/L, 83.1 (78.6 to 87.6) Pmol/L for 
serum creatinin, 237 (207 to 267) pmol/L for vitamin B12 and 13.7 (12.4 to 15.0) nmol/L for 
folate.
The genotype frequencies were 34.9% (n=59), 45.6% (n=77), 19.5% (n=33), and 27.6% 
(n=117), 47.6% (n=202), 24.8% (n=105) for AA, AG, GG genotypes in cases and controls, 
respectively. These correspond to minor (G) allele frequencies of 0.42 and 0.49 for cases 
and controls, respectively. We found that individuals with the 324AA genotype, 
corresponding with those having the highest tHcy, were at higher risk for recurrent venous 
thrombosis compared with 324GG subjects, although this estimation did not reach statistical 
significance (OR 1.61 [95%CI 0.97 to 2.65], p=0.06). The odds ratio for individuals with the 
324GA genotype was 1.21 (95% CI 0.76 to 1.94, p=0.18).
Table 20. Haplotype frequencies and relative change in tHcy in population-based controls using the G-T-A-T 
haplotype (corresponding with SNP 1, 2, 3 and 4, respectively) as a reference 
Haplotype Frequency Crude change tHcy % [95% CI] 
G-T-A-T 0.355 0a
A-C-G-T 0.312 -3.2 [-9.7 to 3.4] 
A-T-A-T 0.167 1.3 [-7.3 to 9.8] 
G-C-G-T 0.120 -13.3 [-23.6 to -3.1] b
A-C-G-C 0.046 -3.3 [-15.8 to 9.2] 
a Reference category, b p-ANOVA = 0.01
Table 21. COMT single-locus genotype effects on tHcy concentrations in population-based controls 
Variant Genotype n (%) MAFb Crude mean tHcy 
[95% CI] (Pmol/l) 
Crude change % 
[95% CI] 
P
rs2097603 AA 117 (27.7) 10.7 [10.0 to 11.5] 0a
(n=422) AG 208 (49.3) 10.3 [9.8 to 10.8] -4.1 [-12.1 to 4.7] 
 GG 97 (23.0) 0.48 (G) 10.3 [9.5 to 11.1] -4.2 [-13.6 to 6.3] 0.474
rs4633 TT 120 (29.1) 10.8 [10.4 to 11.5] 0a
(n=413) TC 199 (48.2) 10.4 [9.9 to 11.0] -3.0 [-11.0 to 5.6] 
 CC 94 (22.8) 0.47 (C) 10.0 [9.2 to 10.8] -7.3 [-16.3 to 2.6] 0.143
rs4680 GG 105 (24.8) 0.49 (G) 9.6 [8.7 to 10.7] 0a
(n=424) GA 202 (47.6) 10.5 [9.6 to 11.5] 8.8 [-0.00 to 0.18] 
 AA  117 (27.6) 10.8 [10.0 to 11.5] 10.4 [0.01 to 0.21] 0.036
rs174699 TT 365 (86.9) 10.4 [10.0 to 10.8] 0a
(n=420) TC 53 (12.6)  10.2 [9.2 to 11.3] -2.4 [-12.7 to 9.1]  
 CC 2 (0.5) 6.8 (C) 10.7 [6.3 to 18.3] 2.8 [-39.8 to 75.1] 0.748 
a reference category, b MAF, minor allele frequency 
&KDSWHU
- 81 -
'LVFXVVLRQ
We screened for the rs4680 variant as well as three other SNPs dispersed over the COMT 
gene (rs2097603, rs4633 and rs174699) and performed haplotype analysis in order to 
identify whether a specific haplotype was related to tHcy. We show that rs4680 was 
singularly associated with tHcy levels in a Dutch population study, and was responsible for 
the observed haplotype effect. The small, but non-significant, effect on tHcy that was 
observed for variant rs4633 (not shown) is likely to be explained by its high correlation with 
rs4680 (Table 2) 229,235. Interestingly, the 324AA genotype (rs4680) was more prevalent in 
venous thrombosis cases suggesting that this variant may affect recurrent venous 
thrombosis risk as well.  
The 324G>A (rs4680) polymorphism has been extensively studied for its effect at the 
molecular level, mostly because of its potential role in schizophrenia susceptibility. Functional 
studies showed that the COMT 324AA genotype is associated with decreased enzyme 
activity in vitro and in human brain extracts 231,236 although the Val-allele was expressed at a 
slightly lower level in human brain 232. In the past, Goodman et al. 160 showed that the COMT 
324G>A variant affected tHcy in controls, while Geisel et al. did not find such an effect in 
elderly subjects 129. In addition, it has been suggested that other variants might explain the 
observed associations 229. Our results show that 324AA genotype is significantly associated 
with increased tHcy levels, which may support the observation of higher expression of the 
Met-allele by Bray et al. 232. The higher levels of tHcy associated with the 324AA genotype 
may explain why these subjects tend to have a higher risk for venous thrombosis. However, 
a disturbed methylation by COMT in itself may also be involved, especially since the vascular 
system is constantly exposed to circulating catecholamines and catecholestrogens. It has 
been shown that catecholestrogens may have beneficial effects on the vascular system by 
reducing fibrinogen and overall fibrinolysis potential 237, although negative effects have also 
been reported 59. The measurement of plasma AdoMet and AdoHcy levels, the ratio of which 
is a marker of methylation capacity, and in vitro methylation studies could provide additional 
evidence for disturbed methylation in subjects carrying this variant. It should be noted that we 
included patients with a history of venous thrombosis, which may give an overestimation of 
the relative risk. Additional studies are required to study whether the COMT 324G>A 
polymorphism is related to a first thrombotic event. 
One may raise the question whether it is plausible that the flux through the COMT enzyme is 
high enough to generate a relatively large difference in tHcy (about 10%) between subjects 
having the 324GG and 324AA genotype. Studies with Parkinson’s disease patients whose 
tHcy levels rose upon L-DOPA treatment 238-240, indicate that a higher COMT flux is reflected 
in plasma tHcy levels. In addition, a recent genome-wide linkage scan performed by Souto 
and colleagues identified another methyltransferase, Nicotinamide N-methyltransferase 
(NNMT), as a possible major determinant of tHcy 241. This shows that not only 
methyltransferases with a high flux-rate, like guanidinoacetate- and 
phosphatidylethanolamine methyltransferase 242, contribute to homocysteine synthesis, but 
also methyltransferases with an apparently modest contribution to overall methyltransferase 
activity.
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In conclusion, the 324AA genotype (rs4680) is associated with increased tHcy in the general 
population. Subjects with the 324AA genotype also tend to have a higher risk for recurrent 
venous thrombosis compared to subjects with the 324GG genotype. These data may give a 
hint as to what is the high-risk allele in COMT-related disorders, like cardiovascular disease 
and schizophrenia in particular.  
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Chapter 7
Stable-isotope Dilution Liquid Chromatography-electrospray Injection Tandem 
Mass Spectrometry Method for Fast, Selective Measurement of S-
adenosylmethionine and S-adenosylhomocysteine in Plasma 
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It has been postulated that changes in S-adenosylhomocysteine (AdoHcy), a potent inhibitor 
of transmethylation, provide a mechanism via which elevated homocysteine causes its 
detrimental effects. We aimed to develop a rapid and sensitive method to measure AdoHcy 
and its precursor S-adenosylmethionine (AdoMet). We used stable-isotope dilution electron 
spray injection liquid chromatography tandem mass spectrometry (LC-ESI-MS/MS) to 
measure AdoMet and AdoHcy in plasma. Acetic acid was added to prevent AdoMet 
degradation. Phenylboronic acid containing solid-phase extraction (SPE) columns were used 
to bind AdoMet, AdoHcy and their internal standards and for sample cleanup. An HPLC C-18 
column directly coupled to the LC-MS/MS was used for separation and detection. In plasma 
samples, the interassay CVs for AdoMet and AdoHcy were 3.9% and 8.3%, while the 
intraassay CV were 4.2% and 6.7%, respectively. Mean recovery for AdoMet was 94.5% and 
96.8% for AdoHcy. The quantification limits were 2.0 and 1.0 nmol/L for AdoMet and 
AdoHcy, respectively. Immediate acidification of the plasma samples with acetic acid 
prevented the observed AdoMet degradation. In a group of controls (mean tHcy 11.2 Pmol/L) 
plasma AdoMet and AdoHcy were 94.5 nmol/L and 12.3 nmol/L, respectively. Stable-isotope 
dilution LC-ESI-MS/MS allows a sensitive and rapid measurement of AdoMet and AdoHcy. 
The SPE columns enable a simple cleanup step and no metabolite derivatisation is needed. 
The instability of AdoMet is a serious problem and can be prevented easily by immediate 
acidification of the samples. 
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Increased plasma total homocysteine (tHcy) is a risk factor for many pathological conditions 
including cardiovascular disease, congenital abnormalities, certain malignancies and 
neurological disorders 59,243. However, whether increased homocysteine itself is causally 
related to these disease states or is a marker of impaired one-carbon metabolism remains 
subject of debate.  
Homocysteine is a sulphur-containing amino acid derived from demethylation of the essential 
amino acid methionine. After condensation of methionine and ATP, S-adenosylmethionine 
(AdoMet), the principle methyldonor in the human body, is formed. The methyl group can be 
donated to a variety of macromolecules, such as DNA, RNA, proteins and lipids, as well as to 
(small) precursor molecules such as guanidinoacetate and catechol(amine)s. The 
demethylated product of AdoMet is S-adenosylhomocysteine (AdoHcy) which is hydrolyzed 
to homocysteine and adenosine in a reversible reaction catalyzed by AdoHcy hydrolase.  
Efficient removal of adenosine and homocysteine is essential for cellular function as the 
equilibrium of the reaction catalyzed by AdoHcy hydrolase strongly favors the formation of 
AdoHcy, a strong inhibitor of most cellular methylation reactions. In vivo studies have 
demonstrated that increased tHcy is associated with increased plasma AdoHcy levels and a 
reduced AdoMet / AdoHcy ratio 244, also called methylation index, which correlates well with 
global DNA hypomethylation in cardiovascular disease patients 57 as well as different tissues 
including lymphocytes, brain and liver 55,60. It has been suggested that AdoHcy-mediated 
hypomethylation provides an alternative mechanism for the pathogenesis of diseases related 
to hyperhomocysteinemia. Moreover, several studies have shown that AdoHcy is a stronger 
risk factor for cardiovascular disease than homocysteine 56,57, a finding that makes the 
determination of AdoMet and AdoHcy an important tool to evaluate the clinical conditions 
associated with hyperhomocysteinemia.  
Because the concentratioins of AdoMet and AdoHcy in body fluids are low (about 10-100 
nmol/l), their measurement is time-consuming and difficult. In addition, AdoMet is unstable 
and partially degrades into AdoHcy in untreated samples (this study). We therefore aimed to 
develop a sensitive and rapid high-throughput method for simultaneous measurement of 
AdoMet and AdoHcy in biological samples using liquid chromatography-electron spray 
injection tandem mass spectrometry (LC-ESI-MS/MS). 
0DWHULDOVDQG0HWKRGV
6DPSOHFROOHFWLRQDQGVWRUDJH
Blood samples were drawn from the antecubital vein into 4.5 mL evacuated glass tubes 
containing EDTA (BD Vacutainer Systems, Plymouth, UK), placed on ice immediately and 
centrifuged at 3500 g for 5 minutes with minimal delay. The plasma was separated and 
stored at -20ºC until analysis. For AdoMet and AdoHcy measurements, 500 PL of plasma 
was directly acidified with 50PL 1 mol/L acetic acid to a final acetic acid concentration of 
0.091 M, mixed thoroughly and then stored at -20qC. All study participants gave informed 
consent.
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Plasma total homocysteine concentrations were measured in our laboratory by an 
automated HPLC method with reverse-phase separation and fluorescent detection. The 
HPLC system consisted of a Gilson 232-401 sample processor, Spectra Physics 8800 
solvent delivery system and LC 304 fluorometer 178.
3ODVPDVDPSOHSUHSDUDWLRQIRU$GR0HWDQG$GR+F\PHDVXUHPHQWV
Sample cleanup was performed with solid-phase extraction (SPE) columns (Varian Inc.), 
containing phenylboronic acid, which at pH of 7 to 8 selectively bind cis diol groups. The 
SPE columns were preconditioned by addition of five 1-mL volumes of 0.1 M formic acid and 
five 1-mL volumes of 20 mM ammonium acetate (pH 7.4). Before SPE, the acidified samples 
were neutralised with 55 PL 1 mol/L ammonia to a pH of 7.4 to 7.5, and 110 Pl internal 
standard [1.5 PM for 2H3-AdoMet (CDN Isotopes) and 0.41 PM for 13C5-AdoHcy 245] was 
added. The mixture was then applied to the SPE column for binding of AdoMet, AdoHcy and 
their internal standards 2H3-AdoMet and 13C5-AdoHcy. Water-soluble impurities were 
removed by washing the column twice with one mL 20 mmol/L ammoniumacetate (pH 7.4) 
246 and AdoHcy and AdoMet were eluted in one mL 0.1 mol/L formic acid. After SPE, AdoMet 
and AdoHcy were stable for at least 6 months (at -20qC) because elution from the SPE 
column by formic acid (pH 2-3) stabilises AdoMet and AdoHcy. The samples (20 Pl) were 
loaded on an equilibrated (0.2 mL/L acetic acid) Symmetry-Shield HPLC C-18 column [100 
mm x 2.1 mm i.d.; Waters Corporate] and eluted in a gradient (0%-0.3%) of methanol in 0.2 
mL/L aqueous acetic acid delivered by a HP 1100 binary pump (Agilent Technologies) with 
the splitter (Acurate; LC Packings) in the 1:4 mode allowing the injection of 4 PL sample into 
the electrospray injection chamber. The retention times were 2.40 and 2.80 minutes for 
AdoMet and AdoHcy, respectively. AdoMet and AdoHcy levels were measured by LC-ESI-
MS/MS with the Micromass Quattro LC (Waters) in the positive-ion (ESI+) mode. Optimal 
multiple reaction monitoring conditions were obtained for four channels: AdoMet (m/z 
399>250), 2H3-AdoMet (m/z 402>250), AdoHcy (m/z 385>136) and 13C5-AdoHcy (m/z 
390>136). Data were acquired and processed by Quanlynx for Windows NT software 
(Micromass).
$GR0HWDQG$GR+F\TXDQWLILFDWLRQDQGLRQVXSSUHVVLRQ
Calibrators (AdoMet and AdoHcy) and internal standards (2H3-AdoMet and 13C5-AdoHcy)
were included in each analytical run for calibration. Briefly, stock solutions of AdoMet and 
AdoHcy in deionized water were diluted in ammonium acetate (pH 7.4) to concentrations of 
10, 20, 50, 100, 200, 400 and 800 nmol/L for AdoMet and 5, 10, 20, 50, 100, 200 and 400 
nmol/L for AdoHcy. We added 110 Pl of internal standard to 500 Pl of calibration solution and 
then processed as described above for the samples. Calibration curves were obtained by 
plotting ratios of the peak area (calibrator/internal standard) against the concentration of the 
calibrator. We quantified AdoMet and AdoHcy by interpolating the observed peak area ratio 
(m/z 399 and 385 peaks for endogenous AdoMet and AdoHcy vs m/z 402 and m/z 390 
peaks for the 2H3-AdoMet and 13C5-AdoHcy internal standards) on the linear regression line 
&KDSWHU
- 90 -
for the calibration curve. When AdoMet or AdoHcy concentrations were low, the samples 
were measured again, and an additional low-range calibration curve was prepared (2, 5, 10, 
20 and 50 nmol/L or 1, 2.5, 5, 10 and 20 nmol/L for AdoMet and AdoHcy, respectively) as 
described above.  
Ion suppression was calculated from the peak areas of the internal standards added to the 
calibrator solutions and compared with the peak areas of the internal standard that was 
added to each plasma sample. The relative change in peak area of the internal standard was 
attributed to matrix effects.  
6WDWLVWLFV
Linear regression analysis (Excel) was used to verify linearity of the calibration curves and 
one-way ANOVA (SPSS, version 12.0) was used to assess differences in AdoMet and 
AdoHcy concentrations in pooled plasma samples.  

5HVXOWV
&KURPDWRJUDSK\DQGPDVVVSHFWUD
Shown in Figure 8 are typical chromatograms of a control plasma prepared and subjected to 
LC-ESI-MS/MS analysis as described in the Materials and Methods section. Elution time 
were 2.4 min for AdoMet and 2H3-AdoMet and 2.8 minutes for AdoHcy and 13C5-AdoHcy. 
Decomposition MS/MS mass spectra of AdoMet and AdoHcy are shown in Figure 9. Optimal 
multiple reaction monitoring conditions were obtained in the positive-ion mode: AdoMet, m/z 
399>250 (adenosine) and AdoHcy, m/z 385>136 (adenine).  
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/LQHDULW\RI$GR0HWDQG$GR+F\
The calibration curve was linear over the ranges 10-800 nmol/L for AdoMet and 5-400 nmol/L 
for AdoHcy, as determined by 3 separate measurements. The coefficient of linear correlation 
(r2) was >0.999 for the calibration curves of both AdoMet (ƒ) and AdoHcy (i) (see Figure 10). 
For the lower-range calibration curves (2-50 nmol/L for AdoMet and 1-20 nmol/L for AdoHcy), 
the coefficient of linear correlation was also >0.999 for both curves. The quantification limits, 
Figure 8.  Typical MRM chromatograms of control serum 
The left panels show the peak of endogenous AdoMet monitored at
m/z 399>250 (A) and the internal standard peak of 2H3-AdoMet
monitored at m/z 402>250 (B) eluting at 2.4 minutes. The right
panels show the peak of endogenous AdoHcy monitored at m/z
385>136 (C) and the internal standard peak 13C5-AdoHcy
monitored at m/z 390>136 (D) eluting at 2.8 minutes
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derived from the lower-range calibration curve, were 2.0 nM for AdoMet and 1.0 nM for 
AdoHcy (mean signal-to-noise ratio>10).  
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Figure 9. Mass fragmentogram of AdoMet 
and AdoHcy generated in the positive-ion 
mode  
A) AdoMet (m/z 399) and products (m/z 250,
adenosine);
B) AdoHcy (m/z 385) and products (m/z 136, 
adenine)
Figure 10. Calibration curves for AdoMet and AdoHcy determination by LC-MS/MS 
Standard calibration curves were linear over a range of 10 to 800 nmol/L for AdoMet (ƒ) and 5 to 400 nmol/L for
AdoHcy (i) with a coefficient of linear correlation >0.999 for both metabolites 
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Recovery experiments were performed within the physiological ranges of AdoMet and 
AdoHcy, as determined in healthy controls (see below), by use of nonacidified pooled 
plasma samples. The AdoMet concentration of the test pool was 77.3 nmol/L, and for 
AdoHcy 17.6 nmol/L. Mean recoveries were 94.5% for AdoMet (100 nmol/L added to the test 
pool) and 96.8% for AdoHcy (20 nmol/L added to the testpool) with CVs of 5.0% and 6.1% 
respectively (see Table 25A). The precision data for the method are presented in Table 25B. 
For this purpose, a large test pool of plasma was collected and treated according to the 
standard procedure used by our laboratory to assure metabolite stability over time (see also 
next section). The intraassay CVs (n=9) for AdoMet and AdoHcy were 4.2% and 6.7%, 
respectively, and the interassay CVs (n=12) for AdoMet and AdoHcy were 3.9% and 8.3%, 
respectively (Table 25B). Ion suppression in plasma was 30% and 20% for AdoMet and 
AdoHcy, respectively. This assay comprises a fast sample preparation step (10 samples in 
30 minutes) and a measurement / column regeneration time of 8.5 minutes, which enables 
us to handle 100 samples/day. 
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6WDELOLW\RI$GR0HWDQG$GR+F\
We observed a decrease in AdoMet over time in nonacidified plasma samples and a 
simultaneous increase of AdoHcy, suggesting a partial degradation of AdoMet into AdoHcy in 
our plasma samples. We therefore evaluated the AdoMet degradation rate during storage in 
treated and nontreated EDTA plasma samples. After only 3 h at room temperature, a marked 
decrease in AdoMet (~10%) and an increase in AdoHcy (~24%) were observed in the 
nonacidified plasma samples. This degradation process was not prevented by sample 
storage at -20qC, and after 1 month, the AdoMet concentrations had decreased to 43% of the 
initial value (p=0.009), and AdoHcy had increased to 150% of the initial value (p=0.067).
Acidification of aliquots of the same plasma samples (with 1 mol/L acetic acid) stabilised both 
AdoMet and AdoHcy (Table 26). A decrease in AdoMet and a parallel increase in AdoHcy 
were also observed in nontreated plasma samples when the samples were collected in 
sodium citrate (pH 5.5) or heparin Vacutainer Tubes (BD Vacutainer Systems; data not 
shown). These observations are in line with earlier results of Stabler and Allen, who 
observed the same phenomenon in plasma and urine samples that were stored at room 
temperature and in  samples stored at  4qC and below 247. Even the use  of  acidic citrate (pH 
Table 25. Recovery (A) and precision (B) of AdoMet and AdoHcy assay in plasma by LC-MS/MS
A) Recovery of the assay Testpoola Added Mean r SD CV, % Mean recovery, % 
AdoMet (nmol/L, n=6) 77.3 100 171.8r8.6 5.0 94.5 
AdoHcy (nmol/L, n=3) 17.6 20 37.0r2.3 6.1 96.8 
    
B) Precision of the assay Intra assay (n=9) Inter assay (n=12) 
 Meanb SD CV Mean SD CV 
AdoMet (nmol/L) 126.1 5.4 4.2 131.2 5.1 3.9 
AdoHcy (nmol/L) 19.7 1.3 6.7 16.9 1.4 8.3 
Testpool of nonacidified a or acidified b plasma 
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4.3) may not prevent degradation as the pH increases to ~6.0 after blood sampling 248. We 
therefore acidified plasma samples for AdoMet and AdoHcy measurements with acetic acid 
(final concentration, 0.091 mol/L acetic acid; final pH 4.5-5.0) with minimal delay after blood 
sampling to prevent AdoMet degradation. At this pH, no protein precipitation was observed.  

$GR0HWDQG$GR+F\FRQFHQWUDWLRQVLQFRQWUROLQGLYLGXDOV
As controls, 26 apparently healthy individuals from the Radboud University Nijmegen 
Medical Centre [mean (SD) age, 28.3 (8.2) years; 69% women) participated in this study to 
verify our method. Plasma samples were prepared for AdoMet, AdoHcy and tHcy 
determination as described. Mean (SD) concentrations were 11.2 (4.8) Pmol/L for tHcy 
(range, 7.0-29.7 Pmol/L), 94.5 (15.2) nmol/L for AdoMet (range, 69.4-121.8 nmol/L), and 
12.3 (3.7) nmol/L for AdoHcy (range, 6.2-21.9 nmol/L). The resulting mean AdoMet / AdoHcy 
ratio was 8.5 (3.0). The AdoMet and AdoHcy values we obtained from control individuals are 
summarized in Table 27, along with data reported by other groups.  
'LVFXVVLRQ
Interest in AdoMet and AdoHcy measurement has increased over the last few years, 
particularly since increased AdoHcy and decreased cellular methylation capacity have 
emerged as a mechanism explaining the association between hyperhomocysteinemic 
individuals and increased risk for cardiovascular and neurological diseases 56,57,59,249.
In this report we present a highly selective and sensitive high-throughput method for the 
simultaneous measurement of AdoMet and AdoHcy in plasma samples by means of stable-
isotope dilution LC-ESI-MS/MS. Phenylboronic acid-containing SPE columns were used for 
AdoMet and AdoHcy extraction, and no metabolite derivatisation was needed. Our method 
meets the criteria of minimal time required for sample preparation (10 samples in 30 min) 
and measurement / column regeneration (8.5 min), enabling us to process 100 samples per 
day. The method was linear over a broad range for both AdoMet and AdoHcy (r2 >0.999). 
Recoveries >94% were obtained at physiological concentrations, and the inter- and 
intraassay CVs were <10%. Quantification limits of the assay were 2.0 and 1.0 nmol/L for 
AdoMet and AdoHcy, respectively, enabling measurement of AdoMet and AdoHcy within the 
(patho)physiological range.  
Several methods to measure AdoMet and AdoHcy have been described, including HPLC 
with fluorescence detection 250-252, coulometric electrochemical detection 253, and stable-
isotope dilution LC-MS/MS 245,247(Table 3). The disadvantages of the published methods 
include long sample preparation times attributable to the use of inorganic chemicals (e.g., 
phosphate buffers 245 or perchloric acid for deproteinisation 247), which are less compatible 
with MS. Other time-consuming steps include derivatisation 251, sample analysis, and column 
regeneration 247,250,253. Our method used MS-compatible buffers and solutions, thereby 
reducing potential ion suppression effects. The use of stable isotopes enables the 
adjustment for ion suppression due to matrix effects or early eluting compounds. 
The observation that AdoMet is unstable in untreated samples and partially degrades into 
AdoHcy, as observed by us (this study) and others 247, may confound the results obtained in 
previous studies that report relatively low AdoMet and high AdoHcy concentrations. The 
&KDSWHU
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sensitivity of the assay may be compromised, and the AdoMet / AdoHcy ratio may change 
because the quantitative decrease in AdoMet is not reflected by the increase in AdoHcy. To 
prevent this degradation process, we acidified plasma samples with acetic acid to a pH<5.0 
immediately after blood sampling and centrifugation. Interassay CVs calculated over a 4-
month period indicated that acidification of plasma samples with acetic acid stabilises 
AdoMet and AdoHcy for at least 4 months.  
We measured AdoMet and AdoHcy in 26 healthy individuals and found AdoMet and AdoHcy 
concentrations similar to those reported by others 247,250, and our calculated methylation 
index approached values observed by Stabler and Allen, and Melnyk et al. 247,253. We found 
only a slight correlation between tHcy and AdoHcy (data not shown). This may be 
attributable to the fact that most of our observations were within the physiological range for 
Hcy; we may have observed a stronger correlation if hyperhomocysteinemic individuals had 
been included in the study.  
In conclusion, the presented method provides a fast, reliable way for the routine 
measurement of AdoMet and AdoHcy in plasma, enabling investigation of disturbed 1-carbon 
metabolism in various disease states associated with hyperhomocysteinemia. 
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$EVWUDFW
Hyperhomocysteinemia is a risk factor for arterial vascular disease and venous thrombosis. 
High homocysteine causes an increase in S-adenosylhomocysteine, a strong inhibitor of S-
adenosylmethionine-dependent transmethylation, which is thought to explain the association 
between high homocysteine and cardiovascular disease. Methylation is a covalent 
modification involved in key processes like gene expression, genomic stability, protein-
protein interactions and protein maturation. In contrast to DNA methylation, protein 
methylation is poorly studied due to technical difficulties. The introduction of high-throughput 
and sensitive methods for mass determination is of great benefit to proteomic applications, 
including the identification of posttranslational modifications. We aimed to study the 
proteome of cultured human umbilical vein endothelial cells (HUVECs) and protein 
methylation by means of SDS-PAGE fractionation, followed by in-gel trypsin digestion, 
peptide extraction and nano-liquid chromatography Fourier transform ion cyclotron 
resonance mass spectrometry (nano-LC FTICR MS). 
We identified about 1500 proteins in cultured HUVECs, which could, after orthologous 
clustering, be assigned to the following main eukaryotic orthologous group (KOG)-divisions: 
Cellular processes and signaling (22.0%), Information storage and processing (10.3%), and 
Metabolism (9.2%). Based on peptide counts, we enlisted the most abundant proteins and 
provided additional data, like GI/IPI entry, mass and KOG (sub)divisions for each of those 
proteins. In order to illustrate the potential for identifying methylation sites we examined the 
Von Willebrand Factor precursor protein in more detail. A sequence coverage of 53.3% 
(1500 amino acids out of 2813) was obtained, and fourteen methylation sites were identified 
at arginine or lysine residues. The ions scores (mean 53) and expectation values (mean 
0.027) indicate that these sites are likely to represent true methylation sites.  
Our study shows that we are able to identify proteins in complex samples and assign 
methylation sites within specific proteins. Future studies should focus on nano-LC FTICR MS 
in combination with stable-isotope labeling, allowing the quantification of global and specific 
protein methylation for studying differential protein methylation in vitro.
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,QWURGXFWLRQ
High levels of plasma total homocysteine (tHcy) are associated with an increased risk of 
cardiovascular disease. Endothelial dysfunction, an early marker of atherosclerosis, is one of 
the proposed mechanisms via which high tHcy compromises the vascular system 49,254,255.
The endothelium makes up the inner lining of the blood vessel, and is involved in important 
processes like regulation of blood flow, production of bioactive molecules (hormones, growth 
factors), production of (anti)coagulation factors (such as Von Willebrand factor and nitric 
oxide), and immune responses. Because the endothelium is directly exposed to the blood, 
toxic metabolites including reactive oxygen species may disturb endothelial function and 
ultimately lead or contribute to vascular damage.  
The exact mechanism how high tHcy causes endothelial dysfunction and subsequent 
vascular disease is still obscure, but some studies suggest that a disturbed methylation may 
be involved 55,60. Methylation of macromolecules, like proteins, represents an important 
modification involved in numerous processes. Because the addition of a methyl group to 
proteins may cause steric hindrance or affect protein properties (such as hydrophobicity), 
methylation may be important for protein-protein interactions or interactions between proteins 
and other molecules (such as DNA and RNA). As such, protein methylation is thought to be 
involved in protein repair and turnover, gene expression, maturation of RNA-binding proteins 
and cellular signaling 256-258.
Several studies have shown that high tHcy is associated with an increase in S-
adenosylhomocysteine (AdoHcy), a strong inhibitor of S-adenosylmethionine (AdoMet)-
dependent transmethylation 55-57,60. The inhibitory effect of AdoHcy is thought to affect many 
methyltransferases 228 and, hence, disturbed methylation may represent a general 
mechanism via which homocysteine causes disease. Recently, Bjorklund suggested that 
disturbed protein methylation may be involved in the etiology of neural tube defects 227.
The study of protein methylation has been hindered because it is laborious, requires large 
amounts of sample and the techniques are not applicable for studying complex samples 259.
The increasing accuracy in mass determination by mass spectrometry has greatly facilitated 
the study of proteomes, and posttranslational modifications, including methylation. In 
general, these methods use the mass shift, introduced by the addition of a methyl group 
(14.0157 Da), to find peptides that contain modified amino acids. Recently, Rappsilber and 
co-workers used precursor ion scanning mass spectrometry to study arginine dimethylated 
peptides 260. They focused on the FUS/TLS and Sam68 proteins and were able to identify 
several arginine dimethylated sites within these proteins.  
We aimed to study the proteome of cultured human umbilical vein endothelial cells 
(HUVECs). Because of the potential role of disturbed protein methylation in disease, we also 
studied protein specific methylation in HUVECs. After SDS-PAGE of crude HUVEC extracts, 
we performed in-gel digestion followed by nano-LC FTICR MS analysis for the separation 
and sequencing of peptides. We used Mascot software for the identification of peptides and 
their methylation sites.   

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0DWHULDOVDQG0HWKRGV
&HOOFXOWXUH
Culture medium was prepared by suppletion of M199 medium (Sigma-Aldrich) with 0.1% 
heparin, 10% newborn calf serum (Gibco), 10% human serum (Biowhittaker), 1% glutamine 
(ICN), 1% penicillin/streptomycin and 7.5 mg / 50 ml growthfactor (home-made calf brain 
extract). The medium was sterilized using a 0.2 Pm filter. HUVECs were harvested from fresh 
umbilical veins by collagenase treatment (0.06%, Worthington/Aristofarma) and grown to 
confluence (cobblestone) on 1% gelatin-coated wells in complete medium at 37qC (5% CO2). 
Cells were diluted (1:3) after every passage and grown in 175 cm2 culture flasks. Cells were 
harvested at the fourth passage by trypsin treatment, washed in phosphate-buffered saline 
and collected at 3000 rpm for 5 minutes (4qC). Cells were snap-frozen in liquid nitrogen and 
stored at –80qC until further analysis. 
6DPSOHSUHSDUDWLRQ
Cells were resuspended in lysis buffer (7M ureum, 2M thioureum, 4% CHAPS, 5% glycerol 
and 1 mM protease inhibitors [Complete, Roche]) and sonicated on ice (3 x 5 seconds) to 
facilitate cell lysis. The membrane and cytosolic fractions were separated by centrifugation 
(Sorvall RC5B plus DuPont, 20.000 g, 1 hour at 4qC). The membrane fraction was solubilized 
in membrane buffer (5M urea, 2M thiourea, 10% glycerol, 50mM Tris-HCl pH 8.0, 2% SBS-
10, 5mM TCEP and 1 mM protease inhibitors) and diluted in tricine buffer (+2% E-
mercaptoethanol, both from Bio-Rad). The protein concentration of the cytoplasmic fraction 
was measured by the method of Lowry and samples were diluted in tricine buffer (+2% E-
mercaptoethanol). Thirty microgram of both fractions was separated on a 12% SDS-
polyacrylamide gel (90 minutes, 100V). Each lane was cut into 10 slices, which were then 
prepared for FT-MS analysis. 
Gel slices were cut into pieces with a scalpel and proteins were in-gel reduced (10 mM DTT) 
and alkylated (50 mM iodoacetamide in 50 mM NH4HCO3). Proteins were in-gel digested 
overnight at 37qC in a solution containing 12.5 ng/Pl trypsin (Promega). Peptides were 
extracted from the gel by 2% trifluoro acetic acid (TFA) and the extract was desalted and 
concentrated using C18-stage tips. Peptides were eluted in 2-4 Pl buffer containing 0.5% 
acetic acid and 1% TFA (buffer A), and then diluted ten times in a buffer containing 80% 
acetonitrile, 0.5% acetic acid and 1% TFA (buffer B). Extracts were stored at -20qC until 
analysis.
)706DQDO\VLV
Digested proteins were separated using an Agilent 1100 LC system (Agilent, Palo Alto, CA, 
USA). The peptides were loaded onto 100 Pm columns packed by bomb loading with 3 Pm
C18 beads (Reprosil-Pur C18 AQ, Dr Maisch GMBH, Ammerbuch-Entringen, Germany). Peptides 
were eluted in a gradient of solution B (80% acetonitrile, 0.5% acetic acid) in solution A 
(0.5% acetic acid). First a gradient of 3% solution B (97% solution A) to 10% (90% solution 
A) was built up in 5 minutes. In the next 55 minutes, the gradient increased to 30% solution B 
(70% solution A), and then in seven minutes from 30% solution B (70% solution A) to 
equivalent amounts of solution A and B to elute the residual peptides. A flow of 600 nl/min 
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during loading and 300 nl/min during elution was used. Peptides were eluted directly into the 
mass spectrometer (LTQ FTICR MS, Thermo Electron Corporation, Bremen, Germany) by 
nano-electrospray ionization. In each cycle, full scan MS spectra were recorded (400-1500 
m/z) in the Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FTICR MS). 
The four most abundant ions were selected data-dependent and fragmented in the linear ion 
trap by collision-induced dissociation (using helium as a collision gas) to determine their 
amino acid sequence.  
'DWDDQDO\VLV
The mass spectrometry data were converted to a Mascot Generic data format with a Perl 
script and searched against the International Protein Index (IPI) database (version 3.03, 02-
14-2005, http://www.ebi.ac.uk/IPI/IPIhelp.html) using Mascot (Matrix Science Inc., Boston, 
MA USA). The search algorithm was set to perform a tryptic search allowing 4 miscleavages 
and searched for carbamidomethyl modifications on cysteine residues, mono- di- and 
trimethylation of both arginine and lysine residues and possible oxidation of methionine. A 
mass accuracy of 20 ppm for the FTICR MS and 0.8 Da for the Linear Ion Trap was used. 
Protein hits were extracted from the Mascot search file using MSQuant 
(http://msquant.sourceforge.net/) and a Mascot (ions) score of 30 and peptide delta score 
>10 were used for peptide selection and protein identification. Using these cut-off values, the 
false positive rate for identifying proteins based on a single peptide is negligible (E. 
Lasonder, personal communication). The ions score and related expectation value (e-value), 
two statistical measures allowing a better estimation of significance in order to reduce the 
possibility of false positives, were used for the identification of methylated peptides.  

5HVXOWV
+89(&SURWHRPH
The obtained mass data from both the MS and MS/MS spectra were compared to a protein 
database and enable peptide and protein identification. We were able to identify 1517 
proteins in our HUVEC extracts. The mean protein sequence coverage in the whole set of 
proteins was about 25%, which allows protein identification with high confidence. In order to 
cluster these proteins according to their function, we performed orthologous (functional) 
clustering. This way the proteins are assigned to one of the three “eukaryotic orthologous 
group” (KOG) divisions. The percentage of proteins assigned to each KOG division is given 
in parenthesis: “1) Cellular processes and signaling” (22.0%), “2) Information storage and 
processing” (10.3%) and “3) Metabolism” (9.2%), while 52.1% was not annotated or poorly 
characterized (6.4%) using this cluster algorithm. Within each KOG division, the proteins can 
be assigned to subgroups. From the proteins assigned to KOG division 1, most were 
involved in posttranslational modification, protein turnover and chaperones (28.4%), signal 
transduction (19.8%), trafficking (18.1%) or were cytoskeletal proteins (17.2%). In KOG 
division 2, most proteins were involved in translation, ribosomal structure and biogenesis 
(47.4%), RNA processing and modification (26.6%) and transcription (9.5%) and chromatin 
structure (11.8%). Finally, within KOG 3 most proteins were involved in energy production 
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(27.1%), lipid (17.2%), carbohydrate (16.5%) or amino acid (15.9%) transport and 
metabolism. 
$EXQGDQWSURWHLQVLQ+89(&V
All proteins that were identified by 30 or more peptide hits are listed in Table 28 (n=96). For 
these most abundant proteins, a total 13072 of peptides were identified with a mean Mascot 
score of 52 (SD 17). These proteins could be assigned into KOG divisions “1) Cellular 
processes and signaling” (35.9%), “2) Information storage and processing” (13.6%) and “3) 
Metabolism” (5.8%), while 41.8% was not annotated or poorly characterized (2.9%). Among 
the most abundant proteins were cytoskeletal proteins like D-actinin, lamin A/C, actin and 
myosin heavy chain. In addition, proteins involved in posttranslational modification, protein 
turnover and chaperones, like 14-3-3 protein, peroxiredoxin, calnexin and heat-shock protein 
E-1 were abundantly present. Lastly, proteins involved in translation, like 60S and 40S 
ribosomal proteins, elongation factor D and eukaryotic initiation factor were also identified in 
HUVEC extracts. See Table 28 for details on IPI/GI entry, description, mass and KOG 
(sub)division for these proteins. 

3URWHLQPHWK\ODWLRQVLWHVRQ9RQ:LOOHEUDQG)DFWRUSUHFXUVRUSURWHLQ
In order to identify protein specific methylation sites, all peptides with an ions score >20 were 
selected from the data set. Because the addition of a methyl group results in a mass-shift of 
14.02 Da, we were able to detect methylated peptides. Figure 11 shows two MS/MS spectra 
from the same peptide that is either methylated or non-methylated. The differences in 
masses of the whole peptide and the corresponding b-ions show that this peptide contains a 
methylation site. We studied Von Willebrand factor precursor protein (VWFp, IPI00023014) in 
more detail and show the methylation sites within that protein (see Table 29 and Figure 12). 
The sequence coverage was 53.3% (1500 out of 2813 amino acids) for VWFp. We identified 
fourteen (mono) methylation sites dispersed throughout the protein: five methylgroups were 
located at lysine residues and nine at arginine residues. For all peptides specific to VWFp 
and with a presumed methylation site, the mean ions score was 45 (SD 14) and the mean e-
value was 0.0616 (SD 0.1289) (Table 29), meaning that the annotation of methyl groups at 
these amino acid residues most likely represent true methylation sites. The mean ions score 
and e-value of the non-methylated peptides was 58 (SD 17.6) and 0.0093 (SD 0.0029), 
respectively, showing that non-modified peptides can be identified with higher confidence 
(Table 29). The percentage of peptides, for which both methylated and non-methylated 
peptides were identified, that was methylated was 37.4%. Theoretically, based on the mass 
shift ([14.02]n) we should be able to identify dimethylation sites, but the ions scores and 
expectation values (<20 or >1, respectively) did not allow definite annotation of these sites. 
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Figure 11. MS/MS spectra derived from the same peptide (YAGSQVASTSEVLK) that is either non-methylated (A) or 
methylated (B). The observed masses, b- and y-ions are shown for each peptide 
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Figure 12. Sequence coverage Von W
illebrand factor precursor and identified m
ethylation sites 
M
atched peptides are show
n in bold (53.3%
), m
ethylation sites in bold and underlined
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We aimed to study the proteome and protein methylation in HUVECs by means of nano-LC 
FTICR MS analysis. We identified about 1500 proteins, from which the most abundant 
represented cytoskeletal proteins, proteins involved in posttranslational modifications, protein 
turnover, chaperones and translation. Recently, Bruneel and co-workers studied the 
proteome of HUVECs by means of 2D gel electrophoresis and matrix-assisted laser 
desorption-ionization time-of-flight (MALDI-TOF) analysis and were able to identify 160 
proteins (http://www.huvec.com) 261,262. We were able to identify a nearly ten-fold higher 
number of proteins, illustrating the power of our FTICR-MS method. Because the databases 
used for orthologous clustering include only few eukaryotic genomes, the annotation within 
the clustering was rather low (50%). 
We aimed to identify methyl groups, which correspond to a mass shift of 14.02 Da relative to 
the non-methylated peptide, and their position within the protein. We used Von Willebrand 
factor precursor protein (VWFp) as an example, because of its size, abundancy and well-
known role as a platelet-vessel wall mediator in the blood coagulation system. VWF is 
synthesized as an inactive precursor protein in endothelial cells and becomes activated, for 
example, upon damage of the vascular endothelial cells. Indeed, we identified the inactive 
form of VWF in our extracts, for which a sequence coverage of 53.3% was obtained and 
fourteen methylation sites were identified on either an arginine or lysine residue with high 
confidence. The mean ions score and expectation values indicate that these residues most 
likely represent methylation sites. Several domains within VWFp have been identified, such 
as the D’/D3 domain (residues 1-272) for factor VIII binding and C1 domain (residues 1744-
1746) for integrin binding on platelets 263. We did not observe methylation sites within these 
domains, however.
There are a few limitations of our study to consider. The sequence coverage is not 100%, 
which is necessary to identify all methylation sites. This could be accomplished by further 
fractionation of the protein mixture or enrichment of specific proteins, i.e. by 
immunoprecipitation with antibodies directed against specific proteins or methylated arginine 
residues. Furthermore, longer recording time of peptide spectra will increase protein 
coverage. Another point of consideration is the potential effect of protein methylation on 
trypsin cleavage. Trypsin is known to cut at the same (arginine and lysine) residues, which 
are potentially methylated. It has been suggested that trypsin may not cleave methylated 
sites as efficiently as non-methylated sites 264. An alternative would be to use chymotrypsin 
(which cleaves at Trp, Phe and Tyr residues) or GluC (which cleaves primarily at Gln 
residues) and, hence, its activity is unlikely to be affected by methylation. 
The identification of protein methylation sites, and the quantitation of this modification, has 
gained increasing interest because of its potential role in cell function. Recently, Bulau and 
co-workers described a method to study global arginine methylation by means of hydrolysis 
of enriched protein samples followed by high-performance liquid chromatography analysis 
265. This may give an indication of overall (arginine) methylation between two (experimental) 
states, but specific proteins or methylation sites will not be identified this way. Ong and 
colleagues 264 described a method, called “stable isotope labelling of amino acids in cell 
culture”  (SILAC), for the identification of methylation sites and their relative or (when using 
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internal standards) absolute quantification. In this technique, cells are cultured in the 
presence of 13CD3-methionine (“heavy” methionine), which is then metabolically converted to 
13CD3-AdoMet. These “heavy” methylgroups are directly incorporated into in vivo methylation 
sites and cause a mass shift relative to the non-methylated peptide. The lysates form “heavy” 
and “light” labelled cells are mixed in known ratios. Quantification is based on individual 
peptides, allowing site-specific quantitation of protein methylation by determining intensity 
ratios of methylated/unmethylated peptide pairs 264.
A disturbed homocysteine metabolism is known to affect methylation status in vivo 55,57,60. An 
increase in AdoHcy, a strong inhibitor of AdoMet-dependent transmethylation, is postulated 
to be the underlying cause. These conditions can be imitated in vitro by manipulating 
homocysteine metabolism. For example, the use of periodate oxidized adenosine (Adox), a 
well-known inhibitor of S-adenosylhomocysteine hydrolase, increases intracellular AdoHcy 
and decreases global DNA methylation in HUVECs 266. In a pilot experiment using Adox-
treated cultured HUVECs, we were able to establish an accumulation of intracellular AdoHcy, 
resulting in a strong decrease in AdoMet/AdoHcy ratio (an indicator of cellular methylation 
capacity). At a concentration of 50 Pmol/L Adox (Sigma-Aldrich), the AdoMet/AdoHcy ratio 
decreased from 5.63 (standard deviation=0.73) in control cells (0 Pmol/L Adox), to 0.82 
(standard deviation=0.08) in treated cells (unpublished results). This will allow us to study 
protein methylation under “hypomethylating” conditions. In addition, the investigation of 
protein methylation in experimental models 267 or patients assumed to have a reduced 
methylation capacity 268 may confirm that this modification also occurs in vivo. However, the 
quantification of protein methylation in primary tissues is not compatible with the SILAC 
method, and would require chemical labeling of proteins, like the isotope-coded affinity tag 
(ICAT) method 269. Ultimately, protein function needs to be studied in order to reveal the 
consequences of differential methylation of specific proteins and potential contribution to 
disease initiation or progression. 
Our study shows that we are able to identify proteins in complex samples and methyl groups 
on peptides derived from specific proteins, as described for Von Willebrand factor precursor 
protein. Future studies should focus on nano-LC FTICR MS in combination with stable-
isotope labeling, allowing the quantification of global and specific protein methylation for 
studying differential protein methylation in vitro. This may contribute to our understanding of 
how a disturbed one-carbon metabolism may contribute to disease development. 

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Chapter 9
Summary,
General discussion
and
Future perspectives 
Part of the General discussion is published in modified form as  
Genetic Determinants of Plasma Total Homocysteine 
Henkjan Gellekink, Martin den Heijer, Sandra G. Heil, Henk J. Blom
Seminars in Vascular Medicine 2005; 5: 98-109
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6XPPDU\
A high plasma total homocysteine (tHcy) is a risk factor for cardiovascular diseases, 
congenital malformations and neurological disorders. Besides environmental factors and 
lifestyle, also genetic factors contribute to the variation in tHcy concentrations. The genetic 
contribution to the variation in tHcy, however, is only partly explained by known genetic 
factors. The aim of the studies described in this thesis was to identify novel genetic 
determinants of tHcy, especially those that are also associated with disease risk. In this 
thesis we focused on recurrent venous thrombosis. A second goal was to develop methods 
to study the role of disturbed transmethylation as a mechanism for homocysteine-related 
pathology.
In Chapter 1, a general introduction on homocysteine metabolism, a description of 
homocysteine-related diseases, and an overview of the genetic variants that have been 
assessed for their effect on tHcy is given.  
The studies presented in this thesis are divided into two parts: Part I describes the search for 
novel determinants of tHcy, focusing on homocysteine remethylation (Chapters 2-4) and on 
genes that are involved in transmethylation (Chapters 5 and 6). Part II of this thesis 
describes the studies that were performed in order to facilitate the study of transmethylation 
as a mechanism for homocysteine-related pathology (Chapter 7 and 8).
In Chapter 2, we studied common variants in genes encoding homocysteine remethylation 
enzymes (MTR 2756A>G, MTRR 66A>G) and their associations with tHcy, folate and 
venous thrombosis risk. Given the importance of vitamin B12 in homocysteine remethylation 
we also assessed vitamin B12 status in relation to venous thrombosis, by assessing plasma 
vitamin B12 and methylmalonic acid (MMA). Interestingly, we found that high MMA, 
indicative of low intracellular vitamin B12 status, increased the risk of venous thrombosis. 
The fact that low plasma vitamin B12 levels did not confer a risk for venous thrombosis, 
suggests that plasma vitamin B12 is not a sensitive marker for vitamin B12 status. Both 
genetic variants had no effect on tHcy, but we observed an interaction between the MTRR 
66GG genotype and high MMA, increasing venous thrombosis risk more than 5-fold.  
In Chapter 3, the molecular genetic analysis of the human DHFR gene is described. This 
gene is essential for the continuous reduction of dihydrofolate to tetrahydrofolate required for 
homocysteine remethylation. We identified a 9-bp repeat in the 5’ upstream region of DHFR, 
but observed no effect on tHcy in the general population. The recently identified 19-bp 
deletion in intron 1 was also assessed for its effect on tHcy. Subjects with the 19-bp del/del 
genotype had lower tHcy levels compared to those with the wild type genotype, suggesting 
that DHFR expression may be increased. No effect on serum and RBC folate levels was 
observed. Since this was the first study to explore the effects of this variant at the metabolic 
level, future studies are awaited to verify our findings on tHcy, as well as gene expression. 
In Chapter 4, we focused on common variants in folate metabolizing enzymes (TYMS 5’ UTR 
28-bp repeat and 3’ UTR 6-bp deletion, RFC1 80G>A and ATIC 346G>C) for their effect on 
tHcy, folate and venous thrombosis risk. In the crude analysis, the RFC1 80AA genotype was 
associated with a lower tHcy, while a higher number of TYMS 28-bp repeats decreased 
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serum and RBC folate levels in the general population. These effects disappeared, however, 
when age, sex and serum creatinin were taken into account. Some of the genotype 
combinations, like TYMS 28 bp 3/3 repeat and RFC1 66AA or TYMS 6 bp no del/del and 
ATIC 346 GG, were associated with lower tHcy and serum folate, respectively, which may 
point to gene-gene interaction. However, the size of our study population does not allow 
definite conclusions to be drawn. No effect for any of the genetic variants on venous 
thrombosis risk, alone or in combination, was observed. 
Because of the possible role for high S-adenosylhomocysteine (AdoHcy), secondary to high 
tHcy, in cardiovascular disease, we sequenced the human AHCY gene (Chapter 5). We 
identified several variants and screened two of them (-34C>T and 112C>T) for their effect on 
tHcy levels and venous thrombosis risk. We did not find an evident effect on tHcy levels or 
venous thrombosis risk but the low frequency of these variants requires larger populations to 
draw firm conclusions.  
Because of its role in transmethylation and homocysteine synthesis, variants within the 
COMT gene may modulate homocysteine levels and methylation of catecholamines. We 
performed haplotype analysis to assess the role of COMT variants as determinants of 
homocysteine (Chapter 6). We show that the functional 324G>A (Val108/158Met) variant 
was associated with tHcy, which explained the observed haplotype effect. COMT 324AA 
individuals had a 10.4% higher tHcy (p=0.036) when compared with those carrying the 
324GG genotype. Interestingly, the odds ratio for subjects with the 324AA genotype for 
recurrent venous thrombosis was 1.61 (95% CI 0.97 to 2.65, p=0.06). This may point to a 
role for COMT as a determinant of tHcy and a possible modulator of recurrent venous 
thrombosis risk. 
In Chapter 7, we describe a method for the measurement of AdoMet and AdoHcy in body 
fluids, the ratio of which is an important indicator of methylation capacity. Our method 
comprises sample concentration and clean up using solid-phase extraction columns, HPLC 
separation and detection by tandem mass spectrometry. The interassay CVs for AdoMet and 
AdoHcy were 3.9% and 8.3%, while the intraassay CV were 4.2% and 6.7%, respectively. 
Mean recovery for AdoMet was 94.5% and 96.8% for AdoHcy. The quantification limits were 
2.0 and 1.0 nmol/L for AdoMet and AdoHcy, respectively. In a group of controls (mean tHcy 
11.2 Pmol/L), mean plasma AdoMet and AdoHcy were 94.5 nmol/L and 12.3 nmol/L, 
respectively. We observed that AdoMet degraded at neutral pH, which could be easily 
prevented by addition of acetic acid. 
Hyperhomocysteinemia is associated with DNA hypomethylation, which is likely due to an 
increase in AdoHcy, a strong inhibitor of AdoMet-dependent transmethylation. Besides DNA 
methyltransferases, AdoHcy may also inhibit protein methyltransferases. The study of large-
scale protein methylation is in its infancy. We performed nano-LC Fourier transform ion 
cyclotron resonance mass spectrometry (nano-LC FTICR MS) in order to study the proteome 
of HUVECs and protein specific methylation (Chapter 8). We identified about 1500 proteins 
that, by means of orthologous clustering, could be assigned to the following categories: 
cellular processes and signalling (22.0%), information storage and processing (10.3%), and 
metabolism (9.2%). Because of the high mass accuracy of our FTICR-MS method, we were 
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able to identify protein methylation sites and used Von Willebrand factor precursor (VWFp) 
protein as an example. Although only 53% of the sequence of VWFp was covered, we were 
able to identify 14 methylation sites at either arginine or lysine residues. This study is a first 
attempt to assess protein methylation in crude extracts. Future studies should focus on nano-
LC FTICR MS in combination with stable-isotope labeling, allowing the quantification of 
global and specific protein methylation for studying differential protein methylation in vitro.
In conclusion, our results show that low intracellular vitamin B12 status (high MMA) is (partly) 
responsible for the high homocysteine levels in our population, which is in agreement with 
the proven role of remethylation in the regulation of tHcy. The effect of the COMT 324G>A 
polymorphism on tHcy suggests that (a disturbed) transmethylation also plays a role in this 
regulation process and possibly in the risk of recurrent venous thrombosis as well. The 
central role of these so-called methyltransferases in homocysteine synthesis makes them 
obvious candidate genes in the search of genetic determinants of tHcy. To study a disturbed 
transmethylation, as a mechanism via which homocysteine exerts its detrimental effects, and 
the role of genetic variants in associated genes in this process, will require methods to 
assess transmethylation. In this thesis we describe a method to measure AdoMet and 
AdoHcy, the ratio of which is called the methylation index, in biological samples. In addition, 
we performed a pilot experiment with the ultimate goal to assess the effect of a disturbed 
homocysteine metabolism on protein methylation. Future genetic and in vitro studies will 
provide evidence to what extent a disturbed transmethylation, as one of the possible 
mechanisms, explains how homocysteine exerts its negative effect and results in diseases 
like cardiovascular diseases, congenital malformations and neurological disorders. 
*HQHUDOGLVFXVVLRQ
After the identification of MTHFR 677C>T variant as an important determinant of tHcy, many 
groups have searched for other polymorphisms that affect tHcy and its related diseases. 
Although a large number of polymorphisms in genes involved in homocysteine and 
folate/cobalamin metabolism have been identified, the MTHFR 677C>T polymorphism is by 
far the strongest genetic determinant of tHcy in the general population. The research 
described in Part I of this thesis aimed to identify novel genetic determinants of tHcy and to 
investigate their potential role in homocysteine-related disease. In the past decade, our 
group studied the effect of about 37 polymorphisms in genes involved in homocysteine 
metabolism for their effect on tHcy in population-based controls. Figure 13 shows the 
obtained results for those genetic variants with the strongest effect on fasting tHcy in the 
general Dutch population identified so far. Some polymorphisms may be regarded as genetic 
determinants of tHcy, although to a lesser extent when compared with the MTHFR 677C>T 
variant. These include the CBS 31bp VNTR (especially after a methionine-load) and the 
polymorphisms in COMT (324G>A) and DHFR (19-bp deletion), the latter two being 
described in this thesis.  
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)RODWHF\FOHDQGKRPRF\VWHLQHUHPHWK\ODWLRQ
The impact of MTHFR enzyme dysfunction on folate and homocysteine in health and disease 
has been confirmed in many studies. Because these data point to a remethylation defect in 
hyperhomocysteinemia, much research has focused on variants in folate-metabolizing genes 
other than MTHFR. We investigated the effect of variants in genes that are related to folate 
metabolism and homocysteine remethylation for their effect on tHcy, folate levels and venous 
thrombosis risk, including DHFR, RFC1, TYMS, ATIC, MTR and MTRR.  
The DHFR gene plays an essential role in folate metabolism and, hence, in homocysteine 
remethylation and DNA synthesis. We were the first to study the effect of the DHFR 19-bp 
deletion on tHcy, and observed a decrease in tHcy for 19-bp del/del subjects. Johnson and 
co-workers identified this del/del genotype as a risk factor for neural tube defects 137, and 
suggested that the deletion removed a potential (Sp1) transcription factor binding site, hence 
leading to a decreased DHFR expression. However, this family of transcription factors (Sp1–
8) comprises both repressive and activating members 270, so the removal of this Sp1 site may 
also lead to an increased DHFR expression thereby facilitating homocysteine remethylation. 
Our observation of a lower tHcy in 19-bp del/del subjects, suggests that DHFR expression is 
increased, and facilitates homocysteine remethylation, with possible repercussions on DNA 
synthesis and, hence, cell proliferation. This presumed effect should be confirmed in 
expression studies.  
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Figure 13. Overview of genetic variants that are associated with altered tHcy in the general Dutch population.  
The frequency of the corresponding genotype is plotted (Y-axis) against the relative change in tHcy (X-axis) compared to the
most frequent homozygous genotype (indicated with an asterisk). 
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In another study, we observed small effects of genotype combinations at the metabolite level 
tHcy, suggesting gene-gene interaction between these specific genetic variants (Chapter 4). 
For example, in individuals with the TYMS 6 bp no del/del genotype, the ATIC 346 C>G 
variant was associated with serum, but not RBC, folate levels (-23% for 346GG relative to 
346AA individuals, p=0.02). Of note, serum folate reflects daily intake (short-term), while 
RBC folate is thought to reflect long-term folate intake. However, this effect was not 
paralleled by an increase in tHcy levels. One possible explanation might be that 
homocysteine remethylation via BHMT in the liver or kidney compensates for the “lack” or 
redistribution of folate in order to maintain tHcy at a constant level. It is questionable what the 
clinical relevance of our observation is, also considering the idea that especially chronically 
low folate levels will lead to disease. 
Also B-vitamins are essential in homocysteine remethylation and, in subjects with normal 
folate status, vitamin B12 deficiency may be an important cause of hyperhomocysteinemia in 
the general population 271. An interesting finding in the study described in Chapter 2 is that 
high plasma MMA, but not low plasma vitamin B12, increases the risk of venous thrombosis. 
This shows that the higher tHcy in our venous thrombosis cases is, at least partly, explained 
by lower intracellular vitamin B12 availability (i.e. high MMA). Some studies suggest that low 
levels of B-vitamins per se increase thrombosis risk 161,163,165-167, in addition to the effects of 
high homocysteine 272,273. However, it is difficult to disentangle the effects of two components 
that are part of the same pathway. We also confirmed that plasma vitamin B12 is not the best 
functional marker of vitamin B12 status 169,272. The use of plasma vitamin B12 for assessing 
vitamin B12 status is questionable, considering the fact that up to 50% of subjects with low 
intracellular vitamin B12 status have normal plasma vitamin B12 levels 274. Given the relation 
between suboptimal vitamin B12 status and cognitive function 183, and its presumed effect on 
transmethylation 186,275, this observation may be of interest for assessing vitamin B12 status 
in the elderly as well. 
The effect of a single polymorphism on metabolites or disease risk is often small and difficult 
to reveal. There is increasing evidence that gene-gene or gene environment interactions may 
modulate tHcy or disease risk 47,184,210,276. Our results suggest that genotype combinations of 
folate-metabolizing enzymes may lower folate or tHcy levels in the general population 
(Chapter 4). In addition, we show that high MMA and the MTRR 66GG genotype may 
increase venous thrombosis risk (Chapter 2). These results should be replicated in large, 
well-documented, populations in order to confirm the importance of interactions as 
contributors to a disturbed folate and homocysteine metabolism or disease.  
+RPRF\VWHLQHDQGWUDQVPHWK\ODWLRQ
Several studies have shown that high homocysteine is related to disturbed transmethylation. 
Irrespective of the underlying cause, hyperhomocysteinemia leads to high AdoHcy levels 
and, as a consequence, to a lower AdoMet/AdoHcy ratio and global DNA hypomethylation 55-
57,60,268. Transmethylation is important in many aspects of cell function, like genomic 
imprinting, RNA stability, protein function and degradation. Therefore, genetic variation within 
methyltransferases that catalyze these reactions have become of great interest, especially 
since these transmethylation reactions contribute to homocysteine synthesis. Up till now, 
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most genetic variants studied were located in genes involved in homocysteine 
transsulfuration or remethylation. Because of their direct involvement in homocysteine 
synthesis, functional variants in methyltransferases may have effects on tHcy levels, in 
addition to the intrinsic effect on the reaction they catalyze. Interestingly, we showed that a 
common haplotype (with a prevalence of about 12% in the general population) in the COMT 
gene was associated with tHcy levels (Chapter 6). This was mainly due to the functional 
324G>A polymorphism, and a 10.4% increase in tHcy for 324AA compared to 324GG 
individuals was observed. We also showed that the COMT 324AA genotype was more 
common in venous thrombosis patients (Chapter 6). One may hypothesize that COMT 
dysfunction itself, i.e. disturbed catecholamine or catecholestrogen metabolism 277, and the 
concomitant effect on tHcy 59, both modulate disease susceptibility. Assessing the effect of 
COMT genotypes on AdoMet and AdoHcy would be a first step to confirm that the 
transmethylation pathway may be affected.  
3DWKRSK\VLRORJ\ಥKRPRF\VWHLQHDQGGLVWXUEHGWUDQVPHWK\ODWLRQ
Plasma AdoHcy represents a sensitive indicator of cardiovascular disease 55-57,223,224 and 
potentially also for the increased risk of cardiovascular disease secondary to end-stage renal 
disease 278,279. Several studies indicate that high AdoHcy leads to DNA hypomethylation 55 in 
cardiovascular disease 57 and renal insufficiency 280. DNA methylation contributes to the 
epigenetic regulation of gene expression, and constitutes an important mechanism for 
transcriptional repression or activation 281. In order to investigate the association between 
disturbed homocysteine metabolism and a disturbed methylation capacity, represented by 
the AdoMet/AdoHcy ratio (also called the methylation index), we developed an assay to 
measure these two metabolites in body fluids (Chapter 7) 225. This mass spectrometry-based 
approach together with the use of stable isotopes enables us to selectively measure AdoMet 
and AdoHcy in a reproducible and sensitive way. An important finding was that AdoMet is not 
stable at pH >5, and partially degrades into AdoHcy. Hence, studies in which nonacidified 
samples were used are likely to be confounded and should be interpreted with caution. We 
found that acidification of plasma with acetic acid could prevent this degradation process. 
The recruitment of new study populations will enable us to study the associations between 
high homocysteine, AdoMet and AdoHcy in the future.  
The inhibition by AdoHcy is not restricted to DNA methyltransferases and also other 
methyltransferases, such as protein methyltransferases, are likely to be inhibited 228. Protein 
methylation is thought to be involved in RNA processing, transcriptional regulation, DNA 
repair and signal transduction 282. It has been postulated that a disturbed protein methylation 
is involved in the pathogenesis of neural tube defects 227. Given the importance of protein 
methylation for proper cell functioning we studied the proteome of human umbilical vein 
endothelial cells (HUVEC) and methylation status of specific proteins. We show in Chapter 8 
that we are able to identify proteins in complex samples and to detect methyl groups on 
specific proteins. The use of stable-isotope labeling of proteins in combination with 
immunoprecipitation should allow the quantification of protein-specific methylation 264. By 
quantitating of methyl groups in complex protein samples, the effect of high AdoHcy on 
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protein-specific or global protein methylation can be studied, which may contribute to our 
understanding of the mechanisms involved in homocysteine-related diseases. 
+RPRF\VWHLQHORZHULQJLQWHUYHQWLRQWULDOV
Meta-analyses, including both retrospective and prospective studies, have shown that high 
homocysteine is associated with an increased risk of cardiovascular disease 17-19. In addition, 
the genetic association studies investigating the MTHFR 677C>T variant as a risk factor for 
arterial vascular disease and thrombosis further support the finding that a disturbed 
homocysteine metabolism causes cardiovascular disease 19,283. The main question to be 
answered is whether homocysteine lowering prevents disease 284. Several intervention 
studies have been published but they did not show a beneficial effect of B-vitamin 
supplementation on (recurrent) vascular events, such as recurrent venous thrombosis, stable 
coronary artery disease, myocardial infarction or stroke 285-287. In two other studies, folic acid 
and vitamin B12 supplementation had a marginal effect on markers of atherosclerosis 288 or 
restenosis rate after coronary angioplasty 289. Very recently, two large clinical trials were 
published, the Norwegian vitamin (NORVIT) trial and the Canadian Heart Outcome 
Prevention Evaluation (HOPE-2) trial. These studies were designed to study the effect of 
vitamin supplementation (folic acid, vitamin B12 and/or B6) on secondary prevention of acute 
myocardial infarction and stroke. Vitamin supplementation in the NORVIT trial decreased 
tHcy by 27% (3.6 Pmol/L) in the treated group (n=937) but had no beneficial effect on 
vascular outcome 290. In the HOPE-2 study, tHcy decreased by 2.4 Pmol/L in the treated 
group (n=2758), but did not reduce the risk for major cardiovascular events in patients with 
vascular disease 291. This may point to homocysteine as an innocent bystander, not causally 
linked to disease. Indeed, an increasing number of studies suggest that homocysteine is a 
marker and that AdoHcy or AdoMet are causally related to disease 56,244,292. Unfortunately, 
these parameters have not been assessed in the large intervention trials described above, 
but it is possible that homocysteine-lowering is not paralleled by a normalization of the 
AdoMet/AdoHcy ratio 293, which is an important predictor of cellular methylation capacity. In 
addition, we showed that low methionine is a risk factor for venous thrombosis, suggesting 
that low substrate for AdoMet synthesis may affect transmethylation processes and 
predispose to disease 294. However, there are some other points to consider when 
interpreting the recent intervention trials. First, the effect of folic acid supplementation is not 
completely understood and may not be limited to a decrease in homocysteine alone. 
Because of its role in DNA synthesis and transmethylation, it is possible that folate might 
accelerate several processes (such as cell proliferation in the vessel wall or increased 
arginine methylation), which may overrule or masque the beneficial effects of homocysteine-
lowering 295. This may be especially true for those subjects that had normal folate status at 
baseline. Secondly, most observational studies focused on homocysteine as a risk factor for 
primary events whereas most trials are designed to study recurrent events. When only the 
primary event is sensitive to treatment, no strong effect from vitamin intervention is to be 
expected. Finally, when considering intervention trials in homocystinuric patients, the 
treatment with B-vitamins prevented cardiovascular disease by 90% 20. This shows that 
cardiovascular disease can be prevented by B-vitamin intervention. Additional intervention 
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studies with lower amounts of vitamin or alternative treatment regimens, such as betaine, are 
warranted.
)XWXUHSHUVSHFWLYHV
6HDUFKLQJIRUQRYHOJHQHWLFGHWHUPLQDQWVRIW+F\
Heritability studies suggest that the variation in plasma total homocysteine levels is under 
genetic control. For example, Souto et al. reported a strong genetic correlation for 
homocysteine (r=0.652) in twenty-one families from the Genetic Analysis of Idiopathic 
Thrombophilia (GAIT) Study. From their data a heritability for homocysteine of approximately 
23% can be derived 44. Another group calculated a heritability for fasting homocysteine levels 
of 47% in coronary artery disease cases, and suggested the presence of a co-dominantly 
expressed major gene, in addition to the effects of the MTHFR 677C>T polymorphism 45.
Finally, in hyperhomocysteinemic cardiovascular disease cases included in the 
HOmocysteine in FAMilies (HOFAM) study we calculated a crude genetic correlation of 22% 
and 67% for fasting and post-load tHcy, respectively 46. Kluijtmans et al. reported that five 
common genetic variants (MTHFR 677C>T & 1298A>C, MTR 2756A>G, MTRR 66A>G and 
CBS 844ins68) account for only a small fraction (9%) of the variability in fasting tHcy in 
young adults which was mainly explained by the MTHFR 677C>T polymorphism 47. Although 
the clinical relevance of post-load hyperhomocysteinemia is not fully understood, the high 
heritability observed in the HOFAM study warrants further exploration of genetic 
determinants of post-load homocysteine levels and their potential (predictive) role in disease. 
Collectively, these data suggest that other genetic determinants of fasting or post-load tHcy 
may emerge as we continue our search.  
If we consider homocysteine metabolism, not all candidate genes have been fully explored. 
In the past cDNA’s or exons of genes selected on a priori assumptions were sequenced to 
identify variation within those regions, leaving intronic and promoter regions more or less 
aside of the screening process. Because these sequences may have important functions in 
gene expression or transcription regulation, we should also look for genetic variation within 
these areas and assess their effect on tHcy. In addition, functional enzyme studies may help 
to identify aberrant proteins as was successfully demonstrated by Kang et al. for thermolabile 
MTHFR, enabling the identification of the 677C>T polymorphism 43,296.
The individual testing of variants in candidate genes has been a great effort albeit with limited 
success. Small effects are often difficult to reveal because these effects may not rise above 
the background level. The concept of gene-gene and gene-environment interaction has 
gained increasing attention. It is thought that several polymorphisms may act in concert 
thereby increasing the risk of a certain phenotype or disease in an additive or synergistic 
fashion. Interactions between common CBS genotypes and MTHFR and MTR genotypes or 
folate polymorphisms and B-vitamin status on tHcy and disease risk have been reported 
184,210,276. Another well-known example of gene-environment interaction is illustrated by the 
fact that low folate status may increase tHcy by 25-100% among MTHFR 677TT individuals 
compared to 677CC subjects 47. Technological improvements will facilitate the screening of 
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(multiple) genetic variants in larger study populations, which will be required to perform 
proper analyses.
What strategies are available to identify new genetic determinants of tHcy? First, haplotype 
analysis is used to assess the impact of several variants within one locus, so-called 
haplotypes, on a phenotypic trait 297,298. This approach may provide more information about 
the impact of that locus, potentially harboring a causative allele, than individual 
polymorphisms do 153,299. The size of the study groups needed for haplotype analysis and the 
time-consuming process to screen for several variants per gene may be limiting factors. The 
use of mass spectrometry was demonstrated to be a valuable tool to screen for twelve (and 
potentially more) important polymorphisms related to homocysteine metabolism in a rapid 
and reproducible way 300. In addition, the increasing use of SNP arrays may overcome these 
problems as the arrays enable the analysis of thousands of SNP’s simultaneously. This 
development also facilitated the introduction of another approach, i.e. genome wide 
association studies, in which SNPs dispersed throughout the genome can be analysed on a 
single array and assessed for their effect on a certain trait 301. In addition, the data generated 
by the HapMap consortium 302 may also provide information as to which variants must be 
genotyped in order to cover all the “haplotype blocks” that exist within a certain gene. 
Another, albeit more time-consuming, approach to identify new determinants of tHcy is 
positional cloning. The first step may be a linkage analysis, which involves the identification 
of a correlation between the inheritance pattern of a phenotypic trait (e.g. homocysteine 
levels) and genetic markers. Once a chromosomal region has been identified, candidate 
genes within this region can be cloned and studied in more detail. Many Mendelian disease 
genes have been successfully identified using this technique, which is also applicable to 
multifactorial diseases 303. The combination of the candidate-gene approach and positional 
cloning may help us to identify genes that have not been previously related to homocysteine 
metabolism but potentially contain variation that predisposes to Hhcy and diseases 
associated with disturbed homocysteine metabolism. 
&DQGLGDWHJHQHVLQK\SHUKRPRF\VWHLQHPLDDQGGLVHDVH
Vitamin B12 is an important cofactor in homocysteine remethylation. We have shown that 
high MMA, indicative of low intracellular vitamin B12 availability, may increase venous 
thrombosis risk. The complex uptake and transport mechanisms of vitamin B12 involve 
several transporter and carrier proteins. Hence, functional genetic variants in vitamin B12 
transport genes like intrinsic factor, cubulin (the intrinsic factor-B12 receptor) or haptocorrin 
may disturb vitamin B12 metabolism and affect tHcy and MMA levels, and predispose to 
venous thrombosis.
The effect of common variants in the COMT gene on tHcy described in Chapter 6 shows that 
methyltransferases may represent an important group of candidate genes in the search for 
genetic determinants of tHcy, especially considering their direct involvement in homocysteine 
synthesis. In addition, functional variants in these genes may pose a negative effect on the 
reaction they catalyze, and potentially contribute to disease risk as well. Besides the COMT 
gene, other methyltransferases have been linked to tHcy levels, such as nicotinamide N-
methyltransferase (NNMT) 241 and glycine N-methyltransferase (GNMT) 304. Other candidates 
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include guanidinoacetate methyltransferase (GAMT) and phosphatidylethanolamine 
methyltransferase (PEMT), both being main contributors to homocysteine synthesis 242. In 
order to study the importance of disturbed methylation capacity in hyperhomocysteinemia, 
promising genetic variants should be related not only to tHcy, but also to AdoMet and 
AdoHcy and ultimately to the methylation status of various substrates, including DNA and 
proteins. An effect of the MTHFR 677C>T polymorphism on DNA methylation has already 
been successfully demonstrated 305. Another candidate is adenosine deaminase (ADA), the 
enzyme responsible for adenosine removal produced during AdoHcy hydrolysis. It has been 
hypothesized that the AdoHcy accumulation in hyperhomocysteinemic individuals reduces 
adenosine levels resulting in a reduction of its vasoprotective actions 222.
Many polymorphisms have been identified in genes involved in homocysteine metabolism. 
The majority of these genes are part of folate metabolism, and in this way involved in 
homocysteine remethylation. In most studies, total serum or red blood cell folate have been 
measured in order to assess the effect of a genetic variant on folate levels. It has been 
demonstrated that the MTHFR 677C>T polymorphism causes an accumulation of formylated 
tetrahydrofolates in erythrocytes 207,306. One may postulate that other functional genetic 
variants also cause a redistribution of folate derivatives, which is not detected when 
measuring total folate levels. The application of methods that discriminate between different 
folate derivatives 307 may reveal shifts in folate distribution that contribute to the development 
of folate-related diseases, in the absence of altered homocysteine levels. 
3DWKRSK\VLRORJ\RIK\SHUKRPRF\VWHLQHPLD
The pathophysiology of hyperhomocysteinemia remains to be elucidated. Our results 
suggest that low vitamin B12 status impairs homocysteine remethylation and in this way 
contributes to hyperhomocysteinemia in our group of recurrent venous thrombosis cases. It 
has been suggested that low vitamin B12 status may affect transmethylation and explain the 
symptoms in neurological disease 186,275. An effect of high MMA on transmethylation may be 
postulated, in a similar way that folate status affects AdoHcy levels and DNA methylation in 
cardiovascular disease and cancer patients 57,305,308. The measurement of AdoMet, AdoHcy 
and global and gene-specific DNA methylation may provide support for the involvement of 
disturbed transmethylation when vitamin B12 levels are low, in this way contributing to 
diseases like venous thrombosis and neurological disorders. 
In addition, there is accumulating evidence that high homocysteine is associated with 
disturbed transmethylation 55,60. The observation that hyperhomocysteinemia is associated 
with global DNA hypomethylation is not easily interpreted, however, and gene-specific 
methylation, and associated effects on gene-expression, would provide more information on 
the functional effects of unbalanced methylation. DNA methylation occurs at cytosine 
nucleotides of repetitive (viral) elements, CpG dinucleotides throughout the genes/genome or 
CpG islands present in promoter regions. Methylation of promoter regions is associated with 
transcriptional repression, hence affecting the activity of the corresponding gene. For 
example, the COMT gene is known to have CpG islands in its promoter region, the 
methylation of which is said to affect its expression 309. Studies of COMT promoter 
methylation in subjects/animal models with high tHcy or AdoHcy and the possible effects on 
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gene expression are warranted. Methods for studying gene-specific DNA methylation, like 
array-based bisulfite sequencing, will be of great help in identifying other genes that are 
susceptible to differential methylation in different experimental conditions 310,311. This way, the 
effects of hyperhomocysteinemia on gene-specific methylation and gene expression can be 
studied, that may potentially contribute to the development of disease. 
If a disturbed methylation in hyperhomocysteinemia is a universal process, than it is likely 
that other molecules such as proteins, lipids and neurotransmitters are also affected. Bulau 
et al. described a method to quantify arginine methylation by high-performance liquid 
chromatography, which allows the assessment of global arginine methylation between two 
samples 265. This approach may be used a prognostic tool, although protein-specific data is 
required to assess which proteins are affected. In order to obtain protein specific data, mass 
spectrometric techniques are of great value, as has been shown by several groups 260,312. For 
example, Ong et al. used stable-isotope labeling of amino acids in cultured cells (SILAC) to 
study protein methylation in a quantitative fashion 264. Once specific proteins have been 
identified that are differentially methylated, the proteome from subjects in which a disturbed 
transmethylation is thought to be involved, or the proteome from animal models, may be 
analysed in order to investigate whether these proteins are altered in vivo too 269. The 
investigation of protein methylation status in health and disease may provide more insight 
into the pathological mechanisms in hyperhomocysteinemia. 
In addition to unbalanced transmethylation, high homocysteine may also reflect a disturbed 
folate metabolism. Because of the importance of folates in purine and thymidylate synthesis, 
high homocysteine may mirror a decreased capacity of DNA synthesis and, hence, cell 
proliferation. This may be of critical importance during “normal” cell turnover or vessel repair 
in response to vascular damage and thus contribute to cardiovascular disease. In addition, 
low folate is associated with uracil misincorporation and chromosomal breakage, which is an 
important feature of cancer development 29. These aspects should be taken into account too, 
when studying the complex mechanisms of homocysteine-related diseases. 
&RQFOXGLQJUHPDUNV
Although the first studies indicated the involvement of a disturbed transsulfuration in 
hyperhomocysteinemia 11,40, the identification of the MTHFR 677C>T polymorphism as a 
determinant of tHcy in the general population, pointed to the involvement of a disturbed 
remethylation instead 43,296,313. Many genes involved in folate and vitamin B12 metabolism 
have been assessed since then, but the effects observed in single populations appear 
difficult to replicate in other populations. The evidence that in most cases multiple genetic 
variants (i.e. genetic background), in combination with lifestyle factors, contribute to 
phenotypic changes, may explain these discrepancies. It will require large well-documented 
populations to reveal small changes in phenotype that may contribute to disease, in addition 
to high-throughput SNP genotyping technology and proper statistical data analysis and 
interpretation. The involvement of a disturbed transmethylation in hyperhomocysteinemic 
subjects is now subject of interest. The observations that an increased flux through the 
transmethylation pathway increases tHcy levels and that hyperhomocysteinemia may cause 
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an inhibition of these processes, warrants the study of methylation parameters, 
methyltransferases and methylation status of their corresponding substrates (such as nucleic 
acids and proteins). This will provide evidence whether unbalanced methylation occurs in 
diseases associated with a disturbed homocysteine metabolism. 
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Een hoog plasma totaal homocysteine (tHcy) is een risicofactor voor onder andere hart- en 
vaatziekten, congenitale afwijkingen en neurologische aandoeningen. Naast het effect van 
omgevingsfactoren en leefstijl is de variatie in tHcy erfelijk bepaald. De genetische bijdrage 
aan de variatie van tHcy kan slechts gedeeltelijk verklaard worden door bekende genetische 
varianten. Het doel van de in dit proefschrift beschreven studies was om onbekende 
genetische determinanten van tHcy te identificeren, en met name die varianten die ook 
geassocieerd zijn met een hoger ziekterisico, waarbij in dit proefschrift recidief veneuze 
trombose centraal staat. Een tweede doel was om methodes te ontwikkelen waarmee de rol 
van een verstoorde transmethylering, als mechanisme voor homocysteine-gerelateerde 
pathologie, bestudeerd kan worden. 
Hoofdstuk 1 van dit proefschrift bestaat uit een algemene inleiding over het homocysteine 
metabolisme, een korte beschrijving van ziekten die geassocieerd zijn met een verstoord 
homocysteine metabolisme en een overzicht van genetische varianten die reeds onderzocht 
zijn in relatie tot tHcy.  
De studies die in dit proefschrift worden beschreven, zijn ondergebracht in twee delen: Deel I
omvat de studies die tot doel hadden om nieuwe determinanten van tHcy te identificeren, 
waarbij wij ons richtten op genen betrokken bij de remethylering (Hoofdstuk 2-4) en 
transmethylering (Hoofdstuk 5 en 6). Deel II van dit proefschrift beschrijft de studies die tot 
doel hadden het bestuderen van transmethylering, als een mechanisme voor homocysteine-
gerelateerde pathologie, beter mogelijk te maken. 
In Hoofdstuk 2 hebben we varianten in genen betrokken bij homocysteine remethylering (de 
methionine synthase [MTR] 2756A>G en methionine synthase reductase [MTRR] 66A>G 
polymorfismen) bestudeerd als mogelijke determinanten van tHcy en serum folaat en als 
risicofactor voor recidief veneuze trombose. Gezien het belang van vitamine B12 
(cobalamine) voor homocysteine remethylering, hebben we ook een lage vitamine B12 
status als risicofactor bestudeerd. Daarvoor hebben we gebruik gemaakt van zowel plasma 
vitamine B12 als plasma methylmalonzuur (MMA), een betrouwbare maat voor de 
intracellulaire beschikbaarheid van vitamine B12. Uit onze studie bleek dat een hoog plasma 
MMA tot een hoger risico voor recidief veneuze trombose leidt. Een laag plasma vitamine 
B12 was géén risicofactor, wat verklaart kan worden met het gegeven dat plasma vitamine 
B12 geen gevoelige maat is voor de intracellulaire vitamine B12 status. De MTR 2756A>G 
en MTRR 66A>G varianten hadden beide géén effect op tHcy of folaat, maar de combinatie 
van MTRR 66GG genotype én hoog MMA (>80e percentiel van de controle populatie) was 
geassocieerd met een 5 maal verhoogde kans op het risico op recidief trombose. 
In Hoofdstuk 3 hebben we de moleculair genetische analyse van het dihydrofolaat reductase 
(DHFR) gen beschreven. Dit gen is essentiëel voor de reductie van dihydrofolaat tot 
tetrahydrofolaat en is vereist voor homocysteine remethylering. Door sequencen van het 
DHFR gen hebben we een 9-bp repeat geïdentificeerd in het gebied voorafgaand aan het 
DHFR gen (aansluitend op het 5’ untranslated region [UTR]). Echter, de repeat had géén 
effect op tHcy of folaat concentraties. Onlangs is een 19-bp deletie beschreven in intron 1 
van dit gen die, gezien het belnag van intron 1 als transcriptiefactor binding site, een effect 
zou kunnen hebben op de genexpressie. Uit onze studie bleek dat mensen die homozygoot 
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zijn voor de deletie een lager tHcy hadden dan mensen met het wild type genotype. Dit zou 
kunnen betekenen dat het DHFR gen sterker tot expressie komt, waardoor homocysteine 
beter omgezet kan worden. Er werd geen effect van deze variant op serum en erytrocyten 
folaat gevonden. Dit is de eerste studie naar het effect van DHFR varianten op tHcy en 
folaat, en toekomstige studies zijn nodig om onze bevindingen, en de effecten op 
genexpressie, verder te bestuderen. 
In Hoofdstuk 4 hebben we vier varianten in genen van het folaat metabolisme (thymidylaat 
synthase [TYMS] 5’ UTR 28-bp repeat and 3’ UTR 6-bp deletie, reduced folate carrier 
[RFC1] 80G>A en AICAR transformylase/IMP cyclohydrolase [ATIC] 346G>C) bestudeerd 
als mogelijke determinanten van folaat en tHcy en als risicofactor voor recidief trombose. In 
de algemene populatie lijkt het RFC1 80AA genotype geassocieerd met een lager tHcy, 
terwijl de TYMS 28-bp repeat een lager serum en erytrocyten folaat tot gevolg had bij een 
groter aantal repeats. Deze effecten verdwenen na correctie voor leeftijd, geslacht en serum 
kreatinine. Sommige genotype combinaties, zoals de TYMS 28 bp 3/3 repeat met RFC1 
66AA of TYMS 6 bp no del/del met ATIC 346 GG, leken een verlagend effect te hebben op, 
respectievelijk, tHcy en serum folate, wat een aanwijzing zou kunnen zijn voor gen-gen 
interacties. Deze observaties moeten in grotere populaties bevestigd worden. Géén van de 
varianten (alléén of in combinatie) had een effect op het risico op recidief trombose. 
Omdat bij mensen met hyperhomocysteinemie ook een verhoogd S-adenosylhomocysteine 
(AdoHcy, de precursor van homocysteine) wordt gevonden, hebben wij het AHCY gen 
(verantwoordelijk voor de hydrolyse van AdoHcy naar homocysteine en adenosine) 
gesequenced (Hoofdstuk 5). We hebben enkele polymorfismen geïdentificeerd (waaronder   
-34C>T en 112C>T) en we hebben onderzocht of deze een effect hadden op tHcy of de kans 
op recidief trombose. We vonden geen duidelijke aanwijzingen dat deze varianten een effect 
hadden op tHcy of het ziekterisico, maar door de lage frequenties van deze polymorfismen 
kan een mogelijk effect ook niet uitgesloten worden. 
Door de rol van catechol-O-methyltransferase (COMT) bij de transmethylering van 
catecholamines en bij homocysteine synthese, kunnen genetische varianten in dit gen een 
invloed hebben op tHcy en transmethylering. Om het effect van de methyltransferase COMT 
op tHcy en recidief trombose te bestuderen hebben we haplotype (genotype op basis van 
meerdere genetische varianten) analyse uitgevoerd (Hoofdstuk 6). We laten zien dat er een 
haplotype bestaat binnen het COMT gen dat geassocieerd is met tHcy; dit effect wordt bijna 
geheel verklaard door de functionele 324G>A variant (Val108/158Met). Mensen met het 
324AA genotype hadden een 10.4% hoger tHcy dan mensen met het 324GG genotype. 
Bovendien kwam het 324AA genotype vaker voor bij recidief trombose patiënten (relatief 
risico 1.61 [95% betrouwbaarheidsinterval 0.97 tot 2.65], p=0.06). Dit wijst op COMT als 
determinant van tHcy en een mogelijk effect van deze variant op het recidief veneuze 
trombose risico. 
In Hoofdstuk 7 beschrijven we een methode voor het meten van S-adenosylmethionine 
(AdoMet)  en S-adenosylhomocysteine (AdoHcy) in lichaamsvloeistoffen. De ratio van deze 
metabolieten is een belangrijke maat voor de methyleringscapaciteit. Onze methode bevat 
een eenvoudige verrijkings- en zuiveringsstap door het gebruik van solid-phase extraction 
kolommetjes, HPLC scheiding en tandem massa spectrometrie detectie. De interassay 
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variatie coëfficiënten (VC) voor AdoMet en AdoHcy zijn respectievelijk 3.9% en 8.3%, en de 
intraassay VC’s zijn 4.2% en 6.7%. De gemiddelde recovery van AdoMet was 94.5% en die 
van AdoHcy 96.8%. De kwantificatie limiet was 2.0 en 1.0 nmol/L voor respectievelijk 
AdoMet en AdoHcy. In een groep controles (n=29, gemiddelde tHcy concentratie 11.2 
Pmol/L) was de gemiddelde AdoMet concentratie 94.5 nmol/L en de gemiddelde AdoHcy 
concentratie 12.3 nmol/L. De bij neutrale pH waargenomen AdoMet degradatie kan 
eenvoudig voorkomen worden door aanzuring van het te meten plasma monster met 
azijnzuur direct na bloedafname. 
Hyperhomocysteinemie is geassocieerd met hypomethylering, waarschijnlijk door een 
stijging van de methyleringsremmer AdoHcy. Omdat niet alleen DNA methyltransferases 
worden geremd door AdoHcy, is het aannemelijk dat óók methyltransferases worden geremd 
die betrokken zijn bij de eiwitmethylering. Het op grote schaal bestuderen van 
eiwitmethylering staat nog in de kinderschoenen. Wij hebben van een techniek gebruik 
gemaakt, die nano-LC Fourier transform ion cyclotron resonance mass spectrometry 
(FTICR-MS) wordt genoemd, om het proteoom van veneuze endotheelcellen uit humane 
navelstrengen (HUVECs) te bestuderen (Hoofdstuk 8). We hebben ongeveer 1500 eiwitten 
geïdentificeerd die na orthologe clustering toegewezen konden worden aan de volgende 
categorieën van eiwitten: cellulaire processen en signaaltransductie (22.0%), informatie 
opslag en verwerking (10.3%) en metabolisme (9.2%). Door de hoge nauwkeurigheid in 
massabepaling, zijn we in staat om methyleringssites (+/-14.0157 Da) in eiwitten te 
identificeren. We hebben het Von Willebrand Factor precursor (VWFp) eiwit als voorbeeld 
uitgewerkt en 14 (arginine/lysine) methyleringssites kunnen identificeren. Deze studie is een 
eerste poging tot het bestuderen van specifieke eiwitmethylering in complexe eiwitlysaten. 
Het gebruik van stabiele isotopen maakt de kwantificering van differentiële eiwitmethylering 
in verschillende experimentele settings mogelijk. 
Samenvattend blijkt uit de resultaten van dit proefschrift dat een lage intracellulaire vitamine 
B12 status (hoog MMA) in onze populatie (deels) verantwoordelijk is voor verhoogde tHcy 
concentraties, wat aansluit op de bewezen rol van remethylering bij de regulatie van tHcy. 
Het effect van de COMT 324G>A variant op tHcy suggereert dat (een verstoring van) de 
transmethylering óók een rol speelt bij de regulatie van tHcy en mogelijk ook bij recidief 
veneuze trombose. De centrale rol van deze zogenaamde methyltransferases in 
homocysteine synthese maakt hen voor de hand liggende kandidaatgenen in de zoektocht 
naar genetische determinanten van tHcy. Een verstoorde transmethylering, als één van de 
mechanismen voor homocysteine-gerelateerde pathologie, en de rol van genetische variatie 
in de betrokken genen, vereist methodes om die transmethylering te bestuderen. In dit 
proefschrift is een methode beschreven om de methyleringsparameters AdoMet en AdoHcy 
te meten in biologische materialen. Daarnaast is een pilot experiment gedaan met als 
uiteindelijke doel om het effect van een verstoord homocysteine metabolisme op 
eiwitmethylering te bestuderen. Toekomstige genetische en in vitro studies zullen moeten 
uitwijzen in hoeverre een verstoorde transmethylering kan verklaren hoe een verstoord 
homocysteine metabolisme leidt tot hart- en vaatziekten, congenitale afwijkingen en 
neurologische aandoeningen. 
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Dankwoord
Ik heb onderzoek mogen doen in een omgeving met mensen die enthousiast, behulpzaam 
en geïnteresseerd zijn. Dat heeft mijn promotietijd tot een aangename tijd gemaakt en heeft 
zeker ook zijn weerslag gehad op het proefschrift zoals het nu verschenen is. Bij deze wil ik 
dan ook mijn collega’s van Lab Kindergeneeskunde en Neurologie en afdeling 
Endocrinologie, die op welke manier dan ook betrokken zijn geweest bij mijn promotie, 
bedanken voor hun inzet en gezelligheid de afgelopen jaren.  
+HQN%ORPHQ0DUWLQGHQ+HLMHU
Jullie gezamenlijke begeleiding heb ik als zeer postief ervaren. Door de biochemische kennis 
en brede wetenschappelijke interesse van Henk gecombineerd met de “artsenvisie”, 
veelzijdigheid en statistische hoogstandjes van Martin heb ik van jullie beider kennis kunnen 
profiteren. Ook in het nakijken van manuscripten vulden jullie elkaar aan, waardoor ik uit het 
commentaar maximaal rendement kon halen. Jullie gaven me de vrijheid om na twee jaar 
“iets anders te doen”, waardoor er niet alléén SNP-werk in mijn proefschrift staat. Daardoor 
heb ik mijzelf ook op andere vlakken kunnen ontwikkelen. Bedankt voor jullie inzet en, op zijn 
tijd, gezelligheid. Henk, succes in Amsterdam en ik hoop dat alles daar volgens plan 
verloopt. Martin, succes met je vele bezigheden als arts/onderzoeker.  
3URI+HUPXV
Als promotor hebt u het onderzoek van een afstand gevolgd. Eens in de zoveel tijd hadden 
we samen een overleg om de vorderingen binnen het onderzoek te bespreken. Daaruit bleek 
betrokkenheid en interesse, waardoor ik altijd met een goed gevoel wegging. Bedankt! 
0LMQSDUDQLPIHQ6DQGUD+HLOHQ,YRQYDQGHU/LQGHQ
Als collega junior-onderzoekers (en Sandra later als post-doc) hebben we samen een kamer 
(kantoortuin) gedeeld en derhalve altijd discussies kunnen voeren als we iets niet begrepen 
of juist wél, zowel op wetenschappelijk gebied als daarbuiten. Ik denk dat dat een essentiëel 
onderdeel is in iemands (wetenschappelijke) ontwikkeling. Ik heb het enorm naar mijn zin 
gehad en wil jullie daarvoor bedanken, evenals voor jullie inzet voor/tijdens mijn promotie. 
Sandra, succes met je carriëre in Wageningen. Ivon, veel succes met de afronding van je 
promotie en verdere carrière.
+RPRF\VWHLQHUHVHDUFKJURHSHQJHDGRSWHHUGHOHGHQ
Ik wil alle collega’s van de homocysteine groep (inclusief Maria, Anita en Henriëtte) 
bedanken voor de gezelligheid, de borrels, barbecues en congressen. Brenda, Alexandra, 
Suzanne en Gerry: op het onderzoekslab hing een goede sfeer en ik heb prettig met jullie 
samengewerkt. Altijd goedlachs en bereid om te helpen. Ik noem met name Gerry’s 
onuitputtelijke energie om het lab toonbaar, en de stagiaires in het gareel, te houden. 
Sterkte! Voor allen, bedankt en succes voor de toekomst! 
'DQNZRRUG
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Dinny van Oppenraaij-Emmerzaal, Addy de Graaf-Hess en Gwendolyn Beckmann: 
Dinny, bedankt voor de leuke samenwerking en je enthousiasme bij het opzetten en 
valideren van de AdoMet/AdoHcy meting. Hopelijk kun je de toepassing van de meting in de 
toekomst uitbreiden. Addy, en later ook Gwendolyn, jullie hebben me geholpen als er weer 
eens een tHcy of totaal eiwit gemeten moest worden, of dat nu voor het prakticum was, voor 
een artikel of eigen gebruik. Ik wil ook Leo Kluijtmans bedanken voor zijn bijdrage aan het 
onderzoek en de publicaties in mijn “beginjaren”. 
&ROOHJDಫVYDQ/.1HQ$IGHOLQJ(QGRFULQRORJLH
Omdat ik bij twee afdelingen een aanstelling had heb ik (af en toe) bij meerdere dagjes-uit of 
borrels aan kunnen schuiven. Ik heb het “aan beide kanten” altijd naar mijn zin gehad. 
Daarnaast zal ik de niet altijd ongevaarlijke mountainbiketochten van LKN zeker onthouden. 
In dat kader hebben Herman en Richard terecht een fiets-licentie voor de deelnemers in het 
leven geroepen. 
Naast het genetische werk heb ik endotheelcellen gekweekt om vervolgens het proteoom te 
bestuderen. Ik wil Joyce en Thea bedanken voor de aanvoer van de navelstrengen en het 
aanleren hoe de endotheelcellen te isoleren en te kweken. Ik ben dank verschuldigd aan 
Wendy, die veel werk heeft verzet om de aangeleverde HUVEC-fracties om te toveren in 
interpreteerbare eiwitlijsten. Edwin en Lambert, bedankt voor jullie bijdrage bij respectievelijk 
de MS-data analyse en 2D-electroforese. Bert, bedankt voor je begeleiding bij dit project.  
Hanneke wil ik bedanken voor de aminozuur-analyses van de HUVEC-extracten. Jammer 
genoeg hadden we niet meer tijd, wellicht hadden we er dan meer uit kunnen halen. 
Daarnaast wil ik mijn collega’s(-promovendi) bedanken en succes wensen: Udo (óók voor de 
last-minute figuurbewerkingen), Suzan W., Nienke, Miranda, Murtada, Rutger, Joyce, Rolf, 
Cindy, Saskia, Paula, Ingrid, Marije en Marloes. De EpiHomLip-club: Sita, Gerly en 
Jacqueline. Ook Hans en Anja wil ik bedanken voor de leuke tijd als “kantoortuincommissie”. 
Maarten van den Hurk, Geert Corstens en Ruud Clarijs: in het begin veel hardgelopen, nu 
iets minder. Misschien toch nog weer eens de 7-heuvelenloop lopen?  
6WXGHQWHQ
Tijdens mijn promotie heb ik vier studenten mogen begeleiden, en met veel plezier. Ik wil 
Femke Philips, Karin von Winckelmann, Daniëlle Groen en Els(je) Cornelissen bedanken 
voor hun inzet. Jullie waren zeer verschillende persoonlijkheden, maar allen even 
enthousiast. Karin en Daniëlle, jullie hebben een vervolgstudie opgepakt waarmee ik jullie 
veel succes wens. Femke en Els, ik vraag me af of jullie in het onderzoek blijven, de tijd zal 
het uitwijzen. Succes! 
6DPHQZHUNLQJHQ
Met Jan-Willem Muntjewerff (GGz, Nijmegen) hebben we gekeken naar genetische variatie 
in relatie tot schizofrenie. Jan-Willem, bedankt voor de leuke samenwerking en gefeliciteerd 
met je proefschrift. Ook wil ik Eduard Struys (VU Medisch Centrum, Amsterdam) bedanken 
voor zijn bijdrage aan het artikel beschreven in hoofdstuk 7. 
'DQNZRRUG
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3URIGU3HU8HODQG+DOYDUG%HUJHVHQDQG7RYH)éOLG
Per, I would like to thank you for letting me visit your lab to learn the vitamin B12 and folate 
assays. I appreciate your presence on January 11th. Halvard, thanks for teaching me the ins 
and outs of the assays in a humoristic way. Tove, thanks for your help in running the many 
samples that I brought with me. Of course, I’d like to thank Øivind, Klaus and Amrei for taking 
me out to see Bergen and for inviting me to the seventies party. It was great fun!  
2XGHUV
Ik heb een omweggetje gemaakt om te komen waar ik nu ben. Jullie hebben me altijd 
gesteund in mijn keuzes en vertrouwen in mij gehad. Dat had ik nodig om tot dit punt te 
komen. Pa, je sprak tijdens de bruiloft van Nathalie en mij de volledige titel van mijn 
proefschrift moeiteloos in één adem uit. Deze woorden zullen ongetwijfeld meer betekenis 
krijgen tijdens de verdediging. Nu op weg naar je eigen promotie! 
6FKRRQRXGHUV
Ook jullie hebben altijd interesse getoond in het onderzoek, hoewel dat laatste betekende dat 
Nathalie uiteindelijk zou verhuizen naar Nijmegen. Bedankt voor jullie steun. 
1DWKDOLH
Lieve Nathalie, we kennen elkaar al een hele tijd en sinds kort zijn we een “echt paar”. Je 
hebt me in 1998 zien vertrekken naar Wageningen en later naar Nijmegen. In 2003, je werk, 
familie en vrienden achterlatend, ben je me gevolgd naar Nijmegen, waar je het nu goed 
naar je zin hebt. Wellicht kunnen we onze toekomstplannen verwezenlijken in Nijmegen, de 
tijd zal het leren. Dank je voor je onvoorwaardelijke steun en vertrouwen. 
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Henkjan Gellekink is geboren op 10 maart 1975 te Enschede, Nederland. In 1995 behaalde 
hij zijn VWO diploma aan het Stedelijk Lyceum in Enschede. Daarna volgde hij het Hoger 
Laboratorium Onderwijs (specialisatie biochemie) aan de Hogeschool Enschede dat in 1999 
met een diploma werd afgesloten. In datzelfde jaar startte hij een studie Biologie aan de 
Radboud Universiteit Nijmegen. Hij liep stage bij de afdeling Pathologie / afdeling Neurologie 
(Prof. dr. H.P.H. Kremer), Radboud Universiteit Nijmegen Medisch Centrum en bij de 
afdeling Cellulaire Dierfysiologie (Prof. dr. E.W. Roubos), Radboud Universiteit Nijmegen. In 
mei 2002 behaalde hij zijn master titel in de Medische Biologie. Aansluitend begon hij een 
promotie onderzoek bij de afdeling Endocrinologie (Promotor Prof. dr. A.R.M.M. Hermus, 
Radboud Universiteit Nijmegen Medisch Centrum) en het Laboratorium voor 
Kindergeneeskunde en Neurologie (Prof. dr. R.A. Wevers, Radboud Universiteit Nijmegen 
Medisch Centrum) onder directe supervisie van dr. H.J. Blom en dr. M. den Heijer (beiden 
co-promotor). Tijdens zijn promotie deed hij onderzoek naar genetische oorzaken van 
hyperhomocysteinemie, maar ook verkende hij het veld van massa spectrometrie om het 
effect van een verstoord homocysteine metabolisme op andere metabolieten en het 
proteoom van endotheelcellen te bestuderen. Het onderzoek dat hij als junior onderzoeker 
uitvoerde is beschreven in dit proefschrift. Henkjan is getrouwd met Nathalie Stol. 
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